Index_NNP Page_NNP Page_NNP Accounting_NNP policies_NNS 89_CD Independent_NNP Auditors_NNS report_VBP 83_CD Accounting_NNP presentation_NN 55,89_CD Intellectual_NNP property_NN 25,157_CD Achieve_NNP commercial_NN and_CC operational_JJ excellence_NN 06,14_CD Interest_NN rate_NN risk_NN management_NN 70_CD Acquisitions_NNS and_CC disposals_NNS 119_CD Internal_NNP control_NN framework_NN 33_CD Annual_JJ General_NNP Meeting_VBG 32_CD Inventories_NNS 105_CD Assets_NNS held_VBN for_IN sale_NN 106_CD Investments_NNP in_IN associates_NNS and_CC joint_JJ ventures_NNS 104_CD Associates_NNPS and_CC joint_JJ ventures_NNS 97,104_CD Investor_NN information_NN 171_CD Be_VBP the_DT best_JJS place_NN for_IN the_DT best_JJS people_NNS to_TO do_VB their_PRP$ best_JJS work_NN 06,16_CD Legal_NNP proceedings_NNS 157-164_CD Board_NNP 28,30_CD Movements_NNS in_IN equity_NN 67,117_CD Build_VBP the_DT best_JJS product_NN pipeline_NN in_IN the_DT industry_NN 06,07-13_CD Net_JJ debt_NN 67,114_CD Cash_NN and_CC cash_NN equivalents_NNS 106_CD New_NNP accounting_NN policies_NNS and_CC future_JJ requirements_NNS 92_CD Combined_NNP Code_NNP 35,82_CD Non-Executive_NNP Director_NNP terms_NNS ,_, conditions_NNS and_CC fees_NNS 44_CD Commitments_NNS 67,122_CD Non-Executive_JJ Directors_NNS remuneration_VBP 46,47_CD Committee_NNP reports_NNS 34,35,37-54_CD Notes_NNS to_TO the_DT financial_JJ statements_NNS 89-170_CD Community_NNP investment_NN 18-19_CD Operating_NN and_CC financial_JJ review_NN and_CC prospects_NNS 55-80_CD Consolidated_NNP balance_NN sheet_NN 85_CD Operating_NN profit_NN 95,96_CD Consolidated_NNP cash_NN ow_NN statement_NN 86_CD Other_JJ intangible_JJ assets_NNS 103,104_CD Consolidated_NNP income_NN statement_NN 84_CD Other_JJ investments_NNS 105_CD Consolidated_NNP statement_NN of_IN recognized_VBN income_NN and_CC expense_NN 88_CD Other_JJ non-current_JJ assets_NNS 105_CD Consumer_NN Healthcare_NNP 09,14,17,23,24,78_CD Other_JJ non-current_JJ liabilities_NNS 113_CD Contact_NN details_NNS 185_CD Other_JJ operating_NN income_NN 78,95_CD Contingent_NNP liabilities_NNS 67,68,114_CD Other_JJ provisions_NNS 113_CD Corporate_JJ Executive_NNP Team_NNP 29_CD Outlook_NNP and_CC risk_VB factors_NNS 71-74_CD Corporate_JJ governance_NN 27-36_CD Pensions_NNS and_CC other_JJ post-employment_NN benets_NNS 67,107-112_CD Corporate_JJ responsibility_NN 06,18,183_CD Pharmaceutical_NNP turnover_NN 57-61_CD Critical_JJ accounting_NN policies_NNS 64_CD Presentation_NN of_IN the_DT financial_JJ statements_NNS 89_CD Description_NN of_IN business_NN 05-26_CD Principal_NN Group_NNP companies_NNS 147-149_CD Dialogue_NN with_IN shareholders_NNS 31_CD Products_NNPS and_CC competition_NN 20-23_CD Directors_NNS and_CC Senior_JJ Management_NN remuneration_NN 44-54_CD Property_NN ,_, plant_NN and_CC equipment_NN 66,101-102_CD Directors_NNS interests_NNS 48_CD Quarterly_JJ trend_NN 172-177_CD Directors_NNS interests_NNS in_IN contracts_NNS 54_CD Reconciliation_NNP to_TO US_NNP accounting_NN principles_NNS 135-146_CD Directors_NNS statements_NNS of_IN responsibility_NN 82,165_CD Regulatory_NNP environment_NN 24-26_CD Dividends_NNPS 63,100,182_CD Related_VBN party_NN transactions_NNS 118_CD Earnings_NNS per_IN share_NN 100_CD Remuneration_NNP Report_NNP 37-54_CD Employee_NN costs_NNS 96_CD Report_NNP of_IN the_DT Directors_NNS 04-80_CD Employee_NN share_NN schemes_NNS 132-134_CD Responsibility_NN for_IN environment_NN ,_, health_NN and_CC safety_NN 26_CD Exchange_NNP rates_NNS 92,180_CD Risk_NNP factors_NNS 71-74_CD Executive_NNP Director_NNP terms_NNS ,_, conditions_NNS and_CC remuneration_NN 42,43_CD Segment_NN information_NN 93-95_CD Finance_NNP costs_NNS 56,63,97_CD Share_NN capital_NN and_CC share_NN premium_NN 116_CD Finance_NNP income_NN 63,97_CD Share_NN options_NNS 49-51_CD ,132_CD -134_CD Financial_NNP instruments_NNS and_CC related_VBN disclosures_NNS 123-131_CD Shareholder_NN information_NN 182-186_CD Financial_NNP position_NN and_CC resources_NNS 66-70_CD Strategy_NNP 06_CD Financial_NNP record_NN 172-181_CD Taxation_NNP 63,97-99_CD Financial_NNP statements_NNS 81-170_CD Taxation_NNP information_NN for_IN shareholders_NNS 186_CD Financial_NNP summary_NN 04_CD Total_JJ Equity_NN 67_CD Financial_NNP trends_NNS and_CC ratios_NNS 56_CD Trade_NNP and_CC other_JJ payables_NNS 66,106_CD Five_CD year_NN record_NN 178-181_CD Trade_NNP and_CC other_JJ receivables_NN 66,106_CD Foreign_NNP exchange_NN risk_NN management_NN 70,123_CD Trademarks_NNPS 05,26_CD Global_JJ manufacturing_NN and_CC supply_NN 17_CD Transition_NN to_TO IFRS_NNP 150-156_CD Glossary_NNP of_IN terms_NNS 187_CD Treasury_NNP policies_NNS 69,70_CD Goodwill_NNP 102_CD US_NNP law_NN and_CC regulation_NN 36_CD Governance_NN and_CC policy_NN 30_CD World_NNP economy_NN 57_CD IFRS_NNP adjustments_NNS 150_CD World_NNP market_NN pharmaceuticals_NNS 57_CD Improve_NNP access_NN to_TO medicines_NNS 15_CD Incentive_NN plans_NNS 51,52_CD GSK_NNP Annual_JJ Report_NNP 2005_CD 188_CD INVESTOR_NN INFORMATION_NNP Corporate_NNP Website_NNP brochure_NN About_IN us_PRP Meeting_VBG global_JJ challenges_NNS Our_PRP$ products_NNS Commitment_NNP to_TO innovation_NN Your_PRP$ health_NN Access_NN to_TO medicines_NNS Responsibility_NNP Therapy_NNP areas_NNS In_IN the_DT community_NN Our_PRP$ mission_NN Research_NNP &_CC Development_NNP A_NNP better_RBR future_JJ What_WP would_MD Investors_NNPS Media_NNP center_NN you_PRP like_VBP to_TO know_VB Careers_NNS about_IN GSK_NNP ?_.
com_NN Corporate_JJ Annual_JJ responsibility_NN review_NN report_NN Access_NNP to_TO medicines_NNS An_DT interview_NN with_IN Research_NNP and_CC innovation_NN the_DT Chairman_NNP and_CC CEO_NNP Ethical_JJ conduct_NN Focus_NN on_IN the_DT patient_JJ Employees_NNS The_DT year_NN of_IN the_DT vaccine_NN Annual_JJ Human_JJ rights_NNS Growing_VBG brands_NNS report_NN Environment_NNP Powering_NNP performance_NN Community_NNP investment_NN Performance_NNP highlights_VBZ Business_NNP operating_VBG review_NN Summary_NNP remuneration_NN report_NN An_DT interview_NN with_IN Corporate_JJ governance_NN the_DT Chairman_NNP and_CC CEO_NNP Summary_NNP financial_JJ statements_NNS Financial_JJ summary_NN Shareholder_NN information_NN Description_NN of_IN business_NN Chairman_NNP and_CC CEOs_NNS Corporate_JJ governance_NN closing_VBG letter_NN Remuneration_NNP report_NN Operating_NN and_CC financial_JJ review_NN and_CC prospects_NNS Financial_JJ statements_NNS Notes_NNS to_TO the_DT financial_JJ statements_NNS Investor_NNP information_NN Do_VBP more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_RBR Head_NNP Office_NNP and_CC Registered_NNP Office_NNP GlaxoSmithKline_NNP plc_NN 980_CD Great_NNP West_NNP Road_NNP Designed_VBN by_IN CGI_NNP London_NNP ._.
Brentford_NNP ,_, Middlesex_NNP TW8_NNP 9GS_NNP Printed_NNP by_IN The_DT Midas_NNP Press_NNP in_IN the_DT UK_NNP ._.
The_DT paper_NN used_VBN in_IN the_DT United_NNP Kingdom_NNP production_NN of_IN this_DT document_NN is_VBZ made_VBN from_IN pulps_NNS harvested_VBD Tel_NNP :_: 44_CD 0_CD 20 8047 5000_CD from_IN sustainable_JJ forests_NNS ,_, also_RB using_VBG sawmill_NN residues_NNS and_CC www_NN ._.
Annual_JJ Review_NNP 2005_CD human_JJ being_VBG Do_VBP more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_RBR 01_CD An_DT interview_NN with_IN Sir_NNP Christopher_NNP Gent_NNP ,_, Chairman_NNP ,_, and_CC JP_NNP Garnier_NNP ,_, Chief_NNP Executive_NNP officer_NN 05_CD Tachi_NNP Yamada_NNP ,_, Chairman_NNP ,_, Research_NNP &_CC Development_NNP ,_, Pharmaceuticals_NNP 06_CD Jean_NNP Stphenne_NNP ,_, President_NNP and_CC General_NNP Manager_NNP ,_, GSK_NNP Biologicals_NNPS 08_CD John_NNP Clarke_NNP ,_, President_NNP ,_, Consumer_NNP Healthcare_NNP 11_CD David_NNP Stout_NNP ,_, President_NNP ,_, Pharmaceutical_NNP Operations_NNP 14_CD Performance_NNP highlights_VBZ 15_CD Business_NN operating_NN review_NN 18_CD The_NNP Board_NNP 19_CD The_DT Corporate_JJ Executive_NNP Team_NNP 20_CD Summary_NNP remuneration_NN report_NN 23_CD Corporate_NNP governance_NN 24_CD Responsibility_NN statements_NNS 25_CD Summary_NNP financial_JJ statements_NNS 26_CD Summary_NNP information_NN under_IN US_NNP GAAP_NNP 27_CD Shareholder_NN information_NN 29_CD Chairman_NNP and_CC CEOs_NNS closing_VBG letter_NN JP_NNP Garnier_NNP left_VBD and_CC Sir_NNP Christopher_NNP Gent_NNP right_JJ Discovering_VBG important_JJ medicines_NNS ,_, eradicating_VBG diseases_NNS ,_, improving_VBG the_DT quality_NN of_IN peoples_NNS lives_NNS and_CC making_VBG medicines_NNS available_JJ to_TO a_DT greater_JJR number_NN of_IN people_NNS ._.
This_DT is_VBZ what_WP we_PRP do_VBP and_CC what_WP we_PRP do_VBP matters_NNS to_TO people_NNS ._.
JP_NNP Garnier_NNP ,_, Chief_NNP Executive_NNP officer_NN An_DT interview_NN with_IN Sir_NNP Christopher_NNP Gent_NNP ,_, Chairman_NNP and_CC JP_NNP Garnier_NNP ,_, Chief_NNP Executive_NNP officer_NN 2005_CD :_: a_DT year_NN of_IN success_NN and_CC progress_NN Thanks_NNS to_TO the_DT efforts_NNS of_IN our_PRP$ employees_NNS around_IN the_DT companys_NNS pipeline_NN is_VBZ one_CD of_IN the_DT largest_JJS and_CC most_RBS world_NN ,_, 2005_CD was_VBD a_DT very_RB successful_JJ year_NN for_IN GSK_NNP ,_, says_VBZ promising_JJ in_IN the_DT industry_NN ,_, with_IN 149_CD projects_NNS in_IN clinical_JJ JP_NNP Garnier_NNP ,_, Chief_NNP Executive_NNP officer_NN ._.
Not_RB only_RB was_VBD it_PRP development_NN as_IN at_IN the_DT end_NN of_IN February_NNP 2006_CD ,_, our_PRP$ best_JJS year_NN ever_RB from_IN a_DT financial_JJ standpoint_NN ,_, we_PRP also_RB including_VBG 95_CD new_JJ chemical_NN entities_NNS NCEs_NNS ,_, 29_CD product_NN made_VBN substantial_JJ progress_NN with_IN our_PRP$ pipeline_NN of_IN line_NN extensions_NNS PLEs_NNS and_CC 25_CD vaccines_NNS ._.
innovative_JJ new_JJ medicines_NNS and_CC vaccines_NNS ._.
In_IN 2006_CD ,_, we_PRP anticipate_VBP further_RB good_JJ news_NN on_IN GSKs_NNP GSK_NNP delivered_VBD an_DT excellent_JJ financial_JJ performance_NN in_IN late-stage_JJ pipeline_NN ,_, which_WDT is_VBZ developing_VBG at_IN a_DT fast_JJ pace_NN ._.
Turnover_NN of_IN 21.7_CD billion_CD grew_VBD by_IN 7_CD %_NN at_IN Eight_CD major_JJ new_JJ assets_NNS are_VBP scheduled_VBN to_TO enter_VB phase_NN constant_JJ exchange_NN rates_NNS CER_NNP ._.
Earnings_NNS per_IN share_NN EPS_NNP III_NNP in_IN 2006_CD ,_, doubling_VBG our_PRP$ late-stage_JJ pipeline_NN ,_, says_VBZ JP_NNP ._.
were_VBD 82.6_CD p_NN ,_, with_IN growth_NN of_IN 18_CD %_NN at_IN CER_NNP ,_, putting_VBG GSK_NNP in_IN the_DT top_JJ tier_NN of_IN global_JJ pharmaceutical_JJ companies_NNS in_IN The_DT pharmaceutical_JJ industry_NN is_VBZ making_VBG a_DT terms_NNS of_IN performance_NN ._.
positive_JJ improvement_NN to_TO peoples_NNS lives_NNS ._.
It_PRP These_DT gures_NNS confirm_VBP the_DT excellent_JJ growth_NN of_IN our_PRP$ key_NN has_VBZ a_DT noble_JJ purpose_NN ._.
It_PRP develops_VBZ medicines_NNS products_NNS and_CC the_DT efficiency_NN of_IN our_PRP$ global_JJ operations_NNS ,_, says_VBZ JP_NNP ._.
and_CC vaccines_NNS that_WDT save_VBP lives_NNS and_CC make_VB people_NNS feel_VB better_JJR ._.
GSKs_NNS performance_NN was_VBD driven_VBN by_IN sales_NNS of_IN key_JJ pharmaceutical_JJ products_NNS ._.
Sales_NNS of_IN Seretide_NNP Advair_NNP ,_, Sir_NNP Christopher_NNP Gent_NNP ,_, Chairman_NNP Avandia_NNP ,_, Coreg_NNP ,_, Lamictal_NNP and_CC Valtrex_NNP all_DT continued_VBD their_PRP$ impressive_JJ growth_NN ,_, says_VBZ JP_NNP ._.
We_PRP also_RB saw_VBD good_JJ Year_NN of_IN the_DT vaccine_NN performance_NN from_IN a_DT number_NN of_IN newer_JJR products_NNS ,_, 2005_CD was_VBD a_DT landmark_NN year_NN for_IN GSKs_NNS vaccines_NNS including_VBG Avodart_NNP for_IN enlarging_VBG prostate_NN ,_, Boniva_NNP business_NN ._.
Sales_NNS increased_VBN by_IN 15_CD %_NN and_CC the_DT company_NN Bonviva_NNP for_IN osteoporosis_NN and_CC Requip_NNP for_IN Restless_NNP Legs_NNP made_VBD a_DT number_NN of_IN significant_JJ strategic_JJ acquisitions_NNS ._.
Syndrome_NN ,_, which_WDT all_DT show_VBP great_JJ promise_NN for_IN the_DT The_DT acquisition_NN of_IN ID_NNP Biomedical_NNP was_VBD an_DT important_JJ future_NN ,_, both_DT for_IN patients_NNS and_CC GSK_NNP ._.
move_NN for_IN GSK_NNP ,_, says_VBZ JP_NNP ,_, which_WDT strengthened_VBD our_PRP$ Looking_VBG into_IN 2006_CD ,_, the_DT strong_JJ growth_NN seen_VBN from_IN key_JJ position_NN in_IN the_DT global_JJ u_NN vaccine_NN market_NN ,_, and_CC products_NNS and_CC from_IN our_PRP$ vaccines_NNS business_NN is_VBZ expected_VBN to_TO increased_VBN our_PRP$ ability_NN to_TO prepare_VB for_IN and_CC respond_VB to_TO a_DT continue_VB and_CC we_PRP anticipate_VBP an_DT EPS_NNP growth_NN of_IN around_IN potential_JJ u_NN pandemic_NN ._.
We_PRP also_RB acquired_VBD a_DT plant_NN in_IN Marietta_NNP ,_, Pennsylvania_NNP Pipeline_NNP progress_NN which_WDT will_MD give_VB us_PRP access_NN to_TO tissue_NN culture_NN technology_NN GSK_NNP continues_VBZ to_TO meet_VB the_DT challenge_NN of_IN increasing_VBG in_IN our_PRP$ vaccine_NN manufacturing_NN ._.
The_DT acquisition_NN of_IN Corixa_NNP Research_NNP &_CC Development_NNP R&D_NNP productivity_NN to_TO discover_VB gives_VBZ us_PRP valuable_JJ adjuvant_JJ technology_NN ,_, enabling_VBG us_PRP to_TO new_JJ medicines_NNS faster_RBR and_CC more_RBR economically_RB ._.
The_DT boost_NN human_JJ immune_JJ response_NN to_TO our_PRP$ vaccines_NNS ._.
GSK_NNP Annual_JJ Review_NNP 2005_CD 01_CD Private_JJ sector_NN expertise_NN is_VBZ critical_JJ for_IN making_VBG rapid_JJ progress_NN ._.
In_IN particular_JJ ,_, I_PRP would_MD like_VB to_TO thank_VB GSK_NNP for_IN its_PRP$ commitment_NN to_TO R&D_NNP on_IN malaria_NN and_CC on_IN other_JJ neglected_VBN diseases_NNS ._.
It_PRP would_MD make_VB a_DT huge_JJ difference_NN if_IN more_JJR companies_NNS followed_VBD GSKs_NNS example_NN ._.
Bill_NNP Gates_NNP Bill_NNP &_CC Melinda_NNP Gates_NNP Foundation_NNP ,_, October_NNP 2005_CD 3,000_CD Each_DT day_NN ,_, malaria_NN causes_VBZ the_DT death_NN of_IN about_IN 3,000_CD people_NNS in_IN sub-Saharan_JJ Africa_NNP ._.
Most_JJS of_IN them_PRP are_VBP children_NNS ._.
GSK_NNP is_VBZ working_VBG in_IN publicprivate_NN partnerships_NNS to_TO create_VB safe_JJ and_CC effective_JJ vaccines_NNS and_CC treatments_NNS against_IN malaria_NN ._.
com_NN On_IN this_DT page_NN you_PRP will_MD nd_VB :_: Access_NN to_TO medicines_NNS :_: Reaching_VBG out_RP to_TO patients_NNS :_: Humanitarian_JJ response_NN :_: JP_NNP in_IN Africa_NNP GSK_NNP also_RB made_VBD good_JJ progress_NN on_IN its_PRP$ pipeline_NN of_IN new_JJ Islands_NNP of_IN hope_NN vaccines_NNS ._.
We_PRP expect_VBP five_CD major_JJ vaccine_NN launches_NNS in_IN In_IN late_JJ 2005_CD ,_, JP_NNP visited_VBD Ghana_NNP and_CC South_NNP Africa_NNP to_TO see_VB the_DT next_JJ five_CD years_NNS ,_, says_VBZ JP_NNP ._.
Perhaps_RB most_RBS exciting_JJ is_VBZ some_DT of_IN GSKs_NNS community_NN activities_NNS ._.
In_IN Ghana_NNP ,_, he_PRP heard_VBD Cervarix_NNP for_IN cervical_JJ cancer_NN ,_, which_WDT we_PRP expect_VBP to_TO le_FW for_IN how_WRB villagers_NNS cope_VB with_IN lymphatic_JJ lariasis_NN LF_NNP or_CC elephantiasis_NN ._.
LF_NNP is_VBZ a_DT disease_NN that_IN the_DT company_NN ,_, working_VBG approval_NN in_IN Europe_NNP in_IN March_NNP 2006_CD and_CC in_IN the_DT USA_NNP by_IN with_IN the_DT World_NNP Health_NNP Organization_NNP ,_, is_VBZ striving_VBG to_TO eradicate_VB the_DT end_NN of_IN the_DT year_NN ._.
This_DT LF_NN program_NN has_VBZ reached_VBN its_PRP$ target_NN in_IN Ghana_NNP of_IN treating_VBG all_DT ten_CD million_CD people_NNS at_IN risk_NN from_IN the_DT Improving_NN access_NN to_TO medicines_NNS disease_NN ._.
In_IN South_NNP Africa_NNP ,_, JP_NNP saw_VBD the_DT impact_NN of_IN HIV_NNP AIDS_NNP GSK_NNP continues_VBZ to_TO seek_VB new_JJ ways_NNS of_IN improving_VBG access_NN and_CC the_DT work_NN of_IN volunteers_NNS in_IN a_DT GSK-supported_JJ clinic_NN to_TO its_PRP$ medicines_NNS for_IN people_NNS who_WP need_VBP them_PRP ,_, but_CC are_VBP north_RB of_IN Johannesburg_NNP ._.
least_JJS able_JJ to_TO obtain_VB them_PRP ._.
This_DT challenge_NN is_VBZ particularly_RB It_PRP was_VBD shocking_JJ and_CC humbling_JJ ,_, yet_RB even_RB in_IN this_DT sea_NN of_IN acute_JJ in_IN the_DT developing_VBG world_NN ,_, where_WRB GSK_NNP has_VBZ been_VBN distress_NN there_EX are_VBP islands_NNS of_IN hope_NN ._.
I_PRP was_VBD inspired_VBN by_IN the_DT offering_NN many_JJ of_IN its_PRP$ medicines_NNS and_CC vaccines_NNS at_IN not-forpeople_NN who_WP have_VBP dedicated_VBN their_PRP$ lives_NNS to_TO working_VBG in_IN these_DT profit_NN prices_NNS for_IN some_DT years_NNS ._.
I_PRP was_VBD able_JJ to_TO witness_NN the_DT realities_NNS of_IN Africa_NNP and_CC whats_NNS really_RB important_JJ there_RB ,_, says_VBZ JP_NNP ._.
I_PRP am_VBP proud_JJ of_IN the_DT However_RB ,_, addressing_VBG this_DT challenge_NN is_VBZ something_NN GSK_NNP role_NN that_WDT GSK_NNP is_VBZ playing_VBG ._.
I_PRP am_VBP grateful_JJ to_TO have_VB experienced_VBN can_MD not_RB do_VB alone_RB ._.
The_DT work_NN of_IN GSK_NNP with_IN organizations_NNS these_DT things_NNS and_CC ,_, crucially_RB ,_, to_TO be_VB in_IN a_DT position_NN to_TO do_VB such_JJ as_IN the_DT Bill_NNP &_CC Melinda_NNP Gates_NNP Foundation_NNP highlights_VBZ something_NN about_IN it_PRP ._.
My_PRP$ determination_NN to_TO do_VB more_JJR has_VBZ the_DT benets_NNS of_IN public-private_JJ partnerships_NNS ._.
provide_VB a_DT way_NN for_IN companies_NNS such_JJ as_IN GSK_NNP and_CC the_DT private_JJ sector_NN to_TO work_VB together_RB ._.
Typically_RB ,_, GSK_NNP provides_VBZ the_DT R&D_NNP ,_, technology_NN ,_, manufacturing_NN and_CC distribution_NN expertise_NN ,_, while_IN other_JJ partners_NNS and_CC governments_NNS help_VBP fund_VB the_DT development_NN and_CC delivery_NN costs_NNS ._.
Public-private_JJ partnerships_NNS use_VBP the_DT respective_JJ strengths_NNS of_IN the_DT partners_NNS and_CC bring_VB out_RP the_DT best_JJS of_IN each_DT ._.
Most_JJS importantly_RB ,_, it_PRP is_VBZ a_DT model_NN that_WDT works_VBZ ._.
In_IN 2005_CD ,_, GSK_NNP entered_VBD three_CD groundbreaking_VBG publicprivate_NN partnerships_NNS to_TO develop_VB vaccines_NNS against_IN the_DT biggest_JJS causes_NNS of_IN death_NN in_IN the_DT developing_VBG world_NN today_NN AIDS_NNP ,_, malaria_NN and_CC tuberculosis_NN ._.
The_DT year_NN saw_VBD a_DT number_NN of_IN natural_JJ disasters_NNS ,_, including_VBG Reaching_VBG out_RP to_TO patients_NNS the_DT Asian_JJ tsunami_NN ,_, the_DT Guatemalan_NNP hurricane_NN ,_, the_DT In_NNP 2005_CD ,_, GSK_NNP introduced_VBD and_CC strengthened_VBD a_DT number_NN New_NNP Orleans_NNP oods_NNS and_CC the_DT earthquake_NN that_WDT struck_VBD of_IN initiatives_NNS aimed_VBN at_IN improving_VBG patients_NNS understanding_VBG parts_NNS of_IN India_NNP and_CC Pakistan_NNP ._.
GSK_NNP was_VBD quick_JJ to_TO respond_VB of_IN GSKs_NNS medicines_NNS ,_, and_CC programs_NNS to_TO help_VB gain_VB access_NN to_TO help_VB victims_NNS of_IN these_DT tragedies_NNS ._.
These_DT initiatives_NNS include_VBP GSKs_NNP pioneering_JJ our_PRP$ employees_NNS for_IN their_PRP$ response_NN to_TO these_DT crises_NNS ._.
It_PRP Clinical_JJ Trial_NNP Register_NNP ,_, which_WDT was_VBD expanded_VBN to_TO contain_VB makes_NNS me_PRP proud_JJ to_TO lead_VB an_DT organization_NN with_IN such_JJ 2,125_CD summaries_NNS of_IN clinical_JJ trials_NNS by_IN the_DT end_NN of_IN 2005_CD ._.
committed_JJ and_CC compassionate_JJ people_NNS ,_, who_WP can_MD respond_VB so_RB effectively_RB to_TO help_VB people_NNS in_IN real_JJ need_NN ,_, In_IN the_DT USA_NNP ,_, GSK_NNP is_VBZ placing_VBG more_JJR emphasis_NN on_IN says_VBZ JP_NNP ._.
education_NN and_CC the_DT patient_NN in_IN direct-to-consumer_NN advertising_NN ,_, and_CC providing_VBG people_NNS with_IN advice_NN on_IN GSKs_NNP For_IN these_DT disasters_NNS alone_RB ,_, GSK_NNP contributed_VBD more_JJR than_IN programs_NNS and_CC the_DT industrys_NNS Partnerships_NNS for_IN 3_CD million_CD in_IN cash_NN and_CC donated_VBD medicines_NNS and_CC vaccines_NNS Prescriptions_NNP Assistance_NNP which_WDT help_VBP people_NNS gain_VB access_NN valued_VBN at_IN over_IN 14_CD million_CD towards_IN the_DT relief_NN efforts_NNS ._.
to_TO the_DT medicines_NNS they_PRP need_VBP ._.
The_DT tragedies_NNS during_IN the_DT year_NN brought_VBD home_NN to_TO me_PRP Through_IN these_DT and_CC other_JJ initiatives_NNS ,_, we_PRP are_VBP seeking_VBG the_DT extent_NN to_TO which_WDT the_DT pharmaceutical_JJ industry_NN is_VBZ to_TO differentiate_VB GSK_NNP as_IN a_DT company_NN nding_VBG solutions_NNS making_VBG a_DT positive_JJ improvement_NN to_TO peoples_NNS lives_NNS ,_, says_VBZ to_TO the_DT healthcare_NN challenges_VBZ that_IN society_NN faces_NNS ._.
It_PRP develops_VBZ I_PRP believe_VBP we_PRP are_VBP well_RB on_IN the_DT way_NN to_TO achieving_VBG that_IN ,_, medicines_NNS and_CC vaccines_NNS that_WDT save_VBP lives_NNS and_CC make_VB says_VBZ Sir_NNP Christopher_NNP Gent_NNP ,_, Chairman_NNP ._.
A_DT broader_JJR contribution_NN GSK_NNP 's_POS global_JJ community_NN investment_NN activities_NNS in_IN 2005_CD were_VBD valued_VBN at_IN 380_CD million_CD ,_, equivalent_JJ to_TO 5.6_CD %_NN of_IN Group_NNP profit_NN before_IN tax_NN ._.
GSK_NNP Annual_JJ Review_NNP 2005_CD 03_CD For_IN our_PRP$ work_NN at_IN GSK_NNP ,_, we_PRP 149_CD GSK_NNP had_VBD 149_CD projects_NNS in_IN seek_VBP greater_JJR insight_NN into_IN the_DT clinic_NN at_IN the_DT end_NN of_IN February_NNP 2006_CD ._.
This_DT included_VBD 95_CD new_JJ chemical_NN the_DT needs_NNS of_IN patients_NNS entities_NNS NCEs_NNS ,_, an_DT increase_NN of_IN 70_CD %_NN over_IN 2001_CD ._.
and_CC to_TO apply_VB these_DT insights_NNS in_IN R&D_NNP to_TO Moncef_NNP Slaoui_NNP pictured_VBD right_RB ,_, will_MD succeed_VB Tachi_NNP create_VB better_JJR medicines_NNS ._.
Yamada_NNP left_VBD as_IN head_NN of_IN R&D_NNP in_IN June_NNP 2006_CD ._.
Tachi_NNP Yamada_NNP ,_, Chairman_NNP ,_, Research_NNP &_CC Development_NNP ,_, Pharmaceuticals_NNP On_IN this_DT page_NN you_PRP will_MD nd_VB :_: Patient_NN insight_NN :_: Partnerships_NNS :_: Maturing_VBG pipeline_NN :_: Confronting_VBG cancer_NN Tachi_NNP Yamada_NNP ,_, Chairman_NNP ,_, Research_NNP &_CC Development_NNP ,_, Pharmaceuticals_NNP Focus_NNP on_IN the_DT patient_JJ Applying_VBG insights_NNS in_IN R&D_NNP for_IN the_DT creation_NN of_IN better_JJR medicines_NNS Tachi_NNP Yamada_NNP was_VBD a_DT physician_NN and_CC teacher_NN of_IN physicians_NNS Confronting_VBG cancer_NN before_IN he_PRP joined_VBD GSK_NNP to_TO work_VB with_IN scientists_NNS and_CC other_JJ Cancer_NN remains_VBZ an_DT area_NN of_IN substantial_JJ unmet_JJ medical_JJ need_NN ._.
He_PRP retains_VBZ a_DT passion_NN for_IN helping_VBG Our_PRP$ strategy_NN is_VBZ focused_VBN on_IN meeting_NN all_DT aspects_NNS of_IN a_DT cancer_NN improve_VB the_DT quality_NN of_IN life_NN for_IN patients_NNS and_CC his_PRP$ patients_NNS treatment_NN ,_, says_VBZ Tachi_NNP ._.
GSK_NNP is_VBZ building_VBG on_IN its_PRP$ existing_VBG oncology_JJ portfolio_NN to_TO good_JJ effect_NN ._.
We_PRP now_RB have_VBP experience_NN as_IN a_DT physician_NN has_VBZ inuenced_VBN his_PRP$ work_NN as_IN an_DT oncology_JJ pipeline_NN which_WDT is_VBZ one_CD of_IN the_DT strongest_JJS and_CC head_NN of_IN R&D_NNP for_IN GSK_NNP ._.
most_RBS promising_JJ in_IN our_PRP$ industry_NN ._.
In_IN November_NNP 2005_CD ,_, investors_NNS and_CC financial_JJ analysts_NNS were_VBD updated_VBN on_IN this_DT In_IN the_DT hospital_NN wards_NNS ,_, I_PRP would_MD sometimes_RB place_VB a_DT rapidly_RB expanding_VBG pipeline_NN ._.
In_IN 2006_CD ,_, GSK_NNP expects_VBZ four_CD new_JJ photograph_NN of_IN the_DT patient_NN above_IN their_PRP$ bed_NN ,_, says_VBZ Tachi_NNP ._.
oncology_JJ medicines_NNS to_TO be_VB in_IN final-stage_JJ clinical_JJ trials_NNS Tykerb_NNP The_DT picture_NN showed_VBD them_PRP when_WRB they_PRP were_VBD active_JJ and_CC lapatinib_NN for_IN breast_NN cancer_NN ,_, eltrombopag_NN for_IN patients_NNS with_IN healthy_JJ ,_, and_CC I_PRP would_MD then_RB challenge_VB my_PRP$ staff_NN to_TO work_VB low_JJ platelet_NN count_NN ,_, casopitant_NN to_TO help_VB patients_NNS overcome_VB towards_IN the_DT goal_NN of_IN helping_VBG the_DT patient_NN back_RB to_TO being_VBG the_DT side-effects_NNS of_IN chemotherapy_JJ and_CC pazopanib_NN for_IN like_IN the_DT person_NN in_IN the_DT picture_NN ._.
I_PRP would_MD urge_VB them_PRP to_TO prevention_NN of_IN tumor_NN growth_NN ._.
focus_NN on_IN the_DT patient_NN and_CC their_PRP$ needs_NNS ._.
Today_NN ,_, it_PRP is_VBZ the_DT same_JJ approach_NN for_IN our_PRP$ work_NN at_IN GSK_NNP ,_, where_WRB we_PRP seek_VBP greater_JJR insight_NN into_IN the_DT needs_NNS of_IN patients_NNS and_CC to_TO apply_VB these_DT insights_NNS in_IN R&D_NNP to_TO create_VB better_JJR medicines_NNS ._.
GSK_NNP projects_NNS in_IN clinical_JJ development_NN As_IN at_IN February_NNP 2006_CD 149_CD 11_CD 118_CD 38_CD %_NN of_IN pipeline_NN 46_CD Late_JJ stage_NN 12_CD 26_CD %_NN of_IN growth_NN pipeline_NN 19_CD 38_CD 25_CD 41_CD 29_CD 25 21 2001 2005_CD New_NNP Chemical_NNP Entities_NNPS NCEs_NNPS NCEs_NNPS Phase_NN I_PRP Phase_NN III_NNP registration_NN Product_NNP Line_NNP Extensions_NNPS NCEs_NNP Phase_NN II_NNP Vaccines_NNP registration_NN ,_, 46_CD NCEs_NNS and_CC 9_CD vaccines_NNS were_VBD in_IN phase_NN II_NNP and_CC 38_CD NCEs_NNS and_CC 7_CD vaccines_NNS were_VBD in_IN phase_NN I._NN This_DT is_VBZ an_DT increase_NN of_IN 70_CD %_NN over_IN the_DT number_NN of_IN NCEs_NNS that_WDT GSK_NNP Tachi_NNP and_CC his_PRP$ teams_NNS also_RB talk_VBP to_TO doctors_NNS and_CC other_JJ had_VBD at_IN the_DT end_NN of_IN 2001_CD ._.
healthcare_NN experts_NNS to_TO gather_VB information_NN that_WDT will_MD help_VB shape_VB the_DT direction_NN and_CC priorities_NNS of_IN the_DT complex_JJ R&D_NNP process_NN that_WDT leads_VBZ to_TO innovative_JJ medicines_NNS of_IN There_EX has_VBZ been_VBN a_DT marked_JJ increase_NN in_IN the_DT value_NN ._.
Through_IN a_DT range_NN of_IN partnerships_NNS ,_, the_DT company_NN size_NN of_IN our_PRP$ NCE_NNP portfolio_NN and_CC an_DT increasing_VBG has_VBZ access_NN to_TO the_DT talent_NN ,_, ideas_NNS and_CC assets_NNS beyond_IN the_DT maturity_NN of_IN the_DT pipeline_NN ._.
boundaries_NNS of_IN its_PRP$ own_JJ R&D_NNP organization_NN ._.
In_IN 2005_CD ,_, GSK_NNP set_VBD up_RP a_DT new_JJ internal_JJ management_NN team_NN to_TO Seven_CD product_NN lings_NNS are_VBP planned_VBN for_IN 2006_CD ,_, including_VBG deliver_VB more_JJR compounds_NNS through_IN partnerships_NNS with_IN two_CD vaccines_NNS Cervarix_NNP for_IN cervical_JJ cancer_NN and_CC a_DT biotechnology_NN companies_NNS ,_, small_JJ and_CC mid-sized_JJ potential_JJ H5N1_NNP pandemic_NN u_NN vaccine_NN see_VBP pages_NNS 6_CD pharmaceutical_JJ companies_NNS and_CC academic_JJ institutions_NNS ._.
and_CC 8_CD ,_, Allermist_NNP for_IN allergic_JJ rhinitis_NNS ,_, eltrombopag_NN for_IN A_DT maturing_VBG pipeline_NN patients_NNS with_IN low_JJ platelet_NN count_NN ,_, Tykerb_NNP for_IN breast_NN The_DT strength_NN of_IN GSKs_NNS work_VBP on_IN medicines_NNS and_CC vaccines_NNS cancer_NN ,_, mepolizumab_NN for_IN hypereosinophilic_JJ syndrome_NN of_IN the_DT future_NN can_MD be_VB seen_VBN in_IN the_DT product_NN development_NN and_CC Lamictal_JJ XR_NNP ,_, a_DT once-daily_JJ formulation_NN for_IN epilepsy_NN ._.
pipeline_NN ,_, one_CD that_WDT is_VBZ growing_VBG and_CC maturing_VBG ._.
At_IN the_DT end_NN of_IN February_NNP 2006_CD ,_, the_DT company_NN had_VBD 149_CD projects_NNS in_IN GSK_NNP also_RB expects_VBZ eight_CD major_JJ new_JJ assets_NNS to_TO enter_VB the_DT clinic_NN including_VBG 95_CD new_JJ chemical_NN entities_NNS NCEs_NNS ,_, 25_CD phase_NN III_NNP development_NN during_IN 2006_CD ,_, signicantly_RB vaccines_NNS and_CC 29_CD product_NN line_NN extensions_NNS PLEs_NNS ._.
Of_IN expanding_VBG the_DT late-stage_JJ pipeline_NN ._.
In_IN addition_NN to_TO the_DT these_DT ,_, 11_CD NCEs_NNS and_CC 9_CD vaccines_NNS were_VBD in_IN phase_NN III_NNP oncology_NN products_NNS ,_, casopitant_NN and_CC pazopanib_NN see_VBP GSK_NNP Annual_JJ Review_NNP 2005_CD 05_CD On_IN this_DT page_NN you_PRP will_MD nd_VB :_: Delivering_VBG medicines_NNS of_IN value_NN :_: Vaccines_NNS performance_NN :_: Vaccines_NNS pipeline_NN :_: Vaccines_NNS investment_NN Confronting_VBG cancer_NN page_NN 5_CD ,_, GSK_NNP expects_VBZ new_JJ assets_NNS Delivering_VBG medicines_NNS of_IN value_NN for_IN Alzheimers_NNP disease_NN ,_, HIV_NNP ,_, meningitis_NN ,_, lupus_NN and_CC GSK_NNP has_VBZ one_CD of_IN the_DT most_RBS promising_JJ pipelines_NNS in_IN the_DT diabetes_NN to_TO enter_VB phase_NN III_NNP development_NN ._.
Our_PRP$ challenge_NN ,_, going_VBG forward_RB ,_, is_VBZ to_TO deliver_VB to_TO patients_NNS the_DT many_JJ medicines_NNS we_PRP have_VBP in_IN There_EX has_VBZ been_VBN a_DT marked_JJ increase_NN in_IN the_DT size_NN of_IN our_PRP$ development_NN ,_, whilst_NN continuing_VBG to_TO grow_VB the_DT NCE_NNP portfolio_NN and_CC an_DT increasing_JJ maturity_NN of_IN the_DT pipeline_NN ,_, says_VBZ Moncef_NNP Slaoui_NNP ,_, who_WP will_MD succeed_VB pipeline_NN ._.
All_PDT this_DT indicates_VBZ that_IN the_DT way_NN we_PRP structure_VBP Tachi_NNP as_IN Chairman_NNP ,_, R&D_NNP ,_, in_IN June_NNP 2006_CD ._.
Along_IN with_IN R&D_NNP is_VBZ paying_VBG off_RP ,_, says_VBZ Tachi_NNP ,_, who_WP is_VBZ retiring_VBG from_IN GSK_NNP my_PRP$ colleagues_NNS in_IN R&D_NNP ,_, we_PRP are_VBP embracing_VBG this_DT in_IN June_NNP 2006_CD to_TO take_VB up_RP a_DT new_JJ role_NN as_IN Executive_NNP challenge_NN and_CC we_PRP fully_RB expect_VBP to_TO be_VB able_JJ to_TO deliver_VB Director_NNP of_IN the_DT Global_NNP Health_NNP Program_NNP for_IN the_DT Bill_NNP &_CC medicines_NNS of_IN great_JJ value_NN for_IN patients_NNS and_CC for_IN GSK_NNP in_IN Melinda_NNP Gates_NNP Foundation_NNP ._.
Jean_NNP Stphenne_NNP ,_, President_NNP and_CC General_NNP Manager_NNP ,_, GSK_NNP Biologicals_NNPS The_DT year_NN of_IN the_DT vaccine_NN Strong_JJ growth_NN and_CC a_DT promising_JJ pipeline_NN GSK_NNP is_VBZ a_DT world-leading_JJ supplier_NN of_IN vaccines_NNS ._.
Our_PRP$ an_DT improved_VBN inuenza_NN vaccine_NN for_IN older_JJR people_NNS :_: and_CC vaccines_NNS business_NN had_VBD one_CD of_IN its_PRP$ best_JJS years_NNS ,_, with_IN sales_NNS vaccine_NN combinations_NNS against_IN meningitis_NNS ._.
growing_VBG by_IN 15_CD %_NN to_TO 1.4_CD billion_CD ,_, says_VBZ Jean_NNP Stphenne_NNP ,_, We_PRP know_VBP more_RBR about_IN the_DT bodys_NNS immune_JJ system_NN and_CC President_NNP and_CC General_NNP Manager_NNP of_IN GSK_NNP Biologicals_NNPS ,_, the_DT how_WRB it_PRP works_VBZ than_IN ever_RB before_RB ,_, which_WDT enables_VBZ us_PRP to_TO companys_NNS vaccines_NNS business_NN ._.
This_DT growth_NN was_VBD led_VBN by_IN produce_NN safer_JJR ,_, stronger_JJR and_CC more_RBR targeted_JJ vaccines_NNS ,_, Infanrix_NNP and_CC helped_VBN by_IN the_DT launches_NNS of_IN Boostrix_NNP and_CC says_VBZ Jean_NNP ._.
Our_PRP$ pipeline_NN of_IN vaccines_NNS promises_VBZ real_JJ opporFluarix_NNP in_IN the_DT USA_NNP ._.
This_DT ,_, together_RB with_IN a_DT strong_JJ product_NN tunities_NNS to_TO improve_VB the_DT quality_NN of_IN health_NN worldwide_NN ._.
pipeline_NN ,_, gives_VBZ us_PRP confidence_NN in_IN the_DT future_JJ prospects_NNS for_IN our_PRP$ business_NN ._.
Vaccines_NNS investment_NN In_IN 2005_CD ,_, GSK_NNP made_VBD a_DT number_NN of_IN moves_NNS to_TO be_VB a_DT major_JJ Vaccines_NNS pipeline_NN force_NN in_IN vaccines_NNS against_IN inuenza_NN ,_, the_DT subject_NN of_IN With_IN 60_CD years_NNS experience_NN ,_, the_DT company_NN continues_VBZ to_TO heightened_VBN global_JJ concern_NN during_IN the_DT year_NN ._.
The_DT build_VBP a_DT very_RB productive_JJ R&D_NNP pipeline_NN and_CC ,_, in_IN the_DT next_JJ company_NN invested_VBD over_IN 1_CD billion_CD to_TO expand_VB its_PRP$ u_JJ five_CD years_NNS ,_, expects_VBZ five_CD major_JJ new_JJ vaccines_NNS to_TO be_VB vaccine_NN manufacturing_NN capabilities_NNS ._.
One_CD of_IN these_DT is_VBZ Cervarix_NNP ,_, for_IN the_DT prevention_NN than_IN doubling_VBG u_JJ vaccine_NN production_NN capacity_NN at_IN its_PRP$ of_IN human_JJ papilloma_NN virus_NN HPV_NNP ,_, which_WDT causes_VBZ cervical_JJ Dresden_NNP site_NN to_TO 80_CD million_CD doses_NNS a_DT year_NN by_IN 2008_CD ._.
GSK_NNP cancer_NN a_DT disease_NN second_JJ only_RB to_TO breast_NN cancer_NN in_IN the_DT also_RB acquired_VBN the_DT Canadian_JJ vaccine_NN manufacturer_NN ID_NNP list_NN of_IN most_JJS common_JJ cancers_NNS affecting_VBG women_NNS ._.
Global_JJ clinical_JJ trials_NNS have_VBP shown_VBN that_IN Cervarix_NNP provides_VBZ Annual_JJ epidemic_JJ excellent_JJ efcacy_NN against_IN HPV16_NNP and_CC HPV18_NNP ,_, which_WDT A_DT seasonal_JJ epidemic_NN ,_, inuenza_NN is_VBZ a_DT significant_JJ economic_JJ are_VBP responsible_JJ for_IN over_IN 70_CD %_NN of_IN cervical_JJ cancers_NNS ._.
burden_NN through_IN hospital_NN and_CC other_JJ healthcare_NN costs_NNS as_RB well_RB as_IN lost_VBN productivity_NN ._.
The_DT World_NNP Health_NNP Organization_NNP says_VBZ an_DT estimated_VBN 5-15_CD %_NN of_IN the_DT global_JJ population_NN is_VBZ affected_VBN with_IN Our_PRP$ pipeline_NN of_IN vaccines_NNS promises_VBZ real_JJ upper_JJ respiratory_JJ tract_NN infections_NNS each_DT year_NN ._.
Although_IN difopportunities_NNS to_TO improve_VB the_DT quality_NN cult_NN to_TO assess_VB ,_, annual_JJ u_NN epidemics_NNS are_VBP thought_VBN to_TO result_VB in_IN 250,000-500_CD ,000_CD deaths_NNS every_DT year_NN around_IN the_DT world_NN ._.
Cervarix_NNP is_VBZ a_DT genuine_JJ breakthrough_NN in_IN womens_NNS healthcare_NN ._.
It_PRP meets_VBZ a_DT clear_JJ medical_JJ need_NN and_CC the_DT sheer_JJ volume_NN of_IN women_NNS who_WP will_MD benefit_VB gives_VBZ it_PRP great_JJ potential_JJ ,_, says_VBZ Jean_NNP ._.
Cervarix_NNP is_VBZ expected_VBN to_TO be_VB submitted_VBN for_IN European_NNP Union_NNP approval_NN in_IN March_NNP 2006_CD and_CC in_IN the_DT USA_NNP before_IN the_DT end_NN of_IN the_DT year_NN ._.
The_DT other_JJ major_JJ new_JJ products_NNS expected_VBN in_IN the_DT next_JJ five_CD years_NNS will_MD be_VB Rotarix_NNP ,_, for_IN rotavirus_NN gastroenteritis_NNS already_RB launched_VBN in_IN a_DT number_NN of_IN countries_NNS in_IN Latin_NNP America_NNP ,_, Africa_NNP and_CC Asia_NNP ,_, with_IN launch_NN in_IN Europe_NNP expected_VBN in_IN the_DT first_JJ half_NN of_IN 2006_CD :_: Streptorix_NNP ,_, for_IN pneumococcal_JJ disease_NN :_: GSK_NNP Annual_JJ Review_NNP 2005_CD 06_CD With_IN vaccines_NNS ,_, 25_CD GSK_NNP had_VBD 25_CD vaccines_NNS in_IN the_DT greatest_JJS successes_NNS are_VBP clinical_JJ development_NN at_IN the_DT end_NN of_IN 2005_CD ,_, with_IN five_CD major_JJ vaccine_NN launches_NNS those_DT we_PRP do_VBP not_RB know_VB about_IN anticipated_VBN in_IN the_DT next_JJ five_CD years_NNS ._.
the_DT people_NNS who_WP have_VBP not_RB suffered_VBN or_CC died_VBN Egg-based_JJ vaccines_NNS are_VBP produced_VBN at_IN Dresden_NNP ,_, Germany_NNP pictured_VBD ,_, from_IN vaccine-preventable_JJ diseases_NNS ._.
where_WRB GSK_NNP is_VBZ more_RBR than_IN doubling_VBG u_JJ vaccine_NN Jean_NNP Stphenne_NNP ,_, President_NNP and_CC General_NNP Manager_NNP ,_, GSK_NNP Biologicals_NNPS production_NN capacity_NN ._.
On_IN this_DT page_NN you_PRP will_MD nd_VB :_: Preparing_VBG for_IN a_DT u_JJ pandemic_NN :_: Consumer_NNP Healthcare_NNP business_NN model_NN :_: Growth_NN opportunity_NN :_: Beating_NN tobacco_NN Biomedical_NNP and_CC a_DT vaccines_NNS production_NN facility_NN in_IN Preparing_VBG for_IN a_DT u_JJ pandemic_JJ Marietta_NNP ,_, Pennsylvania_NNP ,_, which_WDT will_MD focus_VB on_IN the_DT GSK_NNP is_VBZ committed_VBN to_TO doing_VBG everything_NN it_PRP can_MD to_TO development_NN and_CC production_NN of_IN tissue_NN culture_NN support_NN governments_NNS and_CC health_NN authorities_NNS around_IN technology_NN that_WDT will_MD be_VB used_VBN for_IN seasonal_JJ and_CC pandemic_JJ the_DT world_NN in_IN planning_VBG responses_NNS to_TO a_DT possible_JJ global_JJ u_NN vaccines_NNS ._.
The_DT company_NN also_RB purchased_VBD Corixa_NNP in_IN the_DT inuenza_NN pandemic_NN ._.
The_DT company_NN is_VBZ developing_VBG a_DT USA_NNP ,_, a_DT developer_NN of_IN adjuvants_NNS ,_, which_WDT are_VBP agents_NNS that_IN prototype_NN H5N1_CD pandemic_JJ vaccine_NN ,_, and_CC clinical_JJ trials_NNS boost_VBP human_JJ immune_JJ response_NN to_TO vaccine_NN antigens_NNS ._.
testing_NN this_DT vaccine_NN against_IN the_DT H5N1_NNP u_NN strain_NN are_VBP taking_VBG place_NN in_IN 2006_CD ._.
This_DT prototype_NN uses_VBZ an_DT innovative_JJ With_IN approval_NN in_IN 2005_CD by_IN the_DT US_NNP Food_NNP and_CC Drug_NNP adjuvant_JJ which_WDT may_MD allow_VB lower_JJR amounts_NNS of_IN antigen_NN Administration_NNP FDA_NNP ,_, Fluarix_NNP became_VBD the_DT first_JJ to_TO be_VB used_VBN ,_, which_WDT is_VBZ essential_JJ for_IN manufacturing_VBG a_DT large_JJ biological_JJ product_NN to_TO be_VB reviewed_VBN under_IN accelerated_VBN number_NN of_IN doses_NNS in_IN the_DT event_NN of_IN a_DT pandemic_NN ._.
The_DT shortage_NN of_IN u_JJ vaccine_NN in_IN also_RB invested_VBN to_TO signicantly_RB increase_VB production_NN the_DT USA_NNP in_IN 2004_CD was_VBD a_DT reminder_NN of_IN the_DT importance_NN of_IN capacity_NN of_IN GSKs_NNS antiviral_JJ Relenza_NNP to_TO help_VB meet_VB vaccines_NNS in_IN healthcare_NN ,_, says_VBZ Jean_NNP ._.
We_PRP worked_VBD quickly_RB increased_VBN global_JJ demand_NN ._.
Work_NN is_VBZ going_VBG on_IN across_IN with_IN US_NNP government_NN ofcials_NNS to_TO make_VB Fluarix_NNP available_JJ GSK_NNP to_TO anticipate_VB and_CC address_VB all_DT aspects_NNS of_IN a_DT potential_JJ and_CC increase_VB supply_NN at_IN a_DT critical_JJ time_NN ._.
John_NNP Clarke_NNP ,_, President_NNP ,_, Consumer_NNP Healthcare_NNP Growing_VBG brands_NNS Product_NNP innovation_NN aligned_VBN to_TO consumers_NNS needs_VBZ Aquafresh_NNP and_CC Sensodyne_NNP toothpaste_NN ,_, Nicorette_NNP and_CC to_TO be_VB launched_VBN in_IN 2006_CD ,_, accompanied_VBN by_IN a_DT consumer_NN NicoDerm_NNP smoking_NN cessation_NN products_NNS ,_, and_CC Ribena_NNP education_NN program_NN ._.
Like_IN stopping_VBG smoking_NN ,_, weight_NN and_CC Lucozade_NNP drinks_NNS are_VBP among_IN the_DT products_NNS that_WDT loss_NN requires_VBZ a_DT change_NN in_IN behavior_NN ._.
Often_RB ,_, though_IN ,_, make_VB GSK_NNP Consumer_NNP Healthcare_NNP a_DT leading_VBG physicians_NNS dont_NN have_VBP the_DT training_NN or_CC the_DT time_NN to_TO help_VB manufacturer_NN and_CC marketer_NN of_IN consumer_NN brands_NNS ._.
patients_NNS change_VBP their_PRP$ behavior_NN ,_, says_VBZ John_NNP ._.
The_DT new_JJ Consumer_NN Healthcare_NNP sales_NNS in_IN 2005_CD were_VBD 3_CD billion_CD ,_, an_DT OTC_NNP product_NN will_MD not_RB be_VB a_DT get-slim-quick_JJ pill_NN ._.
Proper_JJ increase_NN of_IN 2_CD %_NN over_IN 2004_CD ._.
diet_NN and_CC appropriate_JJ exercise_NN will_MD still_RB be_VB part_NN of_IN the_DT overall_JJ weight_NN loss_NN program_NN and_CC our_PRP$ education_NN Redening_VBG the_DT business_NN model_NN efforts_NNS will_MD be_VB a_DT major_JJ component_NN in_IN supporting_VBG this_DT ._.
Like_IN others_NNS in_IN the_DT consumer_NN healthcare_NN industry_NN ,_, GSK_NNP operates_VBZ in_IN a_DT competitive_JJ and_CC changing_VBG environment_NN ._.
Beating_NN tobacco_NN Consumers_NNS are_VBP demanding_VBG better_JJR quality_NN ,_, better_JJR value_NN Since_IN GSK_NNP Consumer_NNP Healthcares_NNP pioneering_JJ switch_NN of_IN and_CC improved_VBD performance_NN ,_, while_IN retailers_NNS have_VBP Nicorette_JJ nicotine_NN gum_NN in_IN the_DT USA_NNP in_IN 1996_CD ,_, the_DT company_NN has_VBZ consolidated_VBN and_CC strengthened_VBD their_PRP$ negotiating_NN innovated_VBD to_TO expand_VB its_PRP$ portfolio_NN ,_, adding_VBG a_DT patch_NN and_CC more_RBR recently_RB a_DT lozenge_NN ._.
This_DT has_VBZ broadened_VBN appeal_NN and_CC power_NN ,_, says_VBZ John_NNP Clarke_NNP ,_, who_WP succeeded_VBD Jack_NNP Ziegler_NNP successfully_RB helped_VBD over_IN five_CD million_CD smokers_NNS escape_VBP their_PRP$ as_IN President_NNP ,_, Consumer_NNP Healthcare_NNP ,_, in_IN February_NNP 2006_CD ._.
tobacco_NN dependence_NN worldwide_NN ._.
As_IN tobacco_NN kills_VBZ many_JJ users_NNS ,_, To_TO conduct_VB business_NN more_RBR effectively_RB in_IN this_DT these_DT Consumer_NNP Healthcare_NNP products_NNS really_RB do_VBP save_VB lives_NNS ._.
environment_NN ,_, Consumer_NNP Healthcare_NNP has_VBZ redened_VBN its_PRP$ While_IN GSK_NNP is_VBZ doing_VBG good_JJ things_NNS for_IN public_JJ health_NN ,_, the_DT business_NN strategy_NN and_CC operating_NN model_NN to_TO deliver_VB faster_JJR opportunities_NNS for_IN these_DT nicotine_JJ replacement_NN therapy_NN NRT_NNP sales_NNS growth_NN ._.
We_PRP expect_VBP to_TO achieve_VB this_DT growth_NN brands_NNS NiQuitin_NNP ,_, Nicabate_NNP ,_, Commit_NNP ,_, NicoDerm_NNP CQ_NNP and_CC Nicorette_NNP continue_VBP to_TO expand_VB as_IN countries_NNS implement_VBP through_IN a_DT vigorous_JJ focus_NN on_IN delivering_VBG new_JJ product_NN smoke-free_JJ legislation_NN ._.
developments_NNS that_WDT are_VBP tightly_RB aligned_VBN with_IN consumer_NN needs_NNS ,_, says_VBZ John_NNP ._.
The_DT new_JJ structure_NN brings_VBZ together_RB our_PRP$ R&D_NNP ,_, marketing_NN and_CC commercial_JJ operating_VBG units_NNS and_CC gives_VBZ us_PRP greater_JJR focus_NN ,_, alignment_NN and_CC simplicity_NN ._.
Growth_NN opportunity_NN Consumer_NN Healthcare_NNP has_VBZ a_DT particularly_RB exciting_JJ new_JJ growth_NN opportunity_NN for_IN the_DT business_NN with_IN Alli_NNP orlistat_NN ,_, an_DT over-the-counter_JJ OTC_NNP weight_NN loss_NN medicine_NN ._.
In_IN January_NNP 2006_CD ,_, a_DT FDA_NNP Advisory_NNP Committee_NNP recommended_VBD that_IN Alli_NNP be_VB approved_VBN for_IN OTC_NNP use_NN in_IN the_DT USA_NNP ._.
If_IN approved_VBN ,_, Alli_NNP will_MD be_VB the_DT only_JJ FDA-approved_JJ weightloss_NN medicine_NN available_JJ over-the-counter_JJ and_CC is_VBZ expected_VBN GSK_NNP Annual_JJ Review_NNP 2005_CD 08_CD 23_CD million_CD Millions_NNS of_IN people_NNS use_VBP and_CC 23_CD million_CD bottles_NNS of_IN Lucozade_NNP Sport_NNP Hydro_NNP Active_NNP were_VBD sold_VBN in_IN 2005_CD ._.
trust_NN our_PRP$ Consumer_NN Healthcare_NNP The_DT most_RBS recent_JJ innovation_NN for_IN Lucozade_NNP ,_, products_NNS every_DT day_NN ._.
Hydro_NNP Active_NNP has_VBZ been_VBN specially_RB formulated_VBN to_TO We_PRP are_VBP focused_VBN on_IN delivering_VBG even_RB better_JJR help_NN replace_VB the_DT salts_NNS and_CC uids_NNS you_PRP lose_VBP during_IN exercise_NN ,_, keeping_VBG you_PRP products_NNS that_WDT give_VBP consumers_NNS what_WP they_PRP need_VBP ._.
better_RB hydrated_VBN than_IN water_NN alone_RB ._.
John_NNP Clarke_NNP ,_, President_NNP ,_, Consumer_NNP Healthcare_NNP I_PRP was_VBD really_RB surprised_JJ 21_CD million_CD when_WRB the_DT doctor_NN told_VBD me_PRP I_PRP had_VBD diabetes_NN ._.
Nearly_RB 21_CD million_CD Americans_NNPS have_VBP diabetes_NN ,_, Within_IN a_DT few_JJ weeks_NNS of_IN almost_RB one-third_NN of_IN whom_WP are_VBP undiagnosed_JJ ._.
The_DT incidence_NN of_IN the_DT disease_NN starting_VBG Avandia_NNP my_PRP$ blood_NN sugar_NN has_VBZ risen_VBN 14_CD %_NN in_IN the_DT past_JJ two_CD years_NNS ._.
levels_NNS returned_VBD to_TO normal_JJ Maggie_NNP Lopez_NNP pictured_VBD nds_VBZ that_IN Avandia_NNP helps_VBZ her_PRP to_TO lead_VB the_DT sort_NN of_IN life_NN and_CC I_PRP soon_RB had_VBD my_PRP$ energy_NN back_RB ._.
Maggie_NNP Lopez_NNP ,_, Daytona_NNP Beach_NNP ,_, Florida_NNP ,_, USA_NNP On_IN this_DT page_NN you_PRP will_MD nd_VB :_: Pharma_NNP key_JJ growth_NN drivers_NNS :_: New_NNP products_NNS :_: Improving_NN osteoporosis_NN treatments_NNS David_NNP Stout_NNP ,_, President_NNP ,_, Pharmaceutical_NNP Operations_NNP Powering_NNP performance_NN Driving_VBG growth_NN through_IN people_NNS and_CC products_NNS Our_PRP$ performance_NN in_IN 2005_CD was_VBD undoubtedly_RB due_JJ to_TO published_VBN that_IN reinforced_VBD the_DT use_NN of_IN Lamictal_NNP as_IN first-line_JJ the_DT contributions_NNS from_IN all_DT our_PRP$ staff_NN around_IN the_DT world_NN ,_, maintenance_NN treatment_NN for_IN bi-polar_JJ disorder_NN where_WRB the_DT and_CC they_PRP deserve_VBP congratulations_NNS on_IN the_DT years_NNS licence_NN allows_VBZ ,_, and_CC GSK_NNP led_VBD once-daily_RB Coreg_NNP CR_NNP with_IN achievements_NNS ._.
Their_PRP$ enthusiasm_NN and_CC passion_NN about_IN the_DT FDA_NNP towards_IN the_DT end_NN of_IN 2005_CD ._.
helping_VBG to_TO improve_VB healthcare_NN is_VBZ clear_JJ ,_, says_VBZ David_NNP New_NNP products_NNS Stout_NNP ,_, President_NNP ,_, Pharmaceutical_NNP Operations_NNP ._.
New_JJ products_NNS also_RB started_VBD to_TO deliver_VB significant_JJ sales_NNS ._.
Key_NNP growth_NN drivers_NNS Avodart_NNP for_IN enlarging_VBG prostate_NN ,_, for_IN example_NN ,_, GSK_NNP pharmaceutical_JJ sales_NNS in_IN 2005_CD were_VBD 18.7_CD billion_CD ,_, performed_VBN well_RB and_CC accounted_VBD for_IN over_IN 40_CD %_NN of_IN new_JJ an_DT increase_NN of_IN 8_CD %_NN over_IN 2004_CD ,_, led_VBN by_IN the_DT companys_NNS prescription_NN sales_NNS in_IN its_PRP$ class_NN in_IN the_DT USA_NNP ._.
This_DT was_VBD key_JJ pharmaceutical_JJ growth_NN drivers_NNS and_CC vaccines_NNS see_VBP exceptionally_RB fast_JJ growth_NN and_CC Avodart_NNP will_MD be_VB an_DT page_NN 6_CD ._.
Our_PRP$ biggest-selling_JJ product_NN ,_, Seretide_NNP Advair_NNP ,_, exciting_JJ product_NN for_IN us_PRP ,_, says_VBZ David_NNP ._.
had_VBD another_DT strong_JJ year_NN and_CC continued_VBD to_TO gain_VB market_NN share_NN across_IN all_DT regions_NNS ,_, driven_VBN by_IN its_PRP$ efcacy_NN in_IN treating_VBG Avandia_NNP Avandamet_NNP goes_VBZ from_IN strength_NN these_DT debilitating_NN conditions_NNS ,_, says_VBZ David_NNP ._.
We_PRP believe_VBP physicians_NNS accept_VB market_NN share_NN by_IN value_NN in_IN the_DT anti-asthma_NN and_CC COPD_NNP and_CC like_IN it_PRP ,_, and_CC increasingly_RB use_VB it_PRP as_IN a_DT therapy_NN class_NN of_IN 27_CD %_NN in_IN Europe_NNP and_CC 33_CD %_NN in_IN the_DT USA_NNP ,_, first-line_JJ treatment_NN for_IN many_JJ patients_NNS an_DT increase_NN of_IN two_CD percentage_NN points_NNS in_IN both_DT cases_NNS compared_VBN with_IN 2004_CD ._.
where_WRB the_DT licence_NN allows_VBZ ._.
Osteoporosis_NNP ,_, a_DT disease_NN in_IN which_WDT bones_NNS become_VBP brittle_JJ Market_NN share_NN by_IN value_NN and_CC more_RBR likely_JJ to_TO break_VB ,_, affects_VBZ an_DT estimated_VBN 75_CD Seretide_NNP Advair_NNP Avandia_NNP Avandamet_NNP 40_CD %_NN million_CD people_NNS in_IN the_DT USA_NNP ,_, Europe_NNP and_CC Japan_NNP ._.
An_DT 35_CD 33_CD 31_CD estimated_VBD one_CD in_IN three_CD women_NNS will_MD sustain_VB an_DT 29_CD 30_CD %_NN 27_CD 25_CD osteoporosis-related_JJ fracture_NN in_IN their_PRP$ lifetime_NN ._.
Boniva_NNP Bonviva_NNP ,_, developed_VBD with_IN Roche_NNP ,_, was_VBD launched_VBN 20_CD %_NN 14_CD in_IN the_DT USA_NNP in_IN April_NNP 2005_CD ,_, and_CC in_IN several_JJ countries_NNS in_IN 11_CD 10_CD %_NN Improving_NN treatments_NNS Bisphosphonate_NNP treatments_NNS for_IN osteoporosis_NN involve_VBP taking_VBG Europe_NNP USA_NNP Europe_NNP USA_NNP a_DT tablet_NN with_IN a_DT full_JJ glass_NN of_IN water_NN first_JJ thing_NN in_IN the_DT morning_NN ,_, September_NNP 2004_CD September_NNP 2005_CD then_RB remaining_VBG upright_JJ and_CC delaying_VBG eating_NN or_CC drinking_NN for_IN 30-60_CD minutes_NNS ._.
With_IN Boniva_NNP Bonviva_NNP ,_, women_NNS have_VBP to_TO Sales_NNS of_IN diabetes_NN treatments_NNS were_VBD also_RB strong_JJ ._.
Diabetes_NNP follow_VB this_DT dosing_NN routine_JJ just_RB once_RB a_DT month_NN ,_, instead_RB of_IN affects_VBZ more_JJR than_IN 190_CD million_CD people_NNS worldwide_JJ ._.
GSK_NNP four_CD times_NNS as_IN required_VBN with_IN weekly_JJ bisphosphonate_NN treatments_NNS ._.
Data_NNS have_VBP shown_VBN that_IN two_CD out_IN of_IN three_CD women_NNS launched_VBD Avandia_NNP for_IN the_DT treatment_NN of_IN type_NN 2_CD diabetes_NN preferred_VBN the_DT once-monthly_JJ dosing_NN of_IN Boniva_NNP Bonviva_NNP over_IN in_IN 1999_CD and_CC a_DT combination_NN product_NN ,_, Avandamet_NNP ,_, for_IN a_DT once-weekly_JJ treatment_NN ,_, nding_VBG it_PRP more_RBR convenient_JJ ._.
Avandia_NNP Avandamet_NNP new_JJ injectable_JJ form_NN of_IN Boniva_NNP was_VBD approved_VBN for_IN use_NN in_IN the_DT goes_VBZ from_IN strength_NN to_TO strength_NN ._.
We_PRP believe_VBP physicians_NNS USA_NNP in_IN January_NNP 2006_CD ._.
This_DT quarterly_JJ treatment_NN may_MD bring_VB accept_VB and_CC like_VB it_PRP ,_, and_CC increasingly_RB use_VB it_PRP as_IN a_DT first-line_JJ the_DT benets_NNS of_IN Boniva_NNP for_IN the_DT treatment_NN of_IN postmenopausal_JJ treatment_NN for_IN many_JJ patients_NNS where_WRB the_DT licence_NN allows_VBZ ,_, osteoporosis_NN to_TO even_RB more_RBR women_NNS ._.
The_DT product_NN group_NN was_VBD expanded_VBN further_RBR in_IN February_NNP 2006_CD with_IN the_DT launch_NN in_IN the_DT USA_NNP of_IN a_DT xeddose_JJ combination_NN treatment_NN ,_, Avandaryl_NNP ,_, which_WDT combines_VBZ Avandia_NNP with_IN a_DT sulfonylurea_NN ._.
In_IN 2005_CD ,_, Avandia_NNP Avandamet_NNP achieved_VBD a_DT market_NN share_NN by_IN value_NN in_IN oral_JJ anti-diabetics_NNS of_IN 14_CD %_NN in_IN Europe_NNP and_CC 35_CD %_NN in_IN the_DT USA_NNP ,_, up_RB 3_CD and_CC 6_CD percentage_NN points_NNS respectively_RB ._.
Other_JJ growth_NN drivers_NNS included_VBD Lamictal_NNP ,_, Valtrex_NNP and_CC Coreg_NNP ,_, which_WDT did_VBD well_RB in_IN their_PRP$ respective_JJ markets_NNS of_IN bipolar_NN disorder_NN and_CC epilepsy_NN ,_, herpes_NNS and_CC heart_NN disease_NN ,_, delivering_VBG a_DT total_NN of_IN over_IN 2.1_CD billion_CD in_IN sales_NNS ,_, up_RB 25_CD %_NN over_IN 2004_CD ._.
During_IN the_DT year_NN new_JJ guidelines_NNS were_VBD GSK_NNP Annual_JJ Review_NNP 2005_CD 11_CD On_IN this_DT page_NN you_PRP will_MD nd_VB :_: Commercial_NNP and_CC operational_JJ excellence_NN :_: Maintaining_VBG high_JJ standards_NNS :_: Seretide_NNP Advair_NNP patient_JJ prole_NN Europe_NNP in_IN September_NNP 2005_CD ,_, as_IN the_DT first_JJ ever_RB oral_JJ communication_NN from_IN senior_JJ management_NN to_TO treatment_NN administered_VBN as_IN one_CD tablet_NN once-a-month_JJ employees_NNS on_IN areas_NNS where_WRB policy_NN is_VBZ changing_VBG or_CC there_EX for_IN postmenopausal_JJ osteoporosis_NN ._.
Since_IN its_PRP$ launch_NN ,_, are_VBP concerns_NNS about_IN compliance_NN :_: global_JJ induction_NN Boniva_NNP has_VBZ achieved_VBN 10_CD %_NN share_NN of_IN new_JJ prescriptions_NNS courses_NNS that_WDT include_VBP training_NN on_IN the_DT GSK_NNP Code_NNP of_IN in_IN the_DT oral_JJ bisphosphonate_NN market_NN in_IN the_DT USA_NNP ._.
The_DT Conduct_NNP to_TO ensure_VB new_JJ employees_NNS understand_VBP the_DT injectable_JJ form_NN of_IN Boniva_NNP Bonviva_NNP was_VBD approved_VBN for_IN importance_NN of_IN ethical_JJ conduct_NN from_IN their_PRP$ first_JJ day_NN :_: and_CC use_VB in_IN the_DT USA_NNP ,_, and_CC recommended_VBD for_IN approval_NN in_IN an_DT annual_JJ certication_NN process_NN which_WDT extends_VBZ to_TO all_DT Europe_NNP in_IN January_NNP 2006_CD ._.
It_PRP is_VBZ the_DT first_JJ intravenous_JJ senior_JJ managers_NNS globally_RB and_CC all_DT middle_JJ managers_NNS in_IN bisphosphonate_NN to_TO be_VB approved_VBN for_IN the_DT treatment_NN of_IN the_DT UK_NNP and_CC USA_NNP ._.
We_PRP are_VBP committed_VBN to_TO ensuring_VBG our_PRP$ business_NN practices_NNS Another_DT launch_NN in_IN the_DT USA_NNP in_IN 2005_CD was_VBD Requip_NNP for_IN meet_VBP high_JJ standards_NNS and_CC that_IN our_PRP$ employees_NNS behave_VBP Restless_JJ Legs_NNP Syndrome_NNP RLS_NNP ,_, a_DT chronic_NN and_CC disruptive_JJ ethically_RB and_CC honestly_RB ._.
We_PRP strive_VBP to_TO operate_VB to_TO high_JJ condition_NN characterised_VBN by_IN an_DT urge_NN to_TO move_VB the_DT legs_NNS ,_, ethical_JJ standards_NNS ,_, act_NN responsibly_RB and_CC comply_VB with_IN the_DT particularly_RB at_IN night_NN ._.
The_DT condition_NN is_VBZ common_JJ ,_, underlaw_NN ._.
This_DT is_VBZ vital_JJ because_IN of_IN the_DT simple_JJ fact_NN that_IN GSK_NNP diagnosed_VBD and_CC can_MD have_VB a_DT significant_JJ effect_NN on_IN sleep_NN products_NNS are_VBP important_JJ to_TO the_DT health_NN of_IN people_NNS around_IN and_CC daily_JJ activities_NNS ._.
Since_IN it_PRP was_VBD launched_VBN for_IN RLS_NNP in_IN the_DT the_DT world_NN ,_, says_VBZ David_NNP ._.
USA_NNP ,_, the_DT volume_NN of_IN new_JJ prescriptions_NNS for_IN Requip_NNP has_VBZ quadrupled_VBN ,_, with_IN sales_NNS of_IN 156_CD million_CD ,_, up_RB 34_CD %_NN ._.
On_IN top_NN of_IN the_DT world_NN Approval_NN in_IN Europe_NNP for_IN Requip_NNP Adartrel_NNP as_IN a_DT treatment_NN In_IN 2005_CD ,_, Mogens_NNP Jensen_NNP ran_VBD and_CC cycled_VBD 7,000_CD miles_NNS from_IN for_IN RLS_NNP is_VBZ expected_VBN in_IN the_DT first_JJ half_NN of_IN 2006_CD ._.
his_PRP$ home_NN in_IN Denmark_NNP to_TO a_DT base_NN camp_NN in_IN Tibet_NNP as_IN a_DT warm_JJ up_RP for_IN his_PRP$ bid_NN to_TO become_VB the_DT first_JJ asthmatic_JJ to_TO climb_VB Commercial_JJ and_CC operational_JJ excellence_NN Mount_NNP Everest_NNP ._.
Although_IN he_PRP was_VBD not_RB successful_JJ frostbite_NN GSK_NNP continued_VBD to_TO make_VB good_JJ progress_NN towards_IN forced_VBN Mogens_NNP to_TO abandon_VB his_PRP$ climb_NN not_RB far_RB from_IN the_DT commercial_JJ and_CC operational_JJ excellence_NN to_TO improve_VB summit_NN his_PRP$ effort_NN displayed_VBD a_DT formidable_JJ strength_NN of_IN character_NN and_CC physical_JJ tness_NN undiminished_VBN by_IN disease_NN ._.
underlying_VBG performance_NN ,_, with_IN tight_JJ cost_NN control_NN Diagnosed_VBN with_IN asthma_NN in_IN 1998_CD ,_, Mogens_NNP was_VBD determined_VBN underpinning_JJ operations_NNS ._.
Through_IN the_DT companys_NNS not_RB to_TO allow_VB it_PRP to_TO control_VB his_PRP$ life_NN and_CC stop_VB his_PRP$ sporting_VBG Worldwide_NNP Sales_NNS Force_NNP Excellence_NN initiative_NN ,_, sales_NNS activities_NNS ._.
After_IN trying_VBG different_JJ medications_NNS ,_, he_PRP found_VBD representatives_NNS are_VBP in_IN a_DT position_NN to_TO strengthen_VB the_DT Seretide_NNP very_RB effective_JJ in_IN controlling_VBG his_PRP$ symptoms_NNS ._.
With_IN product_NN knowledge_NN of_IN physicians_NNS so_IN they_PRP can_MD deliver_VB the_DT help_NN of_IN Seretide_NNP ,_, I_PRP have_VBP taken_VBN control_NN of_IN my_PRP$ asthma_NN patient-specic_JJ treatment_NN options_NNS more_RBR efficiently_RB and_CC and_CC not_RB allowed_VBN my_PRP$ asthma_NN to_TO control_VB me_PRP ,_, he_PRP says_VBZ ._.
We_PRP are_VBP committed_VBN to_TO ensuring_VBG our_PRP$ business_NN practices_NNS meet_VBP high_JJ standards_NNS and_CC that_IN our_PRP$ employees_NNS behave_VBP ethically_RB and_CC honestly_RB ._.
In_IN manufacturing_NN and_CC supply_NN ,_, GSK_NNP introduced_VBD the_DT Vision_NNP Factory_NN initiative_NN which_WDT is_VBZ identifying_VBG improvements_NNS in_IN productivity_NN and_CC cost_NN reduction_NN ._.
We_PRP started_VBD the_DT year_NN with_IN some_DT manufacturing_NN problems_NNS that_WDT stopped_VBD production_NN of_IN two_CD medicines_NNS at_IN our_PRP$ Cidra_NNP plant_NN in_IN Puerto_NNP Rico_NNP ._.
Our_PRP$ people_NNS are_VBP working_VBG with_IN the_DT FDA_NNP to_TO implement_VB solutions_NNS and_CC minimize_VB the_DT interruption_NN to_TO supply_VB ,_, says_VBZ David_NNP ._.
The_DT learning_NN from_IN this_DT ,_, combined_VBN with_IN the_DT Vision_NNP Factory_NN initiative_NN ,_, will_MD increase_VB the_DT operational_JJ excellence_NN of_IN our_PRP$ manufacturing_NN operations_NNS in_IN the_DT future_NN ,_, ensuring_VBG product_NN quality_NN and_CC patient_NN safety_NN are_VBP paramount_JJ ._.
Maintaining_VBG high_JJ standards_NNS GSK_NNP audits_NN its_PRP$ operations_NNS to_TO ensure_VB that_IN relevant_JJ standards_NNS expected_VBN ,_, such_JJ as_IN those_DT in_IN marketing_NN practices_NNS ,_, are_VBP reached_VBN or_CC exceeded_VBN ._.
GSK_NNP has_VBZ in_IN place_NN a_DT number_NN of_IN mechanisms_NNS to_TO support_VB compliance_NN with_IN policies_NNS and_CC procedures_NNS ._.
These_DT include_VBP direct_JJ GSK_NNP Annual_JJ Review_NNP 2005_CD 13_CD 2005_CD performance_NN highlights_VBZ 82.6_CD p_NN 4.7_CD bn_NN earnings_NNS per_IN share_NN free_JJ cash_NN ow_NN 18_CD %_NN CER_NNP growth_NN in_IN 2005_CD increase_NN of_IN 26_CD %_NN over_IN 2004_CD 25_CD 95_CD vaccines_NNS in_IN clinical_JJ development_NN NCEs_NNS in_IN clinical_JJ development_NN at_IN the_DT end_NN of_IN 2005_CD at_IN the_DT end_NN of_IN 2005_CD with_IN five_CD major_JJ vaccine_NN launches_NNS 70_CD %_NN increase_NN over_IN 2001_CD anticipated_VBN in_IN the_DT next_JJ five_CD years_NNS 35_CD %_NN 27_CD %_NN market_NN share_NN by_IN value_NN of_IN market_NN share_NN by_IN value_NN of_IN Avandia_NNP Avandamet_NNP in_IN the_DT USA_NNP Seretide_NNP Advair_NNP in_IN Europe_NNP increase_NN of_IN 6_CD percentage_NN increase_NN of_IN 2_CD percentage_NN points_NNS over_IN 2004_CD points_NNS over_IN 2004_CD 380m_CD 136m_JJ value_NN of_IN community_NN albendazole_NN tablets_NNS donated_VBD investment_NN in_IN 2005_CD to_TO help_VB eliminate_VB lymphatic_JJ lariasis_NN equivalent_NN to_TO 5.6_CD %_NN of_IN profit_NN before_IN tax_NN GSK_NNP Annual_JJ Review_NNP 2005_CD 14_CD Business_NN operating_NN review_NN for_IN the_DT year_NN to_TO 31st_CD December_NNP 2005_CD Excellent_JJ 2005_CD performance_NN for_IN GSK_NNP Pharmaceuticals_NNP Within_IN Anti-virals_NNPS ,_, HIV_NNP product_NN sales_NNS grew_VBD 5_CD %_NN to_TO 1.6_CD GSK_NNP continues_VBZ to_TO be_VB the_DT global_JJ leader_NN in_IN respiratory_JJ billion_CD ,_, with_IN sales_NNS from_IN new_JJ products_NNS Epzicom_NNP Kivexa_NNP and_CC pharmaceuticals_NNS with_IN sales_NNS of_IN its_PRP$ three_CD key_JJ products_NNS ,_, Lexiva_NNP together_RB more_JJR than_IN doubling_VBG to_TO 226_CD million_CD Seretide_NNP Advair_NNP ,_, Flixotide_NNP Flovent_NNP and_CC Serevent_NNP ,_, amounting_VBG offsetting_VBG the_DT performance_NN of_IN Trizivir_NNP down_IN 6_CD %_NN to_TO 303_CD to_TO 4.0_CD billion_CD ,_, up_RB 15_CD %_NN ._.
Sales_NNS of_IN Seretide_NNP Advair_NNP ,_, the_DT million_CD and_CC Epivir_NNP down_IN 12_CD %_NN to_TO 261_CD million_CD ._.
Sales_NNS of_IN Groups_NNS largest_JJS product_NN grew_VBD 22_CD %_NN to_TO 3.0_CD billion_CD ._.
the_DT herpes_NNS treatment_NN Valtrex_NNP grew_VBD 21_CD %_NN to_TO 695_CD million_CD ._.
Performance_NNP is_VBZ being_VBG driven_VBN by_IN the_DT USA_NNP up_IN 26_CD %_NN to_TO 470_CD In_IN the_DT USA_NNP ,_, Advair_NNP sales_NNS rose_VBD 26_CD %_NN to_TO 1.7_CD billion_CD ,_, with_IN million_CD where_WRB the_DT product_NN is_VBZ the_DT clear_JJ market_NN leader_NN in_IN continued_JJ gains_NNS in_IN market_NN share_NN throughout_IN the_DT year_NN ._.
Sales_NNS were_VBD strong_JJ in_IN both_DT European_JJ and_CC International_JJ markets_NNS both_DT up_RB 16_CD %_NN to_TO 1_CD billion_CD and_CC 0.3_CD billion_CD Anti-bacterial_JJ anti-malarial_JJ sales_NNS declined_VBD 3_CD %_NN worldwide_JJ respectively_RB ._.
and_CC 27_CD %_NN in_IN the_DT USA_NNP reecting_VBG generic_JJ competition_NN ._.
Pharmaceutical_NNP turnover_NN by_IN therapeutic_JJ area_NN :_: GSK_NNP turnover_NN in_IN 2005_CD grew_VBD 7_CD %_NN ,_, driven_VBN by_IN 2005_CD 2004_CD Growth_NN m_NN m_NN CER_NNP %_NN the_DT growth_NN of_IN key_JJ products_NNS Respiratory_NNP 5,054_CD 4,394_CD 14_CD Central_NNP nervous_JJ system_NN 3,219_CD 3,462_CD 8_CD Central_NNP nervous_JJ system_NN CNS_NNP sales_NNS declined_VBD 8_CD %_NN to_TO 3.2_CD Anti-virals_NNS 2,598_CD 2,359_CD 9_CD billion_CD ._.
Total_JJ Paxil_NNP sales_NNS fell_VBD 42_CD %_NN to_TO 615_CD million_CD ,_, due_JJ to_TO Anti-bacterials_JJ generic_JJ competition_NN and_CC the_DT interruption_NN in_IN supply_NN to_TO Paxil_NNP anti-malarials_NNS 1,519_CD 1,547_CD 3_CD CR_NN during_IN the_DT year_NN ._.
Partially_RB mitigating_VBG this_DT decline_NN was_VBD Metabolic_NNP 1,495_CD 1,251_CD 18_CD the_DT strong_JJ performance_NN of_IN the_DT product_NN in_IN Japan_NNP ,_, up_IN 17_CD %_NN Vaccines_NNS 1,389_CD 1,194_CD 15_CD to_TO 197_CD million_CD ._.
Oncology_NNP and_CC emesis_NN 1,016_CD 934_CD 8_CD Total_JJ Wellbutrin_NNP product_NN sales_NNS fell_VBD 2_CD %_NN to_TO 739_CD million_CD ._.
Cardiovascular_NNP and_CC Wellbutrin_NNP IR_NNP and_CC SR_NNP sales_NNS fell_VBD 68_CD %_NN to_TO 92_CD million_CD due_JJ to_TO urogenital_JJ 1,331_CD 932_CD 41_CD generic_JJ competition_NN but_CC this_DT was_VBD largely_RB offset_VBN by_IN the_DT Other_JJ 1,040_CD 1,027_CD very_RB strong_JJ performance_NN of_IN Wellbutrin_NNP XL_NNP up_IN 38_CD %_NN to_TO 647_CD million_CD ._.
18,661_CD 17,100_CD 8_CD In_IN Metabolic_NNP ,_, the_DT diabetes_NN treatments_NNS Avandia_NNP Avandamet_NNP GSKs_NNP underlying_VBG growth_NN was_VBD driven_VBN by_IN continue_VBP to_TO perform_VB very_RB strongly_RB ,_, with_IN overall_JJ sales_NNS of_IN strong_JJ sales_NNS performance_NN of_IN key_JJ products_NNS :_: 1.3_CD billion_CD up_IN 18_CD %_NN ._.
In_IN the_DT USA_NNP ,_, sales_NNS grew_VBD 14_CD %_NN to_TO 977_CD million_CD ._.
Avandia_NNP Avandamet_NNP is_VBZ also_RB establishing_VBG a_DT Seretide_NNP Advair_NNP 3.0_CD billion_CD up_IN 22_CD %_NN strong_JJ position_NN in_IN Europe_NNP ,_, with_IN sales_NNS rising_VBG 52_CD %_NN to_TO 157_CD Vaccines_NNS 1.4_CD billion_CD up_IN 15_CD %_NN million_CD helped_VBN by_IN the_DT launch_NN of_IN Avandamet_NNP throughout_IN the_DT region_NN ._.
Sales_NNS in_IN International_JJ markets_NNS rose_VBD 13_CD %_NN to_TO Avandia_NNP Avandamet_NNP 1.3_CD billion_CD up_IN 18_CD %_NN 195_CD million_CD ._.
Lamictal_JJ 0.8_CD billion_CD up_IN 24_CD %_NN Boniva_NNP Bonviva_NNP ,_, a_DT new_JJ once-monthly_JJ oral_JJ bisphosphonate_NN Valtrex_NNP 0.7_CD billion_CD up_IN 21_CD %_NN for_IN the_DT treatment_NN of_IN osteoporosis_NN ,_, which_WDT was_VBD developed_VBN Coreg_NNP 0.6_CD billion_CD up_IN 32_CD %_NN with_IN Roche_NNP ,_, had_VBD a_DT strong_JJ launch_NN in_IN the_DT USA_NNP and_CC now_RB has_VBZ a_DT 10_CD %_NN share_NN of_IN new_JJ prescriptions_NNS for_IN oral_JJ bisphosphonates_NNS ._.
Boniva_NNP injection_NN ,_, the_DT first-ever_JJ quarterly_JJ The_DT strong_JJ growth_NN of_IN GSKs_NNS epilepsy_NN and_CC bi-polar_JJ disorder_NN treatment_NN for_IN osteoporosis_NN ,_, was_VBD approved_VBN in_IN the_DT USA_NNP in_IN treatment_NN Lamictal_NNP continued_VBD ,_, with_IN sales_NNS up_IN 24_CD %_NN to_TO 849_CD January_NNP 2006_CD and_CC received_VBD a_DT positive_JJ opinion_NN from_IN the_DT million_CD ,_, driven_VBN by_IN the_DT indication_NN for_IN the_DT maintenance_NN CHMP_NNP in_IN Europe_NNP on_IN 27th_JJ January_NNP 2006_CD ._.
treatment_NN of_IN bi-polar_JJ disorder_NN ._.
The_DT vaccines_NNS business_NN performed_VBD well_RB with_IN total_JJ sales_NNS Requip_NNP sales_NNS rose_VBD 34_CD %_NN to_TO 156_CD million_CD following_VBG its_PRP$ launch_NN rising_VBG 15_CD %_NN to_TO 1.4_CD billion_CD ,_, led_VBN by_IN Infanrix_NNP ._.
Vaccine_NN sales_NNS in_IN the_DT USA_NNP for_IN Restless_NNP Legs_NNP Syndrome_NNP RLS_NNP in_IN Q2_NNP 2005_CD ._.
were_VBD particularly_RB strong_JJ in_IN the_DT USA_NNP ,_, where_WRB turnover_NN rose_VBD In_IN Europe_NNP ,_, final_JJ approval_NN of_IN Requip_NNP Adartrel_NNP for_IN RLS_NNP is_VBZ 26_CD %_NN to_TO 338_CD million_CD ,_, helped_VBN by_IN the_DT launch_NN of_IN two_CD new_JJ expected_VBN in_IN the_DT first_JJ half_NN of_IN 2006_CD ._.
products_NNS Fluarix_NNP and_CC Boostrix_NNP ._.
GSK_NNP Annual_JJ Review_NNP 2005_CD 15_CD Business_NN operating_NN review_NN continued_VBD In_IN Oncology_NNP and_CC emesis_NN ,_, sales_NNS of_IN Zofran_NNP grew_VBD 9_CD %_NN to_TO 837_CD Operating_NN profit_NN million_CD ,_, driven_VBN by_IN the_DT US_NNP performance_NN ,_, which_WDT was_VBD up_RB 12_CD %_NN The_DT operating_NN profit_NN margin_NN increased_VBD 2.9_CD percentage_NN to_TO 639_CD million_CD ._.
points_NNS as_IN operating_NN profit_NN of_IN 6,874_CD million_CD increased_VBD 19_CD %_NN in_IN sterling_NN terms_NNS ._.
At_IN constant_JJ exchange_NN rates_NNS In_IN Cardiovascular_NNP and_CC urogenital_JJ ,_, Coreg_NNP for_IN heart_NN disease_NN operating_NN profit_NN increased_VBD 16_CD %_NN and_CC the_DT margin_NN increased_VBD sales_NNS grew_VBD 32_CD %_NN to_TO 573_CD million_CD ._.
Avodart_NNP for_IN benign_JJ 2.5_CD percentage_NN points_NNS ._.
prostatic_JJ hyperplasia_NN enlarging_VBG prostate_NN had_VBD a_DT very_RB strong_JJ year_NN with_IN sales_NNS more_RBR than_IN doubling_VBG to_TO 129_CD million_CD ._.
By_IN This_DT reected_VBD lower_JJR charges_NNS relating_VBG to_TO legal_JJ matters_NNS and_CC January_NNP 2006_CD the_DT product_NN accounted_VBD for_IN 42_CD %_NN of_IN new_JJ share-based_JJ payments_NNS ,_, higher_JJR product_NN and_CC asset_NN disposals_NNS prescriptions_NNS in_IN the_DT US_NNP 5-Alpha_NNP Reductase_NNP Inhibitor_NNP market_NN ._.
and_CC increases_NNS in_IN advertising_NN ,_, promotion_NN and_CC selling_NN that_WDT were_VBD below_IN the_DT rate_NN of_IN turnover_NN growth_NN ._.
Partially_RB offsetting_VBG these_DT items_NNS were_VBD higher_JJR costs_NNS related_VBN to_TO GSKs_NNS submissions_NNS to_TO the_DT regulatory_JJ authorities_NNS programs_NNS to_TO deliver_VB future_JJ cost_NN savings_NNS and_CC increased_VBN in_IN the_DT USA_NNP and_CC EU_NNP for_IN the_DT first_JJ time_NN and_CC R&D_NNP expenditure_NN ._.
approvals_NNS during_IN 2005_CD were_VBD :_: Taxation_NNP USA_NNP Europe_NNP The_DT charge_NN for_IN taxation_NN on_IN profit_NN ,_, amounting_VBG to_TO 1,916_CD Submission_NN 5_CD 7_CD million_CD ,_, represents_VBZ an_DT effective_JJ tax_NN rate_NN of_IN 28.5_CD %_NN 2004_CD Approval_NN 6_CD 6_CD 30.4_CD %_NN ._.
The_DT tax_NN rate_NN in_IN 2005_CD of_IN 28.5_CD %_NN benefited_VBD from_IN 11_CD 13_CD higher_JJR tax_NN relief_NN on_IN actual_JJ or_CC potential_JJ exercise_NN of_IN share_NN options_NNS by_IN employees_NNS ,_, arising_VBG from_IN the_DT increase_NN in_IN the_DT share_NN price_NN in_IN the_DT year_NN ._.
Product_NN supply_NN Following_VBG FDA_NNP inspections_NNS in_IN 2003_CD and_CC 2004_CD ,_, which_WDT identied_VBD possible_JJ deficiencies_NNS in_IN manufacturing_VBG practices_NNS EPS_NNP 82.6_CD pence_NN ,_, growth_NN of_IN 18_CD %_NN at_IN the_DT Groups_NNS facility_NN at_IN Cidra_NNP in_IN Puerto_NNP Rico_NNP ,_, the_DT FDA_NNP halted_VBD distribution_NN of_IN supplies_NNS of_IN Paxil_NNP CR_NNP and_CC Avandamet_NNP Earnings_NNS per_IN share_NN in_IN March_NNP 2005_CD ._.
This_DT site_NN is_VBZ engaged_VBN in_IN tableting_VBG and_CC Full_NNP year_NN earnings_NNS per_IN share_NN EPS_NNP of_IN 82.6_CD pence_NN increased_VBD packaging_NN for_IN a_DT range_NN of_IN GSK_NNP products_NNS primarily_RB for_IN 18_CD %_NN ._.
At_IN actual_JJ rates_NNS of_IN exchange_NN ,_, earnings_NNS per_IN share_NN the_DT US_NNP market_NN ._.
In_IN April_NNP 2005_CD ,_, the_DT Group_NNP reached_VBD increased_VBN 21_CD %_NN ._.
The_DT favourable_JJ currency_NN impact_NN on_IN EPS_NNP agreement_NN with_IN the_DT FDA_NNP on_IN a_DT Consent_NNP Decree_NNP ,_, which_WDT of_IN three_CD percentage_NN points_NNS reects_VBZ a_DT strengthening_NN of_IN provides_VBZ for_IN an_DT independent_JJ review_NN of_IN manufacturing_VBG at_IN the_DT US_NNP dollar_NN and_CC Euro_NNP relative_JJ to_TO 2004_CD and_CC compares_VBZ the_DT site_NN for_IN compliance_NN with_IN FDA_NNP requirements_NNS ._.
The_DT Decree_NN with_IN a_DT 1_CD %_NN favourable_JJ currency_NN impact_NN on_IN turnover_NN ._.
This_DT also_RB allows_VBZ for_IN potential_JJ future_JJ penalties_NNS if_IN GSK_NNP fails_VBZ to_TO difference_NN principally_RB arises_VBZ from_IN a_DT different_JJ mix_NN of_IN meet_VB its_PRP$ terms_NNS ._.
In_IN June_NNP 2005_CD ,_, the_DT Group_NNP began_VBD recurrencies_NNS in_IN profits_NNS compared_VBN with_IN turnover_NN ._.
supplying_VBG the_DT US_NNP and_CC other_JJ markets_NNS with_IN both_DT Paxil_NNP CR_NNP and_CC Avandamet_NNP ._.
The_DT sales_NNS of_IN these_DT products_NNS were_VBD signicantly_RB impacted_VBN in_IN 2005_CD by_IN this_DT interruption_NN in_IN supply_NN ._.
Presentation_NN The_DT impact_NN upon_IN Avandamet_NNP was_VBD mitigated_VBN by_IN the_DT With_NNP effect_NN from_IN 1st_CD January_NNP 2005_CD ,_, GSK_NNP has_VBZ moved_VBN switching_NN of_IN patients_NNS to_TO Avandia_NNP ._.
For_IN further_JJ details_NNS see_VBP to_TO reporting_VBG its_PRP$ financial_JJ results_NNS in_IN accordance_NN with_IN Note_NN 41_CD to_TO the_DT financial_JJ statements_NNS ,_, Legal_NNP proceedings_NNS ,_, International_NNP Financial_NNP Reporting_NNP Standards_NNPS IFRS_NNP as_IN in_IN the_DT Annual_JJ Report_NNP 2005_CD ._.
adopted_VBN for_IN use_NN in_IN the_DT European_NNP Union_NNP ._.
Consumer_NNP Healthcare_NNP sales_NNS All_DT comparative_JJ gures_NNS are_VBP presented_VBN on_IN this_DT basis_NN ,_, The_DT growth_NN in_IN Consumer_NNP Healthcare_NNP sales_NNS of_IN 2_CD %_NN to_TO except_IN that_DT GSK_NNP has_VBZ taken_VBN advantage_NN of_IN an_DT 2,999_CD million_CD comprised_VBD an_DT OTC_NNP medicines_NNS sales_NNS increase_NN exemption_NN which_WDT permits_VBZ financial_JJ instruments_NNS to_TO be_VB of_IN 1_CD %_NN to_TO 1,437_CD million_CD ,_, a_DT Nutritional_NNP healthcare_NN sales_NNS accounted_VBD for_IN and_CC presented_VBN on_IN a_DT UK_NNP GAAP_NNP basis_NN in_IN increase_NN of_IN 7_CD %_NN to_TO 619_CD million_CD and_CC an_DT Oral_JJ care_NN sales_NNS 2004_CD and_CC 2003_CD and_CC only_RB in_IN accordance_NN with_IN IAS_NNP 32_CD increase_NN of_IN 2_CD %_NN to_TO 943_CD million_CD ._.
Full_JJ details_NNS of_IN the_DT major_JJ differences_NNS from_IN UK_NNP GAAP_NNP as_IN they_PRP apply_VBP to_TO GSK_NNP In_IN OTC_NNP ,_, growth_NN from_IN analgesics_NNS ,_, up_RB 6_CD %_NN ,_, and_CC respiratory_JJ are_VBP given_VBN in_IN Note_NN 40_CD to_TO the_DT financial_JJ statements_NNS f_LS tract_NN ,_, up_IN 5_CD %_NN ,_, helped_VBD offset_VB the_DT loss_NN of_IN sales_NNS from_IN the_DT Transition_NN to_TO IFRS_NNP in_IN the_DT Annual_JJ Report_NNP 2005_CD ._.
dermatological_JJ products_NNS divested_VBN in_IN 2004_CD ._.
In_IN Oral_JJ care_NN ,_, sales_NNS of_IN Sensodyne_NNP and_CC the_DT denture_NN care_NN In_IN order_NN to_TO illustrate_VB underlying_VBG performance_NN ,_, it_PRP is_VBZ the_DT brands_NNS Polident_NNP ,_, Poligrip_NNP and_CC Corega_NNP grew_VBD by_IN 12_CD %_NN and_CC Groups_NNS practice_NN to_TO discuss_VB its_PRP$ results_NNS in_IN terms_NNS of_IN 6_CD %_NN ,_, respectively_RB ,_, helping_VBG to_TO offset_VB lower_JJR sales_NNS of_IN other_JJ constant_JJ exchange_NN rate_NN CER_NNP growth_NN ._.
growth_NN calculated_VBN as_IN if_IN the_DT exchange_NN rates_NNS used_VBN to_TO determine_VB the_DT results_NNS of_IN overseas_JJ companies_NNS in_IN sterling_NN Within_IN Nutritional_NNP ,_, Lucozade_NNP ,_, up_RB 11_CD %_NN ,_, continued_VBD to_TO grow_VB had_VBD remained_VBN unchanged_JJ from_IN those_DT used_VBN in_IN the_DT strongly_RB in_IN Europe_NNP ._.
All_DT commentaries_NNS are_VBP presented_VBN in_IN terms_NNS of_IN CER_NNP unless_IN otherwise_RB stated_VBN ._.
On_IN 23rd_JJ January_NNP 2006_CD ,_, an_DT FDA_NNP Advisory_NNP Committee_NNP recommended_VBD that_IN Alli_NNP orlistat_NN be_VB approved_VBN for_IN over-thecounter_JJ use_NN in_IN the_DT USA_NNP to_TO promote_VB weight_NN loss_NN in_IN overweight_JJ adults_NNS ,_, when_WRB used_VBN along_IN with_IN a_DT reduced_VBN calorie_NN ,_, low-fat_JJ diet_NN ._.
If_IN approved_VBN ,_, Alli_NNP will_MD be_VB the_DT only_JJ FDAapproved_NNP weight-loss_JJ drug_NN available_JJ over-the-counter_JJ ._.
GSK_NNP Annual_JJ Review_NNP 2005_CD 16_CD Business_NN operating_NN review_NN continued_VBD Dividend_NN Tax_NN issues_NNS The_DT Board_NNP has_VBZ declared_VBN a_DT fourth_JJ interim_JJ dividend_NN of_IN 14_CD The_DT Group_NNP has_VBZ open_JJ issues_NNS with_IN the_DT revenue_NN authorities_NNS pence_NN per_IN share_NN ,_, resulting_VBG in_IN a_DT dividend_NN for_IN the_DT year_NN of_IN 44_CD in_IN the_DT USA_NNP ,_, UK_NNP ,_, Japan_NNP and_CC Canada_NNP :_: by_IN far_RB the_DT largest_JJS pence_NN per_IN share_NN ,_, a_DT 2_CD pence_NN increase_NN over_IN the_DT dividend_NN of_IN relates_VBZ to_TO Glaxo_NNP heritage_NN products_NNS ,_, in_IN respect_NN of_IN which_WDT the_DT 42_CD pence_NN per_IN share_NN for_IN 2004_CD ._.
US_NNP Internal_NNP Revenue_NNP Service_NNP IRS_NNP and_CC HM_NNP Revenue_NNP &_CC Customs_NNP HMRC_NNP in_IN the_DT UK_NNP have_VBP made_VBN competing_VBG and_CC contradictory_JJ claims_NNS ._.
2_CD pence_NN increase_NN in_IN dividend_NN resulting_VBG in_IN 44_CD GSK_NNP has_VBZ attempted_VBN to_TO settle_VB the_DT US_NNP dispute_NN ,_, first_RB through_IN pence_NN for_IN the_DT year_NN direct_JJ discussion_NN with_IN the_DT IRS_NNP and_CC subsequently_RB through_IN discussions_NNS between_IN the_DT US_NNP and_CC UK_NNP authorities_NNS under_IN Cash_NNP ow_VBD the_DT terms_NNS of_IN the_DT double_JJ tax_NN convention_NN between_IN the_DT two_CD The_DT net_JJ cash_NN inow_NN from_IN operating_VBG activities_NNS after_IN taxation_NN countries_NNS :_: these_DT discussions_NNS were_VBD terminated_VBN in_IN July_NNP 2003_CD ._.
paid_VBN was_VBD 5,958_CD million_CD ,_, an_DT increase_NN of_IN 1,014_CD million_CD On_IN 6th_JJ January_NNP 2004_CD ,_, the_DT IRS_NNP issued_VBD a_DT Notice_NNP of_IN over_IN 2004_CD ,_, arising_VBG principally_RB due_JJ to_TO higher_JJR operating_VBG deficiency_NN for_IN the_DT years_NNS 1989-1996_CD claiming_VBG additional_JJ profits_NNS ._.
The_DT net_JJ cash_NN outow_NN from_IN investing_VBG activities_NNS was_VBD 1,660_CD On_IN 2nd_JJ April_NNP 2004_CD ,_, the_DT Group_NNP led_VBD a_DT petition_NN in_IN the_DT US_NNP Tax_NNP million_CD ,_, an_DT increase_NN of_IN 740_CD million_CD which_WDT reected_VBD the_DT Court_NNP disputing_VBG the_DT IRS_NNP claim_NN and_CC seeking_VBG a_DT refund_NN of_IN $_$ 1_CD purchase_NN of_IN Corixa_NNP and_CC ID_NNP Biomedical_NNP in_IN 2005_CD for_IN over_IN 1_CD billion_CD in_IN taxes_NNS ._.
On_IN 25th_JJ January_NNP 2005_CD the_DT IRS_NNP issued_VBD a_DT billion_CD purchases_NNS of_IN businesses_NNS in_IN 2004_CD were_VBD 0.3_CD billion_CD ._.
further_RB Notice_NNP of_IN deficiency_NN for_IN the_DT years_NNS 1997-2000_CD claiming_VBG additional_JJ federal_JJ taxes_NNS of_IN $_$ 1.9_CD billion_CD ,_, which_WDT the_DT Free_NNP cash_NN ow_NN was_VBD 4.7_CD billion_CD ,_, an_DT increase_NN of_IN 26_CD %_NN over_IN Group_NNP contested_VBN by_IN ling_VBG a_DT petition_NN in_IN the_DT US_NNP Tax_NNP Court_NNP on_IN 2004_CD ._.
Free_NNP cash_NN ow_NN is_VBZ the_DT amount_NN of_IN cash_NN generated_VBN by_IN 12th_JJ April_NNP 2005_CD ,_, to_TO which_WDT the_DT IRS_NNP led_VBD its_PRP$ statutory_JJ Answer_NNP the_DT business_NN after_IN meeting_VBG its_PRP$ obligations_NNS for_IN interest_NN ,_, tax_NN on_IN 7th_JJ June_NNP 2005_CD ._.
In_IN September_NNP 2005_CD ,_, the_DT Court_NNP agreed_VBD and_CC dividends_NNS paid_VBN to_TO minority_NN interests_NNS ,_, and_CC after_IN capital_NN to_TO consolidate_VB the_DT IRS_NNP claims_NNS for_IN 1997-2000_CD with_IN those_DT for_IN expenditure_NN on_IN non-current_JJ tangible_JJ and_CC intangible_JJ assets_NNS ._.
The_DT total_JJ claims_NNS for_IN these_DT periods_NNS amount_NN to_TO $_$ 4.6_CD billion_CD of_IN additional_JJ federal_JJ taxes_NNS Outlook_NNP and_CC related_JJ interest_NN to_TO 31st_CD December_NNP 2005_CD of_IN $_$ 3.7_CD billion_CD ,_, Seven_CD Pharmaceutical_NNP products_NNS expected_VBN to_TO be_VB net_JJ of_IN federal_JJ tax_NN relief_NN ,_, giving_VBG a_DT total_NN of_IN $_$ 8.3_CD billion_CD ._.
The_DT Groups_NNS petitions_NNS against_IN the_DT IRS_NNP claims_NNS include_VBP counterapproved_VBN launched_VBN in_IN 2006_CD :_: claims_NNS for_IN repayment_NN of_IN federal_JJ taxes_NNS totalling_VBG $_$ 1.8_CD billion_CD ,_, Rotarix_NNP for_IN rotavirus_NN based_VBN partly_RB by_IN reference_NN to_TO an_DT Advance_NNP Pricing_NN Agreement_NN Entereg_NNP for_IN post-operative_JJ bowel_NN disorders_NNS APA_NNP between_IN SmithKline_NNP Beecham_NNP and_CC the_DT IRS_NNP covering_VBG the_DT transfer_NN pricing_NN of_IN Tagamet_NNP between_IN 1991_CD and_CC 1993_CD ._.
Trexima_NNP for_IN migraine_NN On_IN 23rd_JJ December_NNP 2004_CD ,_, the_DT IRS_NNP led_VBD a_DT motion_NN for_IN Avandaryl_NNP for_IN diabetes_NN summary_NN judgement_NN to_TO exclude_VB any_DT evidence_NN relating_VBG to_TO Coreg_NNP CR_NNP for_IN heart_NN failure_NN APAs_NNS from_IN the_DT court_NN proceedings_NNS ._.
On_IN 31st_CD March_NNP 2005_CD ,_, Arranon_NNP for_IN cancer_NN the_DT trial_NN judge_NN denied_VBD the_DT IRS_NNP motion_NN and_CC reserved_VBN ruling_NN on_IN the_DT admissibility_NN of_IN APA_NNP evidence_NN until_IN full_JJ trial_NN ,_, which_WDT Altabax_NNP for_IN infections_NNS is_VBZ scheduled_VBN to_TO commence_VB on_IN 16th_JJ October_NNP 2006_CD ._.
Legal_JJ proceedings_NNS As_IN similar_JJ tax_NN issues_NNS remain_VBP open_JJ for_IN 2001_CD to_TO date_NN ,_, GSK_NNP The_NNP Group_NNP is_VBZ involved_VBN in_IN patent_NN litigation_NN with_IN expects_VBZ to_TO receive_VB further_JJ substantial_JJ claims_NNS by_IN the_DT IRS_NNP for_IN manufacturers_NNS seeking_VBG to_TO market_NN generic_JJ versions_NNS of_IN these_DT years_NNS ._.
GSK_NNP continues_VBZ to_TO believe_VB that_IN the_DT profits_NNS many_JJ of_IN the_DT Groups_NNS most_RBS important_JJ products_NNS ,_, including_VBG reported_VBN by_IN its_PRP$ US_NNP subsidiaries_NNS for_IN the_DT period_NN 1989_CD to_TO date_NN ,_, Wellbutrin_NNP ,_, Seretide_NNP ,_, Avandia_NNP ,_, Imitrex_NNP ,_, Valtrex_NNP ,_, Lamictal_NNP on_IN which_WDT it_PRP has_VBZ paid_VBN taxes_NNS in_IN the_DT USA_NNP ,_, are_VBP more_RBR than_IN and_CC Zofran_NNP ,_, prior_RB to_TO the_DT expiration_NN of_IN the_DT Groups_NNS patents_NNS ._.
sufficient_JJ to_TO reect_VB the_DT activities_NNS of_IN its_PRP$ US_NNP operations_NNS ._.
The_DT Group_NNP is_VBZ currently_RB a_DT defendant_NN in_IN a_DT number_NN of_IN product_NN However_RB ,_, the_DT Group_NNP tax_NN creditor_NN balance_NN at_IN 31st_CD liability_NN lawsuits_NNS ,_, including_VBG class_NN actions_NNS ,_, that_WDT involve_VBP December_NNP 2005_CD of_IN 2.3_CD billion_CD 2004_CD 1.8_CD billion_CD substantial_JJ claims_NNS for_IN damages_NNS related_VBN to_TO the_DT Groups_NNS includes_VBZ a_DT provision_NN for_IN the_DT estimated_VBN amount_NN at_IN which_WDT pharmaceutical_JJ products_NNS ._.
The_DT Group_NNP is_VBZ also_RB a_DT defendant_NN the_DT IRS_NNP dispute_NN might_MD ultimately_RB be_VB settled_VBN ._.
in_IN anti-trust_JJ actions_NNS led_VBD following_VBG adverse_JJ outcomes_NNS in_IN If_IN the_DT IRS_NNP were_VBD to_TO follow_VB the_DT same_JJ methodology_NN as_IN applied_VBN prosecution_NN of_IN patent_NN infringement_NN actions_NNS ._.
Further_RB ,_, the_DT previously_RB in_IN respect_NN of_IN these_DT later_JJ years_NNS ,_, GSK_NNP estimates_VBZ Group_NNP is_VBZ responding_VBG to_TO federal_JJ and_CC state_NN governmental_JJ that_IN the_DT potential_JJ unprovided_JJ exposure_NN in_IN respect_NN of_IN this_DT investigations_NNS in_IN the_DT USA_NNP into_IN pricing_NN ,_, marketing_NN and_CC dispute_NN with_IN the_DT IRS_NNP for_IN the_DT years_NNS 1989-2005_CD amounted_VBD reimbursement_NN of_IN a_DT number_NN of_IN prescription_NN drug_NN to_TO approximately_RB $_$ 11.5_CD billion_CD at_IN 31st_CD December_NNP 2005_CD products_NNS ._.
See_VB Note_VB 41_CD to_TO the_DT financial_JJ statements_NNS ,_, Legal_NNP 2004_CD $_$ 10.1_CD billion_CD ._.
proceedings_NNS ,_, in_IN the_DT Annual_JJ Report_NNP 2005_CD for_IN a_DT discussion_NN of_IN proceedings_NNS and_CC governmental_JJ investigations_NNS in_IN which_WDT GSK_NNP is_VBZ in_IN continuing_VBG discussions_NNS with_IN HMRC_NNP in_IN respect_NN of_IN the_DT Group_NNP is_VBZ currently_RB involved_VBN ._.
UK_NNP transfer_NN pricing_NN and_CC other_JJ matters_NNS which_WDT are_VBP in_IN dispute_NN for_IN the_DT years_NNS 1995_CD to_TO date_NN ._.
However_RB ,_, little_JJ progress_NN has_VBZ been_VBN made_VBN over_IN the_DT past_JJ year_NN and_CC consequently_RB these_DT matters_NNS may_MD become_VB subject_JJ to_TO litigation_NN in_IN due_JJ course_NN ._.
GSK_NNP Annual_JJ Review_NNP 2005_CD 17_CD The_DT Board_NNP The_NNP Board_NNP of_IN Directors_NNS is_VBZ ultimately_RB accountable_JJ for_IN the_DT Groups_NNS activities_NNS ,_, strategy_NN and_CC financial_JJ performance_NN ._.
Sir_NNP Christopher_NNP Gent_NNP Dr_NNP Jean-Pierre_NNP Garnier_NNP Lawrence_NNP Culp_NNP Sir_NNP Crispin_NNP Davis_NNP Julian_NNP Heslop_NNP Sir_NNP Deryck_NNP Maughan_NNP Sir_NNP Ian_NNP Prosser_NNP Dr_NNP Ronaldo_NNP Schmitz_NNP Dr_NNP Lucy_NNP Shapiro_NNP Tom_NNP fide_NNP Swaan_NNP Sir_NNP Robert_NNP Wilson_NNP Dr_NNP Tachi_NNP Yamada_NNP Sir_NNP Christopher_NNP Gent_NNP Aged_VBD 57_CD Dr_NNP Ronaldo_NNP Schmitz_NNP Aged_VBD 67_CD Appointed_VBN on_IN 1st_CD June_NNP 2004_CD ._.
Sir_NNP Christopher_NNP was_VBD the_DT Chief_NNP Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD ._.
Dr_NNP Schmitz_NNP was_VBD Executive_NNP officer_NN of_IN Vodafone_NNP plc_NN ,_, until_IN his_PRP$ retirement_NN in_IN July_NNP 2003_CD ._.
He_PRP formerly_RB a_DT Non-Executive_JJ Director_NNP of_IN Glaxo_NNP Wellcome_NNP plc._NN ._.
He_PRP is_VBZ a_DT Nonis_NNP a_DT Non-Executive_JJ Director_NNP of_IN Lehman_NNP Brothers_NNP Holdings_NNPS Inc_NNP ,_, a_DT member_NN Executive_NNP Director_NNP of_IN Legal_NNP &_CC General_NNP Group_NNP plc_NN and_CC a_DT member_NN of_IN the_DT of_IN the_DT Financial_NNP Reporting_NNP Council_NNP ,_, a_DT Senior_JJ Adviser_NNP at_IN Bain_NNP &_CC Co._NNP and_CC Board_NNP of_IN Directors_NNS of_IN Rohm_NNP and_CC Haas_NNP Company_NNP and_CC Cabot_NNP Chairman_NNP of_IN the_DT advisory_JJ board_NN of_IN Reform_NN ._.
Dr_NNP Jean-Pierre_NNP Garnier_NNP Aged_VBD 58_CD Dr_NNP Lucy_NNP Shapiro_NNP Aged_VBD 65_CD Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD ._.
Dr_NNP Garnier_NNP was_VBD Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD ._.
Dr_NNP Shapiro_NNP was_VBD appointed_VBN an_DT Executive_NNP Director_NNP of_IN SmithKline_NNP Beecham_NNP plc_NN in_IN 1992_CD ,_, formerly_RB a_DT Non-Executive_JJ Director_NNP of_IN SmithKline_NNP Beecham_NNP plc._NN ._.
She_PRP is_VBZ and_CC became_VBD Chief_NNP Executive_NNP officer_NN in_IN April_NNP 2000_CD ._.
He_PRP is_VBZ a_DT NonLudwig_NNP Professor_NNP of_IN Cancer_NNP Research_NNP in_IN the_DT Department_NNP of_IN Executive_NNP Director_NNP of_IN United_NNP Technologies_NNPS Corporation_NNP and_CC a_DT member_NN Developmental_NNP Biology_NNP and_CC Director_NNP of_IN the_DT Beckman_NNP Center_NNP for_IN of_IN the_DT Board_NNP of_IN Trustees_NNPS of_IN the_DT Eisenhower_NNP Exchange_NNP Fellowships_NNP ._.
He_PRP Molecular_JJ and_CC Genetic_JJ Medicine_NN at_IN the_DT Stanford_NNP University_NNP School_NNP of_IN holds_VBZ a_DT PhD_NNP in_IN pharmacology_NN from_IN the_DT University_NNP of_IN Louis_NNP Pasteur_NNP in_IN Medicine_NNP and_CC a_DT Non-Executive_JJ Director_NNP of_IN Anacor_NNP Pharmaceuticals_NNP ,_, France_NNP and_CC an_DT MBA_NNP from_IN Stanford_NNP University_NNP in_IN the_DT USA_NNP ._.
Inc._NNP ._.
She_PRP holds_VBZ a_DT PhD_NNP in_IN molecular_JJ biology_NN ._.
Lawrence_NNP Culp_NNP Aged_VBD 42_CD Tom_NNP fide_NNP Swaan_NNP Aged_VBD 59_CD Appointed_VBN on_IN 1st_CD July_NNP 2003_CD ._.
Mr_NNP Culp_NNP is_VBZ Appointed_VBN on_IN 1st_CD January_NNP 2006_CD ._.
Mr_NNP fide_VBD Swaan_NNP President_NNP and_CC Chief_NNP Executive_NNP officer_NN of_IN Danaher_NNP Corporation_NNP ._.
Prior_RB to_TO is_VBZ a_DT member_NN of_IN the_DT Managing_VBG Board_NNP of_IN ABN_NNP AMRO_NNP ,_, of_IN which_WDT he_PRP was_VBD joining_VBG Danaher_NNP ,_, he_PRP held_VBD positions_NNS in_IN Accenture_NNP ,_, previously_RB Andersen_NNP Chief_NNP Financial_NNP officer_NN until_IN 31st_CD December_NNP 2005_CD ._.
He_PRP will_MD retire_VB from_IN Consulting_NNP ._.
the_DT Board_NNP of_IN ABN_NNP AMRO_NNP on_IN 1st_CD May_NNP 2006_CD ._.
He_PRP is_VBZ a_DT Non-Executive_JJ Director_NNP of_IN the_DT Financial_NNP Services_NNPS Authority_NNP ,_, a_DT member_NN of_IN the_DT Board_NNP of_IN Sir_NNP Crispin_NNP Davis_NNP Aged_VBD 56_CD the_DT Institute_NNP of_IN International_NNP Finance_NNP ,_, Chairman_NNP of_IN the_DT Board_NNP of_IN the_DT Appointed_VBN on_IN 1st_CD July_NNP 2003_CD ._.
Sir_NNP Crispin_NNP is_VBZ Chief_NNP Netherlands_NNP Opera_NNP and_CC a_DT member_NN of_IN the_DT Board_NNP of_IN the_DT Royal_NNP Executive_NNP of_IN Reed_NNP Elsevier_NNP PLC._NNP ._.
Prior_RB to_TO that_DT ,_, he_PRP was_VBD Chief_NNP Executive_NNP Concertgebouw_NNP Orchestra_NNP ._.
of_IN Aegis_NNP Group_NNP plc_NN ,_, which_WDT he_PRP joined_VBD from_IN Guinness_NNP plc_NN ,_, where_WRB he_PRP was_VBD a_DT member_NN of_IN the_DT main_JJ board_NN and_CC Group_NNP Managing_VBG Director_NNP of_IN United_NNP Sir_NNP Robert_NNP Wilson_NNP Aged_VBD 62_CD Distillers_NNPS ._.
He_PRP spent_VBD his_PRP$ early_JJ career_NN with_IN Procter_NNP &_CC Gamble_NNP ._.
Sir_NNP Robert_NNP is_VBZ Non-Executive_JJ Chairman_NN of_IN BG_NNP Group_NNP plc_NN and_CC the_DT Economist_NNP Group_NNP Julian_NNP Heslop_NNP Aged_VBD 52_CD and_CC was_VBD previously_RB Executive_NNP Chairman_NNP of_IN Rio_NNP Tinto_NNP ._.
Mr_NNP Heslop_NNP joined_VBD Glaxo_NNP Wellcome_NNP as_IN Financial_NNP Controller_NNP in_IN April_NNP 1998_CD ._.
In_IN January_NNP 2001_CD ,_, Dr_NNP Tachi_NNP Yamada_NNP Aged_VBD 60_CD following_VBG the_DT merger_NN ,_, he_PRP was_VBD appointed_VBN Senior_JJ Vice_NNP President_NNP ,_, Appointed_VBN on_IN 1st_CD January_NNP 2004_CD ._.
Prior_RB to_TO joining_VBG Glaxo_NNP Wellcome_NNP ,_, he_PRP held_VBD senior_JJ Research_NNP &_CC Development_NNP ._.
Dr_NNP Yamada_NNP was_VBD a_DT Non-Executive_JJ Director_NNP ,_, and_CC finance_NN roles_NNS at_IN Grand_NNP Metropolitan_NNP PLC._NNP ._.
subsequently_RB an_DT Executive_NNP Director_NNP ,_, of_IN SmithKline_NNP Beecham_NNP plc._NN ._.
Prior_RB to_TO joining_VBG SmithKline_NNP Beecham_NNP ,_, he_PRP was_VBD Chairman_NNP of_IN the_DT Department_NNP of_IN Sir_NNP Deryck_NNP Maughan_NNP Aged_VBD 58_CD Internal_NNP Medicine_NNP at_IN the_DT University_NNP of_IN Michigan_NNP Medical_NNP School_NNP and_CC Appointed_VBN on_IN 1st_CD June_NNP 2004_CD ._.
Sir_NNP Deryck_NNP is_VBZ a_DT Physician-in-Chief_NNP of_IN the_DT University_NNP of_IN Michigan_NNP Medical_NNP Center_NNP ._.
He_PRP is_VBZ a_DT Managing_VBG Director_NNP of_IN Kohlberg_NNP Kravis_NNP Roberts_NNP &_CC Co._NNP ._.
He_PRP was_VBD formerly_RB Trustee_NN of_IN the_DT Rockefeller_NNP Brothers_NNPS Fund_NNP and_CC a_DT member_NN of_IN the_DT Advisory_NNP Chairman_NNP and_CC CEO_NNP of_IN Citigroup_NNP International_NNP and_CC of_IN Salomon_NNP Brothers_NNP Board_NNP of_IN Quaker_NNP BioVentures_NNP ,_, Inc._NNP ._.
Inc._NNP ._.
He_PRP is_VBZ a_DT Non-Executive_JJ Director_NNP of_IN Reuters_NNP Group_NNP plc_NN as_RB well_RB as_IN serving_VBG on_IN the_DT Boards_NNPS of_IN Directors_NNS of_IN Carnegie_NNP Hall_NNP ,_, Lincoln_NNP Center_NNP Dr_NNP Moncef_NNP Slaoui_NNP Aged_VBD 46_CD and_CC NYU_NNP Medical_NNP Center_NNP ._.
He_PRP is_VBZ also_RB an_DT International_NNP Advisory_NNP Board_NNP Chairman_NNP Designate_NNP ,_, Research_NNP &_CC Development_NNP ._.
Dr_NNP Slaoui_NNP ,_, Senior_NNP Vice_NNP member_NN of_IN British_JJ American_NNP Business_NNP Inc._NNP and_CC a_DT Board_NNP member_NN of_IN the_DT President_NNP ,_, Worldwide_NNP Business_NNP Development_NNP ,_, has_VBZ been_VBN appointed_VBN to_TO Trilateral_NNP Commission_NNP ._.
He_PRP served_VBD as_IN Vice_NNP Chairman_NNP of_IN the_DT New_NNP York_NNP the_DT Board_NNP with_IN effect_NN from_IN 17th_JJ May_NNP 2006_CD ,_, and_CC will_MD succeed_VB Dr_NNP Stock_NNP Exchange_NNP from_IN 1996_CD to_TO 2000_CD ._.
Yamada_NNP as_IN Chairman_NNP ,_, Research_NNP &_CC Development_NNP on_IN 1st_CD June_NNP 2006_CD ._.
Dr_NNP Slaoui_NNP joined_VBD GSK_NNP Biologicals_NNPS in_IN 1988_CD where_WRB he_PRP engineered_VBD the_DT Sir_NNP Ian_NNP Prosser_NNP Aged_VBD 62_CD development_NN of_IN a_DT robust_JJ vaccines_NNS pipeline_NN ._.
He_PRP has_VBZ a_DT PhD_NNP in_IN Molecular_NNP Appointed_VBN on_IN 23rd_JJ May_NNP 2000_CD ._.
Sir_NNP Ian_NNP Biology_NNP and_CC Immunology_NNP from_IN Universit_NNP Libre_NNP fide_VBD Bruxelles_NNP ._.
was_VBD formerly_RB a_DT Non-Executive_JJ Director_NNP of_IN SmithKline_NNP Beecham_NNP plc._NN ._.
He_PRP was_VBD Chairman_NNP and_CC Chief_NNP Executive_NNP of_IN Bass_NNP plc_NN and_CC ultimately_RB Chairman_NNP Other_JJ Directors_NNS of_IN the_DT demerged_JJ InterContinental_NNP Hotels_NNPS Group_NNP plc._NN ._.
He_PRP was_VBD Chairman_NNP Mr_NNP John_NNP Coombe_NNP ,_, formerly_RB Chief_NNP Financial_NNP officer_NN ,_, retired_VBN from_IN the_DT of_IN the_DT World_NNP Travel_NNP and_CC Tourism_NNP Council_NNP and_CC the_DT London_NNP Stock_NNP Board_NNP on_IN 31st_CD March_NNP 2005_CD ._.
He_PRP is_VBZ Non-Executive_JJ Deputy_NNP Chairman_NNP of_IN BP_NNP plc_NN ,_, a_DT Non-Executive_JJ Director_NNP of_IN Sara_NNP Lee_NNP Corporation_NNP and_CC a_DT member_NN of_IN the_DT CBI_NNP Presidents_NNP Committee_NNP ._.
GSK_NNP Annual_JJ Review_NNP 2005_CD 18_CD The_DT Corporate_JJ Executive_NNP Team_NNP The_NNP executive_NN management_NN of_IN the_DT Group_NNP is_VBZ through_IN the_DT Corporate_NNP Executive_NNP Team_NNP CET_NNP ,_, comprising_VBG the_DT Chief_NNP Executive_NNP officer_NN ,_, the_DT Chief_NNP Financial_NNP officer_NN and_CC other_JJ senior_JJ managers_NNS ._.
JP_NNP Garnier_NNP Rupert_NNP Bondy_NNP Ford_NNP Calhoun_NNP John_NNP Clarke_NNP Marc_NNP Dunoyer_NNP Russell_NNP Greig_NNP Julian_NNP Heslop_NNP Dan_NNP Phelan_NNP David_NNP Pulman_NNP David_NNP Stout_NNP Chris_NNP Viehbacher_NNP Andrew_NNP Witty_NNP Tachi_NNP Yamada_NNP Jennie_NNP Younger_NNP JP_NNP Garnier_NNP David_NNP Pulman_NNP Chief_NNP Executive_NNP officer_NN President_NNP ,_, Global_NNP Manufacturing_NNP and_CC Supply_NNP David_NNP is_VBZ responsible_JJ for_IN the_DT Global_JJ Manufacturing_NNP and_CC Supply_NNP As_IN Chief_NNP Executive_NNP officer_NN ,_, JP_NNP is_VBZ responsible_JJ for_IN the_DT management_NN of_IN the_DT Group_NNP ._.
He_PRP oversees_VBZ all_DT operational_JJ aspects_NNS of_IN the_DT Group_NNP ,_, including_VBG Organisation_NNP and_CC Global_NNP Procurement_NNP ._.
He_PRP joined_VBD Glaxo_NNP in_IN 1978_CD and_CC establishing_VBG policies_NNS ,_, objectives_NNS and_CC initiatives_NNS ,_, and_CC he_PRP directs_VBZ longwas_NNS responsible_JJ for_IN the_DT North_JJ American_JJ supply_NN network_NN ,_, manufacturing_VBG term_NN strategy_NN ._.
He_PRP was_VBD formerly_RB Chief_NNP Executive_NNP officer_NN of_IN SmithKline_NNP strategy_NN and_CC logistics_NNS until_IN his_PRP$ current_JJ appointment_NN in_IN 2002_CD ._.
Beecham_NNP ,_, having_VBG joined_VBN the_DT Group_NNP in_IN 1990_CD ._.
David_NNP Stout_NNP Rupert_NNP Bondy_NNP President_NNP ,_, Pharmaceutical_NNP Operations_NNP Senior_NNP Vice_NNP President_NNP and_CC General_NNP Counsel_NNP David_NNP is_VBZ responsible_JJ for_IN all_DT pharmaceuticals_NNS and_CC vaccines_NNS operations_NNS Rupert_NNP is_VBZ responsible_JJ for_IN legal_JJ matters_NNS across_IN the_DT Group_NNP ,_, together_RB with_IN worldwide_NN ,_, including_VBG the_DT USA_NNP ,_, Europe_NNP ,_, International_NNP ,_, Japan_NNP and_CC Global_NNP Manufacturing_NNP and_CC Supply_NNP ._.
He_PRP joined_VBD SmithKline_NNP Beecham_NNP in_IN 1996_CD environmental_JJ ,_, health_NN and_CC safety_NN issues_NNS ,_, insurance_NN and_CC security_NN ._.
He_PRP was_VBD a_DT lawyer_NN in_IN private_JJ practice_NN before_IN joining_VBG SmithKline_NNP Beecham_NNP in_IN 1995_CD ._.
and_CC was_VBD President_NNP ,_, US_NNP Pharmaceuticals_NNP ,_, until_IN his_PRP$ current_JJ appointment_NN in_IN 2003_CD ._.
Ford_NNP Calhoun_NNP Chief_NNP Information_NNP officer_NN Chris_NNP Viehbacher_NNP President_NNP ,_, US_NNP Pharmaceuticals_NNP Ford_NNP is_VBZ responsible_JJ for_IN information_NN technology_NN ,_, a_DT global_JJ function_NN that_WDT enables_VBZ key_JJ business_NN processes_VBZ across_IN all_DT parts_NNS of_IN the_DT Group_NNP ._.
With_IN doctoral_JJ Chris_NNP is_VBZ responsible_JJ for_IN US_NNP Pharmaceuticals_NNP ._.
He_PRP joined_VBD Wellcome_NNP in_IN and_CC post-doctoral_JJ training_NN in_IN microbiology_NN ,_, genetics_NNS ,_, biomathematics_NNS and_CC 1988_CD and_CC was_VBD responsible_JJ for_IN GSKs_NNP European_NNP Pharmaceuticals_NNP computer_NN science_NN ,_, he_PRP joined_VBD Smith_NNP Kline_NNP &_CC French_NNP in_IN 1984_CD ._.
business_NN before_IN his_PRP$ current_JJ appointment_NN in_IN 2003_CD ._.
John_NNP Clarke_NNP Andrew_NNP Witty_NNP President_NNP ,_, Consumer_NNP Healthcare_NNP President_NNP ,_, Pharmaceuticals_NNP Europe_NNP John_NNP Clarke_NNP succeeded_VBD Jack_NNP Ziegler_NNP as_IN President_NNP ,_, Consumer_NNP Healthcare_NNP Andrew_NNP is_VBZ responsible_JJ for_IN the_DT Groups_NNS pharmaceuticals_NNS operations_NNS in_IN Europe_NNP ._.
He_PRP joined_VBD Glaxo_NNP in_IN 1985_CD and_CC was_VBD Senior_JJ Vice_NNP President_NNP ,_, Asia_NNP on_IN 31st_CD January_NNP 2006_CD ._.
He_PRP joined_VBD Beecham_NNP in_IN 1976_CD and_CC progressed_VBN through_IN roles_NNS in_IN Australasia_NNP ,_, South_NNP Africa_NNP ,_, The_DT Far_NNP East_NNP ,_, Japan_NNP ,_, Canada_NNP Pacic_NNP until_IN his_PRP$ current_JJ appointment_NN in_IN 2003_CD ._.
and_CC the_DT UK_NNP ._.
From_IN 1998_CD to_TO 2003_CD ,_, John_NNP was_VBD President_NNP ,_, Consumer_NNP Tachi_NNP Yamada_NNP Healthcare_NNP Europe_NNP ,_, and_CC in_IN 2004_CD ,_, appointed_VBN President_NNP ,_, Futures_NNP Group_NNP ._.
Chairman_NNP ,_, Research_NNP &_CC Development_NNP Tachi_NNP leads_VBZ the_DT Groups_NNS complex_JJ business_NN of_IN drug_NN discovery_NN and_CC Marc_NNP Dunoyer_NNP President_NNP ,_, Pharmaceuticals_NNP Japan_NNP development_NN ._.
He_PRP joined_VBD SmithKline_NNP Beecham_NNP in_IN 1994_CD as_IN a_DT Non-Executive_JJ Marc_NNP was_VBD appointed_VBN President_NNP ,_, Pharmaceuticals_NNP Japan_NNP in_IN March_NNP 2003_CD ._.
Director_NNP and_CC became_VBD Chairman_NNP ,_, R&D_NNP Pharmaceuticals_NNP in_IN 1999_CD ._.
He_PRP will_MD He_PRP joined_VBD the_DT Group_NNP in_IN 1999_CD and_CC was_VBD Senior_JJ Vice_NNP President_NNP and_CC retire_VB on_IN 1st_CD June_NNP 2006_CD ._.
Regional_NNP Director_NNP ,_, Japan_NNP until_IN his_PRP$ current_JJ appointment_NN ._.
Jennie_NNP Younger_NNP Russell_NNP Greig_NNP Senior_NNP Vice_NNP President_NNP ,_, Corporate_NNP Communications_NNPS &_CC President_NNP ,_, Pharmaceuticals_NNP International_NNP Community_NNP Partnerships_NNS Russell_NNP leads_VBZ the_DT pharmaceutical_JJ operations_NNS outside_IN the_DT USA_NNP ,_, Japan_NNP Jennie_NNP is_VBZ responsible_JJ for_IN the_DT Groups_NNS internal_JJ and_CC external_JJ communications_NNS ,_, its_PRP$ image_NN and_CC partnerships_NNS with_IN global_JJ communities_NNS ._.
and_CC most_JJS of_IN Europe_NNP ,_, covering_VBG more_JJR than_IN 100_CD countries_NNS ._.
He_PRP joined_VBD the_DT Group_NNP in_IN 1980_CD and_CC was_VBD Senior_JJ Vice_NNP President_NNP ,_, Worldwide_NNP Business_NNP She_PRP joined_VBD Glaxo_NNP Wellcome_NNP in_IN 1996_CD as_IN Director_NNP of_IN Investor_NNP Relations_NNP Development_NNP for_IN R&D_NNP prior_RB to_TO his_PRP$ current_JJ appointment_NN in_IN March_NNP 2003_CD ._.
and_CC was_VBD appointed_VBN to_TO her_PRP$ current_JJ position_NN in_IN 2001_CD ._.
Moncef_NNP Slaoui_NNP Julian_NNP Heslop_NNP Chairman_NNP Designate_NNP ,_, Research_NNP &_CC Development_NNP Chief_NNP Financial_NNP officer_NN Julian_NNP became_VBD Chief_NNP Financial_NNP officer_NN on_IN 1st_CD April_NNP 2005_CD ._.
As_IN head_NN of_IN the_DT Moncef_NNP will_MD succeed_VB Tachi_NNP Yamada_NNP as_IN Chairman_NNP ,_, Research_NNP &_CC finance_NN function_NN he_PRP is_VBZ responsible_JJ for_IN activities_NNS such_JJ as_IN financial_JJ Development_NNP on_IN 1st_CD June_NNP ._.
He_PRP will_MD join_VB the_DT CET_NNP on_IN 17th_JJ May_NNP ._.
He_PRP joined_VBD reporting_VBG and_CC control_NN ,_, tax_NN and_CC treasury_NN ,_, investor_NN relations_NNS ,_, finance_VB the_DT Group_NNP in_IN 1988_CD and_CC is_VBZ currently_RB Senior_JJ Vice_NNP President_NNP ,_, Worldwide_NNP Business_NNP Development_NNP ._.
systems_NNS ,_, internal_JJ audit_NN and_CC real_JJ estate_NN ._.
He_PRP joined_VBD Glaxo_NNP Wellcome_NNP as_IN Financial_NNP Controller_NNP in_IN April_NNP 1998_CD ._.
Other_JJ members_NNS Dan_NNP Phelan_NNP John_NNP Coombe_NNP retired_VBD as_IN Chief_NNP Financial_NNP officer_NN on_IN 31st_CD March_NNP 2005_CD ._.
Jack_NNP Ziegler_NNP retired_VBD as_IN head_NN of_IN the_DT Consumer_NNP Healthcare_NNP business_NN on_IN Senior_JJ Vice_NNP President_NNP ,_, Human_NNP Resources_NNPS Dan_NNP is_VBZ responsible_JJ for_IN benets_NNS ,_, compensation_NN ,_, recruitment_NN ,_, organization_NN 31st_CD January_NNP 2006_CD ._.
Robert_NNP Ingram_NNP continues_VBZ to_TO work_VB part-time_JJ as_IN Vice_NNP development_NN ,_, leadership_NN development_NN and_CC succession_NN planning_NN ,_, human_JJ Chairman_NNP of_IN Pharmaceuticals_NNP ,_, acting_VBG as_IN a_DT special_JJ advisor_NN to_TO the_DT Group_NNP resource_NN information_NN systems_NNS and_CC employee_NN health_NN management_NN ._.
and_CC attending_VBG CET_NNP meetings_NNS in_IN that_DT capacity_NN ._.
He_PRP was_VBD a_DT lawyer_NN in_IN private_JJ practice_NN before_IN joining_VBG Smith_NNP Kline_NNP &_CC French_NNP in_IN 1981_CD ._.
GSK_NNP Annual_JJ Review_NNP 2005_CD 19_CD Summary_NNP Remuneration_NNP Report_NNP for_IN the_DT year_NN to_TO 31st_CD December_NNP 2005_CD INTRODUCTION_NNP performance_NN conditions_NNS would_MD be_VB based_VBN on_IN the_DT The_DT Summary_NNP Remuneration_NNP Report_NNP sets_VBZ out_RP the_DT annual_JJ measurable_JJ delivery_NN of_IN strong_JJ financial_JJ performance_NN and_CC remuneration_NN of_IN the_DT Board_NNP earned_VBD in_IN 2005_CD ,_, together_RB with_IN the_DT delivery_NN of_IN superior_JJ returns_NNS to_TO shareholders_NNS as_IN any_DT gains_NNS under_IN long-term_JJ incentive_NN arrangements_NNS ._.
It_PRP also_RB compared_VBN with_IN other_JJ pharmaceutical_JJ companies_NNS :_: describes_VBZ the_DT background_NN and_CC outlines_VBZ the_DT Groups_NNS rea_VBP high_JJ proportion_NN of_IN the_DT total_JJ remuneration_NN opportunity_NN muneration_NN policy_NN ,_, together_RB with_IN the_DT performance_NN graph_NN will_MD be_VB based_VBN on_IN performance-related_JJ remuneration_NN ,_, required_VBN by_IN the_DT Directors_NNS Remuneration_NNP Report_NNP Regwhich_NNP will_MD be_VB delivered_VBN over_IN the_DT medium-term_JJ to_TO longulations_NNS 2002_CD the_DT Regulations_NNPS ._.
term_NN :_: and_CC The_DT Remuneration_NNP Committee_NNP the_DT Committee_NNP is_VBZ no_DT ex-gratia_NN payments_NNS will_MD be_VB made_VBN ._.
responsible_JJ for_IN making_VBG recommendations_NNS to_TO the_DT Board_NNP on_IN the_DT companys_NNS remuneration_VBP policy_NN and_CC ,_, within_IN the_DT Overall_JJ ,_, the_DT policy_NN is_VBZ intended_VBN to_TO provide_VB median_JJ total_JJ terms_NNS of_IN the_DT agreed_JJ policy_NN ,_, determining_VBG the_DT total_JJ individual_JJ remuneration_NN for_IN median_JJ performance_NN ._.
Poor_NNP performance_NN remuneration_NN packages_NNS of_IN the_DT Executive_NNP Directors_NNS and_CC will_MD result_VB in_IN total_JJ remuneration_NN signicantly_RB below_IN the_DT members_NNS of_IN the_DT CET_NNP Executives_NNS ._.
The_DT members_NNS of_IN the_DT pay_NN comparator_NN group_NN median_NN ,_, with_IN the_DT opportunity_NN to_TO Committee_NNP are_VBP set_VBN out_RP on_IN page_NN 23_CD ._.
earn_VB upper_JJ quartile_JJ total_JJ remuneration_NN for_IN exceptional_JJ performance_NN ._.
The_DT Committee_NNP has_VBZ developed_VBN the_DT remuneration_NN policy_NN to_TO align_VB executive_JJ remuneration_NN with_IN the_DT interests_NNS of_IN shareThis_NNP strong_JJ alignment_NN with_IN performance_NN is_VBZ demonstrably_RB holders_NNS whilst_VBP meeting_VBG the_DT imperative_NN of_IN recruiting_NN and_CC in_IN the_DT interests_NNS of_IN shareholders_NNS and_CC provides_VBZ the_DT Executives_NNS retaining_VBG the_DT executive_NN talent_NN essential_JJ to_TO the_DT leadership_NN with_IN unambiguous_JJ signals_NNS about_IN the_DT importance_NN of_IN of_IN the_DT company_NN ._.
delivering_VBG success_NN to_TO the_DT companys_NNS shareholders_NNS ._.
The_DT remuneration_NN policy_NN was_VBD nalised_VBN after_IN undertaking_VBG Commitment_NNP an_DT extensive_JJ consultation_NN process_NN with_IN shareholders_NNS and_CC The_DT Committee_NNP will_MD apply_VB this_DT policy_NN on_IN a_DT consistent_JJ and_CC institutional_JJ bodies_NNS during_IN the_DT course_NN of_IN 2003_CD and_CC 2004_CD ._.
transparent_JJ basis_NN ._.
Any_DT significant_JJ change_NN will_MD be_VB discussed_VBN with_IN shareholders_NNS in_IN advance_NN of_IN implementation_NN ._.
The_DT Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP continues_VBZ Pay_VB and_CC performance_NN comparators_NNS to_TO have_VB regular_JJ dialogue_NN with_IN institutional_JJ investors_NNS The_DT following_JJ table_NN sets_VBZ out_RP the_DT companies_NNS used_VBN for_IN pay_NN regarding_VBG GSKs_NNP remuneration_NN policy_NN ._.
and_CC performance_NN comparison_NN :_: Market_NNP The_NNP remuneration_NN policy_NN is_VBZ designed_VBN to_TO establish_VB a_DT Capitalisation_NNP framework_NN for_IN remuneration_NN which_WDT is_VBZ consistent_JJ with_IN the_DT 31.12.05_CD companys_NNS scale_NN and_CC scope_NN of_IN operations_NNS ,_, meets_VBZ the_DT Company_NN Country_NN m_NN recruitment_NN needs_NNS of_IN the_DT business_NN and_CC is_VBZ closely_RB aligned_VBN Abbott_NNP Laboratories_NNP USA_NNP 35,561_CD with_IN shareholder_NN guidelines_NNS ._.
AstraZeneca_NNP UK_NNP 44,693_CD Bristol-Myers_NNP Squibb_NNP USA_NNP 26,140_CD Deloitte_NNP &_CC Touche_NNP LLP_NNP have_VBP been_VBN appointed_VBN by_IN the_DT Eli_NNP Lilly_NNP USA_NNP 37,396_CD Committee_NNP to_TO provide_VB it_PRP with_IN independent_JJ advice_NN on_IN GlaxoSmithKline_NNP UK_NNP 85,497_CD executive_JJ remuneration_NN ._.
Johnson_NNP &_CC Johnson_NNP USA_NNP 103,950_CD Merck_NNP USA_NNP 40,440_CD REMUNERATION_NNP POLICY_NNP Novartis_NNP Switzerland_NNP 80,419_CD Principles_NNPS Pzer_NNP USA_NNP 99,942_CD The_DT Committee_NNP has_VBZ established_VBN four_CD core_NN principles_NNS Roche_NNP Holdings_NNP Switzerland_NNP 61,334_CD which_WDT underpin_VBP GSKs_NNS remuneration_JJ policy_NN ._.
These_DT are_VBP :_: Sano-Aventis_NNP France_NNP 70,997_CD securing_VBG outstanding_JJ executive_NN talent_NN :_: Schering-Plough_NNP USA_NNP 17,915_CD Takeda_NNP Pharmaceutical_NNP Company_NNP Japan_NNP 27,949_CD pay_NN for_IN performance_NN and_CC only_RB for_IN performance_NN :_: Wyeth_NNP USA_NNP 35,952_CD robust_JJ and_CC transparent_JJ governance_NN structures_NNS :_: and_CC GSKs_NNP executive_NN remuneration_NN consists_VBZ of_IN the_DT a_DT commitment_NN to_TO be_VB a_DT leader_NN of_IN good_JJ remuneration_NN following_VBG components_NNS :_: practice_NN in_IN the_DT pharmaceutical_JJ industry_NN ._.
Base_NNP salary_NN In_IN formulating_VBG the_DT policy_NN ,_, the_DT Committee_NNP decided_VBD that_IN :_: Base_NNP salaries_NNS are_VBP set_VBN by_IN reference_NN to_TO the_DT median_NN for_IN the_DT the_DT remuneration_NN structure_NN must_MD support_VB the_DT business_NN relevant_JJ market_NN ._.
For_IN executives_NNS this_DT is_VBZ the_DT pharmaceutical_JJ in_IN a_DT very_RB competitive_JJ market_NN place_NN :_: pay_VB comparator_NN group_NN ._.
Base_NNP salary_NN is_VBZ the_DT only_JJ element_NN of_IN remuneration_NN that_WDT is_VBZ xed_VBN ._.
UK_NNP shareholder_NN guidelines_NNS will_MD be_VB followed_VBN to_TO the_DT maximum_NN extent_NN consistent_JJ with_IN the_DT needs_NNS of_IN the_DT business_NN Annual_JJ bonus_NN and_CC the_DT company_NN would_MD maintain_VB a_DT regular_JJ dialogue_NN All_DT bonuses_NNS are_VBP determined_VBN on_IN the_DT basis_NN of_IN a_DT formal_JJ review_NN with_IN shareholders_NNS :_: of_IN annual_JJ performance_NN against_IN stretching_VBG financial_JJ targets_NNS based_VBN on_IN profit_NN before_IN interest_NN and_CC tax_NN and_CC are_VBP subject_JJ to_TO global_JJ pharmaceutical_JJ companies_NNS are_VBP the_DT primary_JJ pay_NN detailed_VBN assessment_NN of_IN individual_JJ ,_, business_NN unit_NN and_CC group_NN comparator_NN group_NN :_: achievements_NNS against_IN objectives_NNS ._.
In_IN determining_VBG the_DT bonus_NN awards_NNS for_IN 2005_CD ,_, the_DT Committee_NNP took_VBD into_IN account_NN the_DT excellent_JJ financial_JJ performance_NN during_IN the_DT year_NN and_CC the_DT encouraging_JJ progress_NN in_IN building_VBG the_DT pipeline_NN of_IN new_JJ products_NNS ._.
GSK_NNP Annual_JJ Review_NNP 2005_CD 20_CD Summary_NNP Remuneration_NNP Report_NNP continued_VBD Long-term_JJ incentives_NNS The_DT Committee_NNP has_VBZ decided_VBN that_IN for_IN the_DT awards_NNS granted_VBN The_DT remuneration_NN policy_NN provides_VBZ that_IN annual_JJ long-term_JJ since_IN 2004_CD ,_, there_EX will_MD be_VB no_DT performance_NN retesting_NN ,_, so_RB if_IN incentive_NN awards_NNS will_MD normally_RB be_VB made_VBN up_IN of_IN a_DT perforthe_JJ performance_NN condition_NN is_VBZ not_RB met_VBN after_IN the_DT three-year_JJ mance_NN share_NN award_NN and_CC a_DT share_NN option_NN award_NN ._.
The_DT period_NN ,_, the_DT option_NN will_MD lapse_NN ._.
remuneration_NN policy_NN places_NNS greater_JJR emphasis_NN on_IN the_DT use_NN The_DT performance_NN criteria_NNS relating_VBG to_TO performance_NN shares_NNS of_IN performance_NN shares_NNS rather_RB than_IN share_NN options_NNS ._.
and_CC share_NN options_NNS awarded_VBN and_CC granted_VBN prior_RB to_TO 2006_CD are_VBP The_DT Committee_NNP has_VBZ considered_VBN which_WDT performance_NN given_VBN in_IN the_DT Annual_JJ Report_NNP 2005_CD ._.
conditions_NNS should_MD be_VB applied_VBN to_TO the_DT long-term_JJ incentives_NNS ._.
Pensions_NNS The_DT Committee_NNP concluded_VBD that_IN it_PRP was_VBD appropriate_JJ to_TO The_DT Executives_NNS participate_VB in_IN GSK_NNP senior_JJ executive_NN pension_NN measure_NN performance_NN using_VBG a_DT combination_NN of_IN absolute_JJ plans_NNS ._.
The_DT pension_NN arrangements_NNS are_VBP structured_VBN in_IN financial_JJ results_NNS based_VBN on_IN earnings_NNS per_IN share_NN EPS_NNP and_CC accordance_NN with_IN the_DT plans_NNS operated_VBN for_IN executives_NNS in_IN the_DT the_DT delivery_NN of_IN superior_JJ value_NN to_TO shareholders_NNS based_VBN on_IN country_NN in_IN which_WDT the_DT executives_NNS are_VBP likely_JJ to_TO retire_VB ._.
Benets_NNPS Total_NNP Shareholder_NN Return_NN TSR_NNP measured_VBN against_IN the_DT are_VBP normally_RB payable_JJ at_IN age_NN 60_CD ,_, although_IN it_PRP was_VBD agreed_VBN comparator_NN group_NN ._.
that_IN Dr_NNP Yamada_NNP could_MD retire_VB at_IN age_NN 62_CD ,_, he_PRP will_MD retire_VB from_IN For_IN the_DT Executives_NNS ,_, the_DT level_NN of_IN performance_NN shares_NNS vesting_VBG the_DT company_NN on_IN 1st_CD June_NNP 2006_CD ._.
is_VBZ based_VBN on_IN the_DT companys_NNS TSR_NNP relative_JJ to_TO the_DT performance_NN comparator_NN group_NN over_IN a_DT three-year_JJ measurement_NN period_NN ._.
EXECUTIVE_NN DIRECTOR_NN TERMS_NNS AND_CC CONDITIONS_NNS If_IN GSK_NNP is_VBZ ranked_VBN at_IN position_NN seven_CD the_DT mid-point_NN of_IN the_DT The_DT policy_NN regarding_VBG the_DT Executive_NNP Directors_NNS contracts_NNS performance_NN comparator_NN group_NN ,_, 35_CD %_NN of_IN the_DT shares_NNS will_MD was_VBD the_DT subject_NN of_IN extensive_JJ review_NN and_CC change_NN during_IN vest_NN and_CC if_IN it_PRP is_VBZ below_IN that_DT position_NN then_RB none_NN of_IN the_DT shares_NNS 2003_CD ._.
This_DT resulted_VBD in_IN a_DT new_JJ framework_NN for_IN contracts_NNS for_IN will_MD vest_NN ._.
Only_RB if_IN GSK_NNP is_VBZ one_CD of_IN the_DT top_JJ two_CD companies_NNS will_MD Executive_NNP Directors_NNS appointed_VBN in_IN the_DT future_NN ._.
When_WRB determining_VBG vesting_NN levels_NNS ,_, Dr_NNP Garnier_NNP and_CC Dr_NNP Yamada_NNP agreed_VBD to_TO changes_NNS in_IN their_PRP$ the_DT Committee_NNP will_MD have_VB regard_NN to_TO the_DT companys_NNS contractual_JJ terms_NNS without_IN compensation_NN to_TO bring_VB their_PRP$ underlying_VBG financial_JJ performance_NN ._.
contractual_JJ terms_NNS broadly_RB in_IN line_NN with_IN the_DT new_JJ contractual_JJ The_DT performance_NN conditions_NNS applying_VBG to_TO the_DT share_NN options_NNS framework_NN ,_, including_VBG the_DT reduction_NN of_IN contractual_JJ notice_NN granted_VBN to_TO the_DT Executives_NNS are_VBP linked_VBN to_TO the_DT achievement_NN period_NN from_IN 24_CD to_TO 12_CD calendar_NN months_NNS ._.
However_RB ,_, to_TO of_IN compound_NN annual_JJ EPS_NNP growth_NN in_IN excess_NN of_IN the_DT Retail_NNP honor_NN certain_JJ aspects_NNS of_IN their_PRP$ old_JJ contractual_JJ terms_NNS ,_, Prices_NNS Index_NNP RPI_NNP over_IN three_CD year_NN performance_NN periods_NNS ._.
there_EX are_VBP a_DT number_NN of_IN individual_JJ features_NNS which_WDT will_MD be_VB retained_VBN ._.
In_IN the_DT event_NN of_IN early_JJ termination_NN by_IN the_DT When_WRB setting_VBG EPS_NNP targets_NNS ,_, the_DT Committee_NNP considers_VBZ the_DT company_NN ,_, Dr_NNP Garnier_NNP and_CC Dr_NNP Yamada_NNP would_MD receive_VB a_DT cash_NN companys_VBZ internal_JJ projections_NNS and_CC analysts_NNS forecasts_NNS for_IN sum_NN equivalent_NN to_TO the_DT total_NN of_IN their_PRP$ annual_JJ salary_NN ,_, on_IN target_NN GSKs_NNS EPS_NNP performance_NN ,_, as_RB well_RB as_IN analysts_NNS forecasts_NNS for_IN bonus_NN and_CC pension_NN contributions_NNS for_IN the_DT 12_CD months_NNS notice_VBP the_DT pharmaceutical_JJ industry_NN ._.
Vesting_VBG of_IN share_NN options_NNS granted_VBN in_IN February_NNP 2006_CD Mr_NNP Heslops_NNP contract_NN follows_VBZ the_DT new_JJ framework_NN ._.
increases_NNS on_IN a_DT straight-line_JJ basis_NN for_IN EPS_NNP performance_NN between_IN the_DT hurdles_NNS as_IN set_VBN out_RP in_IN the_DT graph_NN below_IN ._.
TSR_NNP performance_NN graph_NN The_DT graph_NN below_IN sets_NNS out_IN the_DT performance_NN of_IN the_DT company_NN relative_JJ to_TO the_DT FTSE_NNP 100_CD index_NN of_IN which_WDT the_DT company_NN is_VBZ a_DT Exceptional_JJ 100_CD %_NN constituent_NN and_CC to_TO the_DT performance_NN comparator_NN group_NN ._.
It_PRP has_VBZ been_VBN prepared_VBN in_IN accordance_NN with_IN the_DT Regulations_NNPS and_CC Superior_NNP is_VBZ not_RB an_DT indication_NN of_IN the_DT likely_JJ vesting_NN of_IN awards_NNS granted_VBN Baseline_NNP under_IN any_DT of_IN the_DT incentive_NN plans_NNS ._.
Threshold_NN 50_CD %_NN 110_CD 100_CD 0_CD %_NN 90_CD RPI_NNP 3_CD %_NN RPI_NNP 4_CD %_NN RPI_NNP 5_CD %_NN RPI_NNP 6_CD %_NN p._FW a._FW p._FW a._FW p._FW a._FW p._FW a._FW EPS_NNP Target_NNP 80_CD This_DT performance_NN condition_NN is_VBZ substantially_RB consistent_JJ with_IN UK_NNP shareholder_NN guidelines_NNS and_CC expectations_NNS and_CC is_VBZ 70_CD demanding_VBG when_WRB compared_VBN with_IN those_DT operated_VBN by_IN other_JJ global_JJ pharmaceutical_JJ companies_NNS ._.
This_DT is_VBZ consistent_JJ with_IN 60_CD the_DT policy_NN of_IN providing_VBG pay_NN for_IN performance_NN and_CC only_RB for_IN 31_CD 12_CD 00_CD 31_CD 12_CD 01_CD 31_CD 12_CD 02_CD 31_CD 12_CD 03_CD 31_CD 12_CD 04_CD 31_CD 12_CD 05_CD performance_NN ._.
GlaxoSmithKline_NNP Total_NNP Return_NN Index_NNP GlaxoSmithKline_NNP Pharma_NNP Peers_NNP Return_NN Index_NNP FTSE_NNP 100_CD Total_JJ Return_NN Index_NNP GSK_NNP Annual_JJ Review_NNP 2005_CD 21_CD Vesting_JJ percentage_NN Summary_NNP Remuneration_NNP Report_NNP continued_VBD ANNUAL_NNP REMUNERATION_NNP 2005_CD 2004_CD Fees_NNS and_CC Other_JJ Annual_JJ Deferred_JJ Total_JJ annual_JJ Total_JJ annual_JJ salary_NN benets_NNS bonus_NN bonus_NN remuneration_NN remuneration_NN Directors_NNS of_IN GSK_NNP 000 000 000 000_CD 000_CD 000_CD Executive_NNP Directors_NNS Dr_VBP JP_NNP Garnier_NNP $_$ 1,582_CD $_$ 641_CD $_$ 2,812_CD $_$ 1,556_CD $_$ 6,591_CD $_$ 4,559_CD Mr_NNP J_NNP Heslop_NNP 240_CD 9_CD 280_CD 529_CD Dr_NNP T_NNP Yamada_NNP $_$ 763_CD $_$ 739_CD $_$ 1,110_CD $_$ 698_CD $_$ 3,310_CD $_$ 2,303_CD Former_NNP Executive_NNP Director_NNP Mr_NNP J_NNP Coombe_NNP 139 32 171 515_CD Total_NNP Executive_NNP Directors_NNS 1,667_CD 799_CD 2,436_CD 1,238_CD 6,140_CD 4,265_CD Current_JJ Non-Executive_JJ Directors_NNS Mr_NNP L_NNP Culp_NNP $_$ 136_CD $_$ 136_CD $_$ 97_CD Sir_NNP Crispin_NNP Davis_NNP 70_CD 70_CD 57_CD Sir_NNP Christopher_NNP Gent_NNP 500 500 175_CD Sir_NNP Deryck_NNP Maughan_NNP $_$ 146_CD $_$ 146_CD $_$ 57_CD Sir_NNP Ian_NNP Prosser_NNP 100_CD 100_CD 65_CD Dr_NN R_NN Schmitz_NNP 95_CD 95_CD 72_CD Dr_NN L_NNP Shapiro_NNP $_$ 230_CD $_$ 230_CD $_$ 182_CD Sir_NNP Robert_NNP Wilson_NNP 90_CD 90_CD 66_CD Former_JJ Non-Executive_JJ Directors_NNS Dr_VBP M_NNP Barzach_NNP 58_CD 58_CD 78_CD Sir_NNP Christopher_NNP Hogg_NNP 370_CD Sir_NNP Roger_NNP Hurn_NNP 5_CD 5_CD Sir_NNP Peter_NNP Job_NNP 5_CD 5_CD 57_CD Mr_NNP J_NNP McArthur_NNP $_$ 60_CD Mr_NNP D_NNP McHenry_NNP $_$ 42_CD Sir_NNP Richard_NNP Sykes_NNPS 1_CD 1_CD 1_CD Total_JJ Non-Executive_JJ Directors_NNS 1,195_CD 11_CD 1,206_CD 1,180_CD Total_JJ remuneration_NN 2,862_CD 810_CD 2,436_CD 1,238_CD 7,346_CD 5,445_CD Remuneration_NNP for_IN Directors_NNS on_IN the_DT US_NNP payroll_NN is_VBZ reported_VBN in_IN Dollars_NNP ._.
Amounts_NNS have_VBP been_VBN converted_VBN to_TO Sterling_NNP at_IN the_DT average_JJ exchange_NN rates_NNS for_IN each_DT year_NN ._.
Following_VBG the_DT merger_NN ,_, those_DT participants_NNS in_IN the_DT legacy_NN schemes_NNS who_WP elected_VBD to_TO exchange_VB their_PRP$ legacy_NN options_NNS for_IN options_NNS over_IN GSK_NNP shares_NNS were_VBD granted_VBN an_DT additional_JJ cash_NN benefit_NN equal_JJ to_TO 10_CD %_NN of_IN the_DT grant_NN price_NN of_IN the_DT original_JJ option_NN ._.
This_DT additional_JJ benefit_NN known_VBN as_IN the_DT Exchange_NNP Offer_NN Incentive_NNP EOI_NNP is_VBZ only_RB payable_JJ when_WRB the_DT new_JJ option_NN is_VBZ exercised_VBN or_CC lapses_NNS above_IN market_NN value_NN ._.
During_IN the_DT year_NN Dr_NNP Garnier_NNP received_VBD $_$ 174,472_CD 2004_CD $_$ 335,730_CD and_CC Dr_NNP Yamada_NNP received_VBD $_$ 167,405_CD 2004_CD nil_NN relating_VBG to_TO options_NNS exercised_VBN under_IN the_DT EOI_NNP ._.
Those_DT amounts_NNS are_VBP included_VBN in_IN other_JJ benets_NNS in_IN the_DT table_NN above_IN ._.
Non-Executive_JJ Directors_NNS are_VBP required_VBN to_TO receive_VB a_DT significant_JJ part_NN of_IN their_PRP$ fees_NNS in_IN the_DT form_NN of_IN shares_NNS or_CC ADSs_NNS and_CC from_IN 1st_CD October_NNP 2004_CD ,_, all_DT Non-Executive_JJ Directors_NNS ,_, except_IN the_DT Chairman_NNP ,_, are_VBP required_VBN to_TO take_VB at_IN least_JJS 25_CD %_NN of_IN fees_NNS under_IN the_DT fee_NN allocation_NN arrangement_NN ._.
They_PRP can_MD also_RB elect_VB to_TO invest_VB part_NN or_CC all_DT of_IN the_DT remaining_VBG balance_NN of_IN their_PRP$ fees_NNS in_IN the_DT form_NN of_IN shares_NNS or_CC ADSs_NNS ._.
The_DT value_NN of_IN these_DT shares_NNS and_CC ADSs_NNS at_IN the_DT dates_NNS of_IN award_NN are_VBP included_VBN in_IN fees_NNS and_CC salary_NN above_IN ._.
These_DT shares_NNS and_CC ADSs_NNS are_VBP not_RB paid_VBN out_RP until_IN the_DT Director_NNP leaves_VBZ the_DT Board_NNP ._.
In_IN addition_NN to_TO annual_JJ compensation_NN ,_, GSK_NNP operates_VBZ share_NN plans_NNS to_TO provide_VB incentives_NNS to_TO Executive_NNP Directors_NNS to_TO achieve_VB longer-term_JJ growth_NN in_IN shareholder_NN value_NN ._.
Gains_NNS under_IN such_JJ plans_NNS are_VBP recognized_VBN on_IN exercise_NN or_CC maturity_NN of_IN the_DT award_NN ,_, but_CC reect_JJ value_NN earned_VBN over_IN a_DT period_NN of_IN years_NNS ._.
The_DT timing_NN of_IN exercise_NN is_VBZ normally_RB at_IN the_DT discretion_NN of_IN the_DT Director_NNP ._.
Full_JJ details_NNS relating_VBG to_TO the_DT operation_NN of_IN the_DT companys_NNS share_NN plans_NNS may_MD be_VB found_VBN in_IN the_DT 2005_CD Annual_JJ Report_NNP ._.
In_IN 2001_CD ,_, following_VBG the_DT merger_NN ,_, Dr_NNP Garnier_NNP ,_, Mr_NNP Coombe_NNP and_CC Dr_NNP Yamada_NNP were_VBD awarded_VBN a_DT one-off_JJ special_JJ deferred_VBN bonus_NN as_IN members_NNS of_IN the_DT CET_NNP ._.
Each_DT was_VBD awarded_VBN an_DT amount_NN equivalent_NN to_TO his_PRP$ salary_NN on_IN 31st_CD December_NNP 2001_CD and_CC this_DT was_VBD notionally_RB invested_VBN in_IN GSK_NNP shares_NNS or_CC ADSs_NNS on_IN 15th_JJ February_NNP 2002_CD ._.
The_DT amount_NN of_IN the_DT bonus_NN vesting_VBG on_IN 15th_JJ February_NNP 2005_CD was_VBD equivalent_JJ to_TO the_DT then_RB value_NN of_IN shares_NNS or_CC ADSs_NNS notionally_RB acquired_VBN in_IN February_NNP 2002_CD plus_CC dividends_NNS reinvested_VBN over_IN the_DT period_NN ._.
These_DT amounts_NNS were_VBD paid_VBN in_IN February_NNP 2005_CD and_CC are_VBP included_VBN in_IN the_DT table_NN above_IN ._.
Mr_NNP Coombe_NNP waived_VBD his_PRP$ entitlements_NNS to_TO the_DT 2001_CD special_JJ deferred_VBN bonus_NN of_IN 383,924_CD ,_, 2004_CD annual_JJ bonus_NN of_IN 650,370_CD and_CC prorated_VBD 2005_CD bonus_NN of_IN 106,870_CD ._.
The_DT company_NN made_VBD a_DT contribution_NN in_IN 2005_CD to_TO the_DT pension_NN plan_NN of_IN 1,141,164_CD to_TO enhance_VB his_PRP$ pension_NN entitlement_NN ._.
Mr_NNP fide_NNP Swaan_NNP joined_VBD the_DT Board_NNP as_IN a_DT non-executive_JJ Director_NNP on_IN 1st_CD January_NNP 2006_CD ._.
No_DT remuneration_NN is_VBZ shown_VBN for_IN him_PRP in_IN the_DT table_NN above_IN ._.
The_DT accrued_VBN annual_JJ benets_NNS under_IN the_DT dened_VBN benefit_NN pension_NN schemes_NNS operated_VBN by_IN the_DT Group_NNP were_VBD :_: Dr_NNP Garnier_NNP $_$ 1,092,697_CD :_: Mr_NNP Heslop_NNP 74,505_CD :_: and_CC Dr_NNP Yamada_NNP $_$ 209,631_CD ._.
In_IN addition_NN ,_, Dr_NNP Garnier_NNP and_CC Dr_NNP Yamada_NNP are_VBP members_NNS of_IN a_DT money_NN purchase_NN scheme_NN into_IN which_WDT contributions_NNS of_IN $_$ 154,172_CD and_CC $_$ 73,679_CD ,_, respectively_RB ,_, were_VBD paid_VBN during_IN 2005_CD ._.
None_NN of_IN the_DT above_JJ Directors_NNS received_VBD expenses_NNS during_IN the_DT year_NN requiring_VBG separate_JJ disclosure_NN as_IN dened_VBN by_IN the_DT Regulations_NNPS ._.
GSK_NNP Annual_JJ Review_NNP 2005_CD 22_CD Corporate_JJ governance_NN GOVERNANCE_NNP AND_CC POLICY_NNP Audit_NNP Committee_NNP The_NNP Board_NNP and_CC Corporate_NNP Executive_NNP Team_NNP The_NNP Audit_NNP Committee_NNP reviews_VBZ the_DT financial_JJ and_CC internal_JJ The_DT Directors_NNS are_VBP listed_VBN under_IN The_DT Board_NNP on_IN page_NN 18_CD ._.
reporting_VBG process_NN ,_, the_DT system_NN of_IN internal_JJ control_NN and_CC management_NN of_IN risks_NNS and_CC the_DT external_JJ and_CC internal_JJ audit_NN The_DT Board_NNP is_VBZ responsible_JJ for_IN the_DT Groups_NNS system_NN of_IN process_NN ._.
The_DT Committee_NNP also_RB proposes_VBZ to_TO shareholders_NNS corporate_JJ governance_NN and_CC is_VBZ ultimately_RB accountable_JJ for_IN the_DT appointment_NN of_IN the_DT external_JJ auditors_NNS and_CC is_VBZ directly_RB the_DT Groups_NNS activities_NNS ,_, strategy_NN and_CC financial_JJ performance_NN ._.
responsible_JJ for_IN their_PRP$ remuneration_NN and_CC oversight_NN of_IN their_PRP$ The_DT CEO_NNP is_VBZ responsible_JJ for_IN executive_JJ management_NN of_IN the_DT work_NN ._.
The_DT Committee_NNP consists_VBZ entirely_RB of_IN independent_JJ Group_NNP and_CC is_VBZ assisted_VBN in_IN this_DT by_IN the_DT CET_NNP ._.
The_DT CET_NNP meets_VBZ Non-Executive_JJ Directors_NNS ._.
It_PRP meets_VBZ at_IN least_JJS four_CD times_NNS a_DT year_NN ._.
11_CD times_NNS per_IN year_NN and_CC otherwise_RB as_RB necessary_JJ ._.
The_DT Remuneration_NNP Committee_NNP members_NNS and_CC their_PRP$ responsibilities_NNS are_VBP listed_VBN under_IN The_DT Remuneration_NNP Committee_NNP determines_VBZ the_DT terms_NNS of_IN Corporate_NNP Executive_NNP Team_NNP on_IN page_NN 19_CD ._.
service_NN and_CC remuneration_NN of_IN the_DT Executive_NNP Directors_NNS and_CC The_DT Board_NNP comprises_VBZ three_CD Executive_NNP and_CC nine_CD Nonmembers_NNS of_IN the_DT CET_NNP and_CC ,_, with_IN the_DT assistance_NN of_IN external_JJ Executive_NNP Directors_NNS ._.
Whilst_IN the_DT Board_NNP considers_VBZ all_DT of_IN its_PRP$ independent_JJ advisors_NNS ,_, it_PRP evaluates_VBZ and_CC makes_VBZ Non-Executive_JJ Directors_NNS to_TO be_VB independent_JJ in_IN character_NN recommendations_NNS to_TO the_DT Board_NNP on_IN overall_JJ executive_NN and_CC judgement_NN ,_, it_PRP has_VBZ determined_VBN that_IN Dr_NNP Shapiro_NNP should_MD remuneration_VB policy_NN ._.
The_DT Committee_NNP consists_VBZ entirely_RB of_IN not_RB be_VB considered_VBN as_IN independent_JJ under_IN the_DT Combined_VBN independent_JJ Non-Executive_JJ Directors_NNS ._.
It_PRP meets_VBZ at_IN least_JJS Code_NNP on_IN Corporate_NNP Governance_NNP Combined_NNP Code_NNP ._.
This_DT four_CD times_NNS a_DT year_NN and_CC otherwise_RB as_RB necessary_JJ ._.
is_VBZ due_JJ to_TO the_DT remuneration_NN that_IN she_PRP receives_VBZ from_IN the_DT Nominations_NNPS Committee_NNP Group_NNP as_IN a_DT member_NN of_IN the_DT GSK_NNP scientific_JJ Advisory_NNP Board_NNP ._.
The_DT Nominations_NNPS Committee_NNP reviews_VBZ the_DT structure_NN ,_, size_NN The_NNP Board_NNP considers_VBZ that_IN Mr_NNP Culp_NNP ,_, Sir_NNP Crispin_NNP Davis_NNP ,_, Sir_NNP and_CC composition_NN of_IN the_DT Board_NNP and_CC the_DT appointment_NN of_IN Deryck_NNP Maughan_NNP ,_, Sir_NNP Ian_NNP Prosser_NNP ,_, Dr_NNP Schmitz_NNP ,_, Mr_NNP fide_VBD Swaan_JJ members_NNS of_IN the_DT Board_NNP and_CC the_DT CET_NNP ,_, and_CC makes_VBZ and_CC Sir_NNP Robert_NNP Wilson_NNP are_VBP independent_JJ under_IN the_DT Combined_JJ recommendations_NNS to_TO the_DT Board_NNP as_IN appropriate_JJ ._.
Sir_NNP Ian_NNP Prosser_NNP is_VBZ the_DT Senior_JJ Independent_NNP Director_NNP ._.
Committee_NNP also_RB monitors_VBZ the_DT planning_NN of_IN succession_NN to_TO the_DT Board_NNP and_CC Senior_NNP Management_NNP ._.
The_DT Committee_NNP Throughout_IN 2005_CD and_CC up_RB to_TO the_DT date_NN of_IN this_DT publication_NN ,_, consists_VBZ entirely_RB of_IN Non-Executive_JJ Directors_NNS ,_, of_IN whom_WP a_DT a_DT majority_NN of_IN the_DT Board_NNP members_NNS ,_, excluding_VBG the_DT Chairman_NNP ,_, majority_NN are_VBP independent_JJ ,_, and_CC meets_VBZ at_IN least_JJS once_RB a_DT year_NN were_VBD independent_JJ Non-Executive_JJ Directors_NNS ,_, in_IN accordance_NN and_CC otherwise_RB as_RB necessary_JJ ._.
with_IN the_DT recommendations_NNS of_IN the_DT Combined_NNP Code_NNP ._.
Corporate_JJ Responsibility_NNP Committee_NNP Board_NNP process_NN The_DT Corporate_JJ Responsibility_NNP Committee_NNP consists_VBZ entirely_RB The_DT Board_NNP meets_VBZ at_IN least_JJS six_CD times_NNS a_DT year_NN ._.
It_PRP has_VBZ a_DT formal_JJ of_IN Non-Executive_JJ Directors_NNS and_CC provides_VBZ a_DT Board_NNP level_NN schedule_NN of_IN matters_NNS reserved_VBN to_TO it_PRP for_IN decision_NN but_CC forum_NN for_IN the_DT regular_JJ review_NN of_IN external_JJ issues_NNS that_WDT have_VBP otherwise_RB delegates_NNS specic_JJ responsibilities_NNS to_TO Board_NNP the_DT potential_NN for_IN serious_JJ impact_NN upon_IN the_DT Groups_NNS business_NN committees_NNS ,_, as_IN described_VBN below_IN ._.
The_DT Board_NNP works_VBZ to_TO an_DT and_CC reputation_NN and_CC for_IN the_DT oversight_NN of_IN reputation_NN agreed_VBD business_NN agenda_NN in_IN reviewing_VBG the_DT key_JJ activities_NNS of_IN management_NN ._.
The_DT Committee_NNP is_VBZ also_RB responsible_JJ for_IN the_DT business_NN ,_, and_CC receives_VBZ papers_NNS and_CC presentations_NNS to_TO annual_JJ governance_NN oversight_NN of_IN the_DT Groups_NNS worldwide_VBP enable_VB it_PRP to_TO do_VB so_RB effectively_RB ._.
The_DT Board_NNP considers_VBZ and_CC donations_NNS and_CC community_NN support_NN ._.
The_DT Committee_NNP meets_VBZ reviews_VBZ the_DT work_NN undertaken_VBN by_IN its_PRP$ Committees_NNS ._.
formally_RB three_CD times_NNS a_DT year_NN and_CC otherwise_RB as_RB necessary_JJ ._.
The_DT Company_NNP Secretary_NNP is_VBZ responsible_JJ to_TO the_DT Board_NNP and_CC is_VBZ Financial_JJ Results_NNS Committee_NNP available_JJ to_TO individual_JJ Directors_NNS in_IN respect_NN of_IN Board_NNP The_NNP Financial_NNP Results_NNS Committee_NNP reviews_VBZ and_CC approves_VBZ ,_, on_IN procedures_NNS ._.
The_DT Company_NNP Secretary_NNP is_VBZ Mr_NNP Simon_NNP Bicknell_NNP ,_, behalf_NN of_IN the_DT Board_NNP ,_, the_DT Annual_JJ Report_NNP and_CC Form_NN 20-F_NN ,_, the_DT a_DT barrister_NN ,_, who_WP was_VBD appointed_VBN in_IN May_NNP 2000_CD and_CC joined_VBD Annual_JJ Review_NNP and_CC the_DT convening_VBG of_IN the_DT AGM_NNP ,_, together_RB GSK_NNP in_IN 1984_CD ._.
He_PRP is_VBZ secretary_NN to_TO all_PDT the_DT Board_NNP Committees_NNS ._.
with_IN the_DT preliminary_JJ and_CC quarterly_JJ statements_NNS of_IN trading_NN Board_NNP Committees_NNS results_NNS ._.
Each_DT Director_NNP is_VBZ a_DT member_NN of_IN the_DT Committee_NNP and_CC The_NNP Board_NNP has_VBZ established_VBN a_DT number_NN of_IN committees_NNS ._.
the_DT quorum_NN for_IN a_DT meeting_NN is_VBZ any_DT three_CD members_NNS ._.
To_TO be_VB Executive_NNP Directors_NNS are_VBP not_RB members_NNS of_IN the_DT Audit_NNP ,_, quorate_NN ,_, each_DT meeting_NN must_MD include_VB the_DT Chairman_NNP or_CC the_DT Remuneration_NNP ,_, Nominations_NNP or_CC Corporate_NNP Responsibility_NNP Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP and_CC the_DT CEO_NNP or_CC the_DT Committees_NNS ,_, although_IN they_PRP may_MD be_VB invited_VBN to_TO attend_VB CFO_NNP ._.
The_DT Committee_NNP meets_VBZ as_RB necessary_JJ ._.
Each_DT Director_NNP is_VBZ a_DT member_NN of_IN the_DT Corporate_JJ Corporate_JJ Administration_NNP &_CC Transactions_NNS Administration_NNP &_CC Transactions_NNS and_CC Financial_JJ Results_NNS Committee_NNP Committees_NNS ._.
Membership_NN of_IN these_DT Committees_NNS is_VBZ shown_VBN The_DT Corporate_JJ Administration_NNP &_CC Transactions_NNS Committee_NNP in_IN the_DT table_NN below_IN ._.
reviews_NNS and_CC approves_VBZ matters_NNS in_IN connection_NN with_IN the_DT Corporate_JJ administration_NN of_IN the_DT Groups_NNS business_NN ,_, and_CC certain_JJ Audit_NNP Remuneration_NNP Nominations_NNPS Responsibility_NNP corporate_JJ transactions_NNS ._.
The_DT Committee_NNP consists_VBZ of_IN the_DT Sir_NNP Christopher_NNP Gent_NNP C_NNP C_NNP Directors_NNS ,_, CET_NNP members_NNS and_CC the_DT Company_NNP Secretary_NNP ._.
The_DT Mr_NNP L_NNP Culp_NNP M_NNP Committee_NNP meets_VBZ as_RB necessary_JJ ._.
Sir_NNP Crispin_NNP Davis_NNP M_NNP Sir_NNP Deryck_NNP Maughan_NNP M_NNP Remuneration_NNP of_IN Directors_NNS Sir_NNP Ian_NNP Prosser_NNP M_NNP M_NNP M_NNP Information_NNP on_IN the_DT remuneration_NN of_IN Directors_NNS is_VBZ given_VBN in_IN Dr_NNP R_NNP Schmitz_NNP C_NNP M_NNP M_NNP Dr_NNP L_NNP Shapiro_NNP M_NNP the_DT Summary_NNP Remuneration_NNP Report_NNP on_IN pages_NNS 20_CD to_TO 22_CD ._.
Mr_NNP fide_NNP Swaan_NNP M_NNP Sir_NNP Robert_NNP Wilson_NNP M_NNP C_NNP Mr_NNP fide_NN Swaan_NN will_MD succeed_VB Dr_NNP Schmitz_NNP as_IN Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP from_IN September_NNP 2006_CD ._.
GSK_NNP Annual_JJ Review_NNP 2005_CD 23_CD Responsibility_NN statements_NNS ANNUAL_NNP REVIEW_NNP INDEPENDENT_NNP AUDITORS_NNPS STATEMENT_NNP TO_TO THE_DT The_DT Annual_JJ Review_NNP is_VBZ a_DT summary_NN report_NN and_CC does_VBZ not_RB MEMBERS_NNPS OF_IN GLAXOSMITHKLINE_NNP PLC_NNP contain_VBP sufficient_JJ information_NN to_TO allow_VB as_IN full_JJ an_DT underWe_NNP have_VBP examined_VBN the_DT Summary_NNP financial_JJ statements_NNS standing_VBG of_IN the_DT results_NNS and_CC state_NN of_IN affairs_NNS of_IN the_DT Group_NNP which_WDT comprise_VBP the_DT Summary_NNP consolidated_JJ income_NN as_IN is_VBZ provided_VBN by_IN the_DT Annual_JJ Report_NNP 2005_CD ._.
Shareholders_NNS statement_NN ,_, Summary_NNP consolidated_JJ balance_NN sheet_NN and_CC requiring_VBG more_JJR detailed_JJ information_NN may_MD obtain_VB ,_, free_JJ of_IN Summary_NNP consolidated_JJ cash_NN ow_NN statement_NN and_CC the_DT charge_NN ,_, a_DT copy_NN of_IN the_DT Annual_JJ Report_NNP and_CC may_MD also_RB elect_VB Summary_NNP Report_NNP of_IN the_DT Directors_NNS including_VBG the_DT Summary_NNP to_TO receive_VB a_DT copy_NN of_IN the_DT Annual_JJ Report_NNP in_IN future_JJ years_NNS Remuneration_NNP Report_NNP ._.
Respective_JJ responsibilities_NNS of_IN Directors_NNS and_CC auditors_NNS The_DT Independent_NNP Auditors_NNS report_VBP on_IN the_DT full_JJ financial_JJ The_DT Directors_NNS are_VBP responsible_JJ for_IN preparing_VBG the_DT Annual_JJ statements_NNS of_IN the_DT Group_NNP for_IN the_DT year_NN ended_VBD 31st_CD Review_NNP in_IN accordance_NN with_IN applicable_JJ law_NN ._.
Our_PRP$ responDecember_NNP 2005_CD is_VBZ unqualied_JJ and_CC does_VBZ not_RB contain_VB any_DT sibility_NN is_VBZ to_TO report_VB to_TO you_PRP our_PRP$ opinion_NN on_IN the_DT consistency_NN statement_NN concerning_VBG inadequate_JJ accounting_NN records_NNS or_CC of_IN the_DT Summary_NNP financial_JJ statements_NNS within_IN the_DT Annual_JJ failure_NN to_TO obtain_VB necessary_JJ information_NN and_CC explanations_NNS ._.
Review_NNP with_IN the_DT Annual_JJ financial_JJ statements_NNS ,_, the_DT Report_NNP of_IN the_DT Directors_NNS and_CC the_DT Directors_NNS Remuneration_NNP Report_NNP ,_, STATEMENT_NNP BY_NNP THE_DT DIRECTORS_NNS and_CC its_PRP$ compliance_NN with_IN the_DT relevant_JJ requirements_NNS of_IN The_DT Annual_JJ Review_NNP 2005_CD is_VBZ the_DT Summary_NNP Directors_NNS report_VBP Section_NN 251_CD of_IN the_DT United_NNP Kingdom_NNP Companies_NNP Act_NNP 1985_CD and_CC includes_VBZ the_DT Summary_NNP financial_JJ statements_NNS of_IN Glaxoand_NNP the_DT regulations_NNS made_VBD thereunder_RB ._.
We_PRP also_RB read_VBD the_DT SmithKline_NNP plc_NN for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2005_CD ,_, other_JJ information_NN contained_VBN in_IN the_DT Annual_JJ Review_NNP and_CC which_WDT is_VBZ published_VBN in_IN hard-copy_JJ printed_VBN form_NN and_CC on_IN the_DT consider_VB the_DT implications_NNS for_IN our_PRP$ report_NN if_IN we_PRP become_VBP website_JJ ._.
The_DT Business_NN operating_VBG review_NN ,_, the_DT Summary_NNP aware_JJ of_IN any_DT apparent_JJ misstatements_NNS or_CC material_NN inconfinancial_JJ statements_NNS ,_, the_DT Summary_NNP Remuneration_NNP Report_NNP sistencies_NNS with_IN the_DT Summary_NNP financial_JJ statements_NNS ._.
and_CC the_DT Statement_NN on_IN corporate_JJ governance_NN are_VBP summaries_NNS These_DT statements_NNS ,_, including_VBG the_DT opinion_NN ,_, have_VBP been_VBN preof_JJ information_NN in_IN the_DT Annual_JJ Report_NNP 2005_CD ._.
pared_VBN for_IN and_CC only_RB for_IN the_DT companys_NNS members_NNS as_IN a_DT body_NN profit_NN attributable_JJ to_TO shareholders_NNS and_CC total_JJ equity_NN are_VBP also_RB in_IN accordance_NN with_IN Section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP restated_VBN in_IN accordance_NN with_IN US_NNP GAAP_NNP as_IN additional_JJ 1985_CD and_CC for_IN no_DT other_JJ purpose_NN ._.
We_PRP do_VBP not_RB ,_, in_IN giving_VBG this_DT information_NN provided_VBN to_TO US_NNP shareholders_NNS ._.
opinion_NN ,_, accept_VB or_CC assume_VB responsibility_NN for_IN any_DT other_JJ purpose_NN or_CC to_TO any_DT other_JJ person_NN to_TO whom_WP this_DT statement_NN The_DT Directors_NNS are_VBP responsible_JJ for_IN the_DT maintenance_NN and_CC is_VBZ shown_VBN or_CC into_IN whose_WP$ hands_NNS it_PRP may_MD come_VB save_IN where_WRB integrity_NN of_IN the_DT Annual_JJ Review_NNP on_IN the_DT website_NN in_IN accordance_NN expressly_RB agreed_VBN by_IN our_PRP$ prior_JJ consent_NN in_IN writing_VBG ._.
with_IN the_DT UK_NNP legislation_NN governing_VBG the_DT preparation_NN and_CC dissemination_NN of_IN financial_JJ statements_NNS ._.
Access_NN to_TO the_DT website_JJ Basis_NN of_IN opinion_NN is_VBZ available_JJ from_IN outside_IN the_DT UK_NNP ,_, where_WRB comparable_JJ We_PRP conducted_VBD our_PRP$ work_NN in_IN accordance_NN with_IN Bulletin_NNP legislation_NN may_MD be_VB different_JJ ._.
1999_CD 6_CD ,_, The_DT auditors_NNS statement_NN on_IN the_DT Summary_NNP financial_JJ statement_NN issued_VBN by_IN the_DT Auditing_NNP Practices_NNPS Board_NNP for_IN use_NN CORPORATE_JJ GOVERNANCE_NN in_IN the_DT United_NNP Kingdom_NNP ._.
The_DT Combined_NNP Code_NNP on_IN Corporate_NNP Governance_NNP is_VBZ specified_VBN Opinion_NNP by_IN the_DT Listing_NNP Rules_NNP of_IN the_DT Financial_NNP Services_NNPS Authority_NNP for_IN In_IN our_PRP$ opinion_NN the_DT Summary_NNP financial_JJ statements_NNS are_VBP conthe_JJ guidance_NN of_IN listed_VBN companies_NNS Combined_NNP Code_NNP ._.
The_DT sistent_NN with_IN the_DT Annual_JJ consolidated_JJ financial_JJ statements_NNS ,_, Board_NNP considers_VBZ that_IN throughout_IN 2005_CD and_CC up_RB to_TO the_DT date_NN the_DT Report_NNP of_IN the_DT Directors_NNS and_CC the_DT Remuneration_NNP Report_NNP of_IN approval_NN of_IN this_DT review_NN ,_, GlaxoSmithKline_NNP plc_NN applied_VBD of_IN GlaxoSmithKline_NNP plc_NN for_IN the_DT year_NN ended_VBD 31st_CD December_NNP the_DT principles_NNS of_IN the_DT Combined_NNP Code_NNP and_CC ,_, with_IN the_DT 2005_CD and_CC comply_VB with_IN the_DT applicable_JJ requirements_NNS of_IN exception_NN of_IN matters_NNS where_WRB the_DT companys_NNS position_NN is_VBZ Section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC the_DT described_VBN in_IN the_DT Annual_JJ Report_NNP ,_, complied_VBN with_IN the_DT regulations_NNS made_VBD thereunder_RB ._.
provisions_NNS of_IN the_DT Combined_NNP Code_NNP ,_, and_CC the_DT guidance_NN on_IN internal_JJ control_NN issued_VBN by_IN the_DT 1998_CD Turnbull_NNP Committee_NNP ._.
The_DT Annual_JJ Review_NNP ,_, including_VBG Summary_NNP financial_JJ statements_NNS ,_, has_VBZ been_VBN approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS and_CC signed_VBN on_IN its_PRP$ behalf_NN by_IN Sir_NNP Christopher_NNP Gent_NNP LLP_NNP Chairman_NNP Chartered_NNP Accountants_NNPS and_CC Registered_NNP Auditors_NNS 1st_CD March_NNP 2006_CD London_NNP 1st_CD March_NNP 2006_CD GSK_NNP Annual_JJ Review_NNP 2005_CD 24_CD Summary_NNP financial_JJ statements_NNS SUMMARY_NNP CONSOLIDATED_NNP INCOME_NNP STATEMENT_NNP 2005_CD Growth_NN 2004_CD m_NN CER_CD %_NN m_NN Turnover_NN Pharmaceutical_NNP 18,661_CD 8_CD 17,100_CD Consumer_NN Healthcare_NNP 2,999_CD 2_CD 2,886_CD Total_JJ turnover_NN 21,660_CD 7_CD 19,986_CD Cost_NN of_IN sales_NNS 4,764_CD 8_CD 4,360_CD Gross_NNP profit_NN 16,896_CD 7_CD 15,626_CD Selling_NNP ,_, general_JJ and_CC administration_NN 7,250_CD 7,201_CD Research_NNP and_CC development_NN 3,136_CD 8_CD 2,904_CD Other_JJ operating_NN income_NN 364_CD 235_CD Operating_NN profit_NN 6,874_CD 16_CD 5,756_CD Finance_NNP income_NN 257_CD 176_CD Finance_NNP costs_NNS 451_CD 362_CD Share_NN of_IN after_IN tax_NN profits_NNS of_IN associates_NNS and_CC joint_JJ ventures_NNS 52_CD 60_CD profit_NN on_IN disposal_NN of_IN interest_NN in_IN associates_NNS 149_CD profit_NN before_IN taxation_NN 6,732_CD 13_CD 5,779_CD Taxation_NNP 1,916_CD 1,757_CD profit_NN after_IN taxation_NN for_IN the_DT year_NN 4,816_CD 17_CD 4,022_CD profit_NN attributable_JJ to_TO minority_NN interests_NNS 127_CD 114_CD profit_NN attributable_JJ to_TO shareholders_NNS 4,689_CD 3,908_CD 4,816_CD 4,022_CD Basic_JJ earnings_NNS per_IN share_NN pence_NN 82.6_CD p_NN 18_CD 68.1_CD p_NN Diluted_VBN earnings_NNS per_IN share_NN pence_NN 82.0_CD p_VBP 68.0_CD p_JJ SUMMARY_NNP CONSOLIDATED_NNP BALANCE_NNP SHEET_NNP 2005_CD 2004_CD m_NN m_NN Total_JJ non-current_JJ assets_NNS 14,021_CD 12,164_CD Total_JJ current_JJ assets_NNS 13,177_CD 10,780_CD Total_JJ assets_NNS 27,198_CD 22,944_CD Total_JJ current_JJ liabilities_NNS 9,511_CD 8,564_CD Total_JJ non-current_JJ liabilities_NNS 10,117_CD 8,443_CD Total_JJ liabilities_NNS 19,628_CD 17,007_CD Net_JJ assets_NNS 7,570_CD 5,937_CD Shareholders_NNS equity_NN 7,311_CD 5,724_CD Minority_NNP interests_NNS 259_CD 213_CD Total_JJ equity_NN 7,570_CD 5,937_CD SUMMARY_NNP CONSOLIDATED_NNP CASH_NNP FLOW_NNP STATEMENT_NNP 2005_CD 2004_CD m_NN m_NN Net_JJ cash_NN inow_NN from_IN operating_VBG activities_NNS 5,958_CD 4,944_CD Net_JJ cash_NN outow_NN from_IN investing_VBG activities_NNS 1,660_CD 920_CD Net_JJ cash_NN outow_NN from_IN nancing_VBG activities_NNS 2,914_CD 3,407_CD Increase_VBP in_IN cash_NN in_IN the_DT year_NN 1,384_CD 617_CD Exchange_NNP adjustments_NNS 233_CD 93_CD Cash_NN and_CC bank_NN overdrafts_NNS at_IN beginning_NN of_IN year_NN 2,355_CD 1,831_CD Cash_NN and_CC bank_NN overdrafts_NNS at_IN end_NN of_IN year_NN 3,972_CD 2,355_CD Cash_NN and_CC bank_NN overdrafts_NNS at_IN end_NN of_IN year_NN comprise_VBP :_: Cash_NN and_CC cash_NN equivalents_NNS 4,209_CD 2,467_CD Overdrafts_NNPS 237_CD 112_CD 3,972_CD 2,355_CD GSK_NNP Annual_JJ Review_NNP 2005_CD 25_CD Summary_NNP information_NN under_IN US_NNP GAAP_NNP The_NNP following_VBG is_VBZ a_DT summary_NN of_IN the_DT material_NN adjustments_NNS to_TO profit_VB and_CC shareholders_NNS funds_NNS which_WDT would_MD be_VB required_VBN if_IN US_NNP Generally_RB Accepted_JJ Accounting_NN Principles_NNPS US_NNP GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN IFRS_NNP ._.
PROFIT_NN 2005_CD 2004_CD m_NN m_NN profit_NN after_IN taxation_NN for_IN the_DT year_NN under_IN IFRS_NNP 4,816_CD 4,022_CD profit_NN attribtable_JJ to_TO minority_NN interests_NNS 127_CD 114_CD profit_NN attributable_JJ to_TO shareholders_NNS under_IN IFRS_NNP 4,689_CD 3,908_CD US_NNP GAAP_NNP adjustments_NNS :_: Product_NN rights_NNS 1,682_CD 1,651_CD Capitalised_VBN interest_NN 1_CD 17_CD Disposal_NN of_IN interests_NNS in_IN associates_NNS and_CC subsidiaries_NNS 97_CD Equity_NN investments_NNS 2_CD 30_CD Employee_NN costs_NNS 121_CD 113_CD Derivative_JJ instruments_NNS and_CC hedging_VBG 30_CD 50_CD Restructuring_NN 1_CD 12_CD Taxation_NNP 538_CD 747_CD Other_JJ 56_CD 53_CD Net_JJ income_NN under_IN US_NNP GAAP_NNP 3,336_CD 2,732_CD Basic_JJ income_NN per_IN share_NN under_IN US_NNP GAAP_NNP 58.8_CD p_NN 47.6_CD p_VBP Diluted_JJ income_NN per_IN share_NN under_IN US_NNP GAAP_NNP 58.3_CD p_NN 47.5_CD p_NN EQUITY_NN SHAREHOLDERS_NNS FUNDS_NNS 2005_CD 2004_CD m_NN m_NN Total_JJ equity_NN under_IN IFRS_NNP 7,570_CD 5,937_CD Minority_NNP interests_NNS 259_CD 213_CD Shareholders_NNS equity_NN under_IN IFRS_NNP 7,311_CD 5,724_CD US_NNP GAAP_NNP adjustments_NNS :_: Product_NN rights_NNS and_CC goodwill_NN 30,041_CD 31,573_CD Fixed_VBN assets_NNS 212_CD 223_CD Marketable_JJ securities_NNS 49_CD Other_JJ investments_NNS 576_CD 532_CD Employee_NN costs_NNS 1,249_CD 1,230_CD Restructuring_NNP 65_CD 80_CD Derivative_JJ instruments_NNS and_CC hedging_VBG 33_CD 2_CD Dividends_NNS 568_CD 571_CD Deferred_JJ taxation_NN 4,531_CD 4,840_CD Other_JJ 40_CD 40_CD Shareholders_NNS equity_NN under_IN US_NNP GAAP_NNP 34,282_CD 34,042_CD A_DT summary_NN of_IN the_DT material_NN differences_NNS between_IN IFRS_NNP and_CC US_NNP GAAP_NNP that_IN apply_VB to_TO the_DT Group_NNP is_VBZ set_VBN out_RP in_IN the_DT Annual_JJ Report_NNP 2005_CD ._.
GSK_NNP Annual_JJ Review_NNP 2005_CD 26_CD Shareholder_NN information_NN FINANCIAL_NNP REPORTING_NNP DIVIDENDS_NNP Financial_NNP reporting_VBG calendar_NN 2006_CD GSK_NNP pays_VBZ dividends_NNS quarterly_RB ._.
Announcement_NN of_IN 1st_CD Quarter_NN Results_NNS The_DT Board_NNP has_VBZ declared_VBN dividends_NNS for_IN 2005_CD as_IN follows_VBZ :_: April_NNP 2006 2005 2004_CD Announcement_NN of_IN 2nd_CD Quarter_NN Results_NNS Dividends_NNPS per_IN share_NN pence_NN pence_NN July_NNP 2006_CD First_NNP interim_JJ paid_VBN 7th_JJ July_NNP 2005_CD 10_CD 10_CD Announcement_NN of_IN 3rd_CD Quarter_NN Results_NNS Second_JJ interim_NN paid_VBD 6th_JJ October_NNP 2005_CD 10_CD 10_CD October_NNP 2006_CD Third_NNP interim_JJ paid_VBN 5th_JJ January_NNP 2006_CD 10_CD 10_CD Fourth_JJ interim_JJ payable_JJ 6th_JJ April_NNP 2006_CD 14_CD 12_CD Preliminary_JJ Announcement_NN of_IN Annual_JJ Results_NNS February_NNP 2007_CD Total_JJ 44_CD 42_CD Publication_NN of_IN Annual_JJ Report_NNP Review_NNP As_IN a_DT guide_NN to_TO holders_NNS of_IN ADRs_NNS ,_, the_DT table_NN below_IN sets_NNS out_IN March_NNP 2007_CD the_DT dividends_NNS paid_VBD per_IN ADS_NNPS in_IN US_NNP dollars_NNS in_IN the_DT last_JJ five_CD years_NNS translated_VBN into_IN US_NNP dollars_NNS at_IN applicable_JJ exchange_NN Results_NNS Announcements_NNS rates_NNS ._.
Results_NNS Announcements_NNS are_VBP issued_VBN to_TO the_DT London_NNP Stock_NNP Exchange_NNP and_CC are_VBP available_JJ on_IN its_PRP$ news_NN service_NN ._.
Shortly_RB Year_NN US$_$ afterwards_RB ,_, they_PRP are_VBP issued_VBN to_TO the_DT media_NNS ,_, are_VBP made_VBN 2005_CD 1.57_CD available_JJ on_IN the_DT website_NN and_CC are_VBP submitted_VBN to_TO the_DT US_NNP 2004_CD 1.53_CD Securities_NNPS and_CC Exchange_NNP Commission_NNP and_CC the_DT New_NNP York_NNP 2003_CD 1.39_CD Stock_NNP Exchange_NNP ._.
2002_CD 1.24_CD 2001_CD 1.11_CD Financial_JJ reports_NNS The_DT company_NN publishes_VBZ an_DT Annual_JJ Report_NNP and_CC ,_, for_IN the_DT Dividend_NN calendar_NN investor_NN not_RB needing_VBG the_DT full_JJ detail_NN of_IN the_DT Report_NNP ,_, an_DT Fourth_JJ quarter_NN 2005_CD Annual_JJ Review_NNP ._.
These_DT are_VBP available_JJ on_IN the_DT website_NN ._.
The_DT Ex-dividend_NN date_NN 15th_JJ February_NNP 2006_CD Annual_JJ Review_NNP is_VBZ sent_VBN to_TO all_DT shareholders_NNS on_IN the_DT date_NN of_IN Record_NNP date_NN 17th_JJ February_NNP 2006_CD publication_NN ._.
Shareholders_NNS may_MD also_RB elect_VB to_TO receive_VB the_DT Payable_JJ 6th_JJ April_NNP 2006_CD Annual_JJ Report_NNP by_IN writing_VBG to_TO the_DT companys_NNS registrars_NNS ._.
Alternatively_RB ,_, shareholders_NNS may_MD elect_VB to_TO receive_VB notication_NN First_JJ quarter_NN 2006_CD by_IN email_NN of_IN the_DT publication_NN of_IN financial_JJ reports_NNS by_IN Ex-dividend_NN date_NN 10th_JJ May_NNP 2006_CD registering_VBG on_IN www_NN ._.
Copies_NNS of_IN previous_JJ Record_NNP date_NN 12th_JJ May_NNP 2006_CD financial_JJ reports_NNS are_VBP available_JJ on_IN the_DT website_NN ._.
Printed_NNP Payable_NNP 6th_VBZ July_NNP 2006_CD copies_NNS can_MD be_VB obtained_VBN from_IN the_DT registrar_NN in_IN the_DT UK_NNP and_CC from_IN the_DT Customer_NN Response_NNP Center_NNP in_IN the_DT USA_NNP ._.
Second_JJ quarter_NN 2006_CD Publications_NNP Ex-dividend_NN date_NN 2nd_JJ August_NNP 2006_CD In_IN late_JJ March_NNP 2006_CD GSK_NNP will_MD publish_VB on_IN the_DT website_NN its_PRP$ Record_NNP date_NN 4th_JJ August_NNP 2006_CD Corporate_JJ Responsibility_NN Report_NNP covering_VBG performance_NN in_IN Payable_JJ 5th_JJ October_NNP 2006_CD areas_NNS including_VBG community_NN investment_NN ,_, ethics_NNS and_CC Third_JJ quarter_NN 2006_CD integrity_NN ,_, access_NN to_TO medicines_NNS ,_, R&D_NNP ,_, environment_NN and_CC health_NN and_CC safety_NN ._.
Ex-dividend_NN date_NN 1st_CD November_NNP 2006_CD Record_NNP date_NN 3rd_CD November_NNP 2006_CD SHARE_NNP PRICE_NNP Payable_JJ 4th_JJ January_NNP 2007 2005 2004_CD ANNUAL_NNP GENERAL_NNP MEETING_NNP 2005_CD At_IN 1st_CD January_NNP 12.22_CD 12.80_CD The_DT Annual_JJ General_NNP Meeting_VBG will_MD be_VB held_VBN at_IN the_DT Queen_NNP High_NNP during_IN the_DT year_NN 15.44_CD 12.99_CD Elizabeth_NNP II_NNP Conference_NNP Centre_NNP ,_, Broad_NNP Sanctuary_NNP ,_, Low_NNP during_IN the_DT year_NN 11.75_CD 10.42_CD Westminster_NNP ,_, London_NNP SW1P_NNP 3EE_NNP on_IN 17th_JJ May_NNP 2006_CD ._.
At_IN 31st_CD December_NNP 14.69_CD 12.22_CD Increase_VBP decrease_NN 20_CD %_NN 5_CD %_NN CAUTIONARY_NNP STATEMENT_NNP The_NNP table_NN above_IN sets_NNS out_IN the_DT middle_JJ market_NN closing_NN prices_NNS Under_IN the_DT safe_JJ harbor_NN provisions_NNS of_IN the_DT US_NNP Private_NNP derived_VBD from_IN the_DT London_NNP Stock_NNP Exchange_NNP Daily_NNP Ofcial_NNP Securities_NNP Litigation_NNP Reform_NNP Act_NNP of_IN 1995_CD ,_, the_DT company_NN List_NN ._.
The_DT companys_NNS share_VBP price_NN increased_VBN by_IN 20_CD %_NN in_IN 2005_CD cautions_VBZ investors_NNS that_IN any_DT forward_RB looking_VBG statements_NNS from_IN a_DT price_NN of_IN 12.22_CD at_IN 1st_CD January_NNP 2005_CD to_TO 14.69_CD at_IN or_CC projections_NNS made_VBN by_IN the_DT company_NN ,_, including_VBG those_DT 31st_CD December_NNP 2005_CD ._.
This_DT compares_VBZ with_IN an_DT increase_NN in_IN made_VBN in_IN this_DT Annual_JJ Review_NNP ,_, are_VBP subject_JJ to_TO risks_NNS and_CC the_DT FTSE_NNP 100_CD index_NN of_IN 17_CD %_NN during_IN the_DT year_NN ._.
uncertainties_NNS that_WDT may_MD cause_VB actual_JJ results_NNS to_TO differ_VB materially_RB from_IN those_DT projected_VBN ._.
Factors_NNS that_WDT may_MD affect_VB Market_NN capitalization_NN the_DT Groups_NNS operations_NNS are_VBP described_VBN under_IN Legal_JJ The_DT market_NN capitalization_NN of_IN GSK_NNP at_IN 31st_CD December_NNP 2005_CD proceedings_NNS and_CC Risk_NN factors_NNS in_IN the_DT companys_NNS Annual_JJ was_VBD 85_CD billion_CD ._.
At_IN that_DT date_NN GSK_NNP was_VBD the_DT fourth_JJ largest_JJS Report_NNP 2005_CD ._.
company_NN by_IN market_NN capitalization_NN on_IN the_DT FTSE_NNP index_NN ._.
GSK_NNP Annual_JJ Review_NNP 2005_CD 27_CD Shareholder_NN information_NN continued_VBD SMITHKLINE_NNP BEECHAM_NNP PLC_NNP FLOATING_NNP RATE_NNP ORDINARY_NNP SHARES_NNP UNSECURED_NNP LOAN_NNP STOCK_NNP 1990_CD 2010_CD The_DT companys_NNS shares_NNS are_VBP listed_VBN on_IN the_DT London_NNP Stock_NNP The_NNP loan_NN stock_NN is_VBZ not_RB listed_VBN on_IN any_DT exchange_NN but_CC holders_NNS Exchange_NNP LSE_NNP ._.
may_MD require_VB SmithKline_NNP Beecham_NNP plc_NN to_TO redeem_VB their_PRP$ loan_NN stock_NN at_IN par_NN ,_, i._FW e._FW 1_CD for_IN every_DT 1_CD of_IN loan_NN stock_NN held_VBN ,_, on_IN the_DT Registrar_NNP first_JJ business_NN day_NN of_IN March_NNP ,_, June_NNP ,_, September_NNP and_CC The_DT companys_NNS registrars_NNS are_VBP :_: December_NNP ._.
Holders_NNS wishing_VBG to_TO redeem_VB all_DT or_CC part_NN of_IN their_PRP$ Lloyds_NNP TSB_NNP Registrars_NNPS loan_NN stock_NN should_MD complete_VB the_DT notice_NN on_IN the_DT back_NN of_IN their_PRP$ The_DT Causeway_NNP ,_, Worthing_NNP ,_, West_NNP Sussex_NNP BN99_NNP 6DA_NNP loan_NN stock_NN certicate_NN and_CC return_VB it_PRP to_TO the_DT registrar_NN ,_, to_TO arrive_VB www_NN ._.
co._FW uk_FW at_IN least_JJS 30_CD days_NNS before_IN the_DT relevant_JJ redemption_NN date_NN ._.
Tel_NNP :_: 0870 600 3991_CD inside_IN the_DT UK_NNP The_NNP provision_NN of_IN the_DT details_NNS on_IN this_DT page_NN is_VBZ not_RB intended_VBN Tel_NNP :_: 44_CD 0_CD 121 415 7067_CD outside_IN the_DT UK_NNP to_TO be_VB an_DT invitation_NN or_CC inducement_NN to_TO engage_VB in_IN an_DT The_DT registrars_NNS also_RB provide_VBP the_DT following_JJ services_NNS :_: investment_NN activity_NN ._.
Advice_NNP on_IN share_NN dealing_VBG should_MD be_VB obtained_VBN from_IN a_DT stockbroker_NN or_CC independent_JJ financial_JJ GlaxoSmithKline_NNP Investment_NNP Plan_NNP adviser_NN ._.
GlaxoSmithKline_NNP Individual_NNP Savings_NNP Account_NNP GlaxoSmithKline_NNP Corporate_NNP Sponsored_NNP Nominee_NNP SHARE_NNP BUY-BACK_NN PROGRAMME_NNP Shareview_NNP service_NN A_DT total_NN of_IN 6.5_CD billion_CD has_VBZ been_VBN spent_VBN by_IN the_DT company_NN Shareview_NNP dealing_VBG service_NN since_IN 2001_CD on_IN buying_VBG its_PRP$ own_JJ shares_NNS for_IN cancellation_NN or_CC Share_NN dealing_VBG service_NN to_TO be_VB held_VBN as_IN Treasury_NNP shares_NNS ,_, of_IN which_WDT 1_CD billion_CD was_VBD spent_VBN Hoare_NNP Govett_NNP operate_VBP a_DT postal_JJ dealing_VBG service_NN in_IN the_DT in_IN 2005_CD ._.
The_DT program_NN covers_VBZ purchases_NNS by_IN the_DT companys_NNS ordinary_JJ shares_NNS ._.
It_PRP enables_VBZ investors_NNS to_TO buy_VB or_CC company_NN of_IN shares_NNS for_IN cancellation_NN or_CC to_TO be_VB held_VBN as_IN sell_JJ shares_NNS at_IN competitive_JJ commission_NN charges_NNS ._.
Further_JJ Treasury_NNP shares_NNS ,_, in_IN accordance_NN with_IN the_DT authority_NN given_VBN details_NNS may_MD be_VB obtained_VBN by_IN telephoning_VBG 44_CD 0_CD 20_CD 7661_CD by_IN shareholders_NNS at_IN the_DT AGM_NNP in_IN 2005_CD ._.
In_IN May_NNP 2005_CD the_DT company_NN was_VBD authorised_VBN to_TO purchase_VB a_DT Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP maximum_NN of_IN 586.4_CD million_CD shares_NNS ._.
During_IN 2005_CD 72.8_CD corporate_JJ PEPs_NNS million_CD shares_NNS were_VBD purchased_VBN and_CC held_VBN as_IN Treasury_NNP shares_NNS The_DT Share_NN Centre_NNP Limited_NNP see_VBP Note_NN 31_CD to_TO the_DT financial_JJ statements_NNS ,_, Share_NN capital_NN Oxford_NNP House_NNP ,_, Oxford_NNP Road_NNP ,_, Aylesbury_NNP ,_, Bucks_NNP HP21_NNP 8SZ_NNP and_CC share_NN premium_NN account_NN in_IN the_DT Annual_JJ Report_NNP 2005_CD ._.
Tel_NNP :_: 44_CD 0_CD 1296 414 141_CD The_DT exact_JJ amount_NN and_CC timing_NN of_IN future_JJ purchases_NNS ,_, and_CC the_DT extent_NN to_TO which_WDT repurchased_VBD shares_NNS will_MD be_VB held_VBN as_IN AMERICAN_NNP DEPOSITARY_NNP SHARES_NNP Treasury_NNP shares_NNS rather_RB than_IN being_VBG canceled_VBN ,_, will_MD be_VB The_DT companys_NNS shares_NNS are_VBP listed_VBN on_IN the_DT New_NNP York_NNP Stock_NNP determined_VBN by_IN the_DT company_NN and_CC is_VBZ dependent_JJ on_IN market_NN Exchange_NNP NYSE_NNP in_IN the_DT form_NN of_IN American_JJ Depositary_JJ conditions_NNS and_CC other_JJ factors_NNS ._.
Shares_NNP ADSs_NNP and_CC these_DT are_VBP evidenced_VBN by_IN American_JJ Depositary_NNP Receipts_NNPS ADRs_NNPS ,_, each_DT one_CD of_IN which_WDT represents_VBZ INTERNET_NNP two_CD ordinary_JJ shares_NNS ._.
Information_NN about_IN the_DT company_NN ,_, including_VBG details_NNS of_IN the_DT In_NNP general_JJ ,_, the_DT NYSEs_NNP rules_NNS permit_VBP the_DT company_NN to_TO follow_VB share_NN price_NN ,_, is_VBZ available_JJ on_IN GSKs_NNS website_VBP at_IN www_NN ._.
com_NN UK_NNP corporate_JJ governance_NN practices_NNS instead_RB of_IN those_DT that_WDT Information_NNP made_VBD available_JJ on_IN the_DT website_NN does_VBZ not_RB apply_VB in_IN the_DT US_NNP ,_, provided_VBD that_IN the_DT company_NN explains_VBZ any_DT constitute_VBP part_NN of_IN this_DT Annual_JJ Review_NNP ._.
This_DT explanation_NN is_VBZ provided_VBN on_IN the_DT companys_NNS website_VBP ._.
TRADEMARKS_NNS ADR_VBP program_NN administrator_NN Brand_NNP names_NNS appearing_VBG in_IN italics_NNS throughout_IN this_DT The_DT ADR_NNP program_NN is_VBZ administered_VBN by_IN :_: publication_NN are_VBP trademarks_NNS either_CC owned_VBN by_IN and_CC or_CC licensed_VBN to_TO GSK_NNP or_CC associated_VBN companies_NNS ,_, with_IN the_DT The_NNP Bank_NNP of_IN New_NNP York_NNP exception_NN of_IN Boniva_NNP Bonviva_NNP ,_, a_DT trademark_NN of_IN Roche_NNP ,_, Shareholder_NN Relations_NNS Entereg_NNP ,_, a_DT trademark_NN of_IN Adolor_NNP Corporation_NNP ,_, and_CC PO_NNP Box_NNP 11258_CD ,_, Church_NNP Street_NNP Station_NNP Nicoderm_NNP ,_, a_DT trademark_NN of_IN Sano-Aventis_NNP ,_, Elan_NNP ,_, Novartis_NNP New_NNP York_NNP NY_NNP 10286-1258_CD or_CC GSK_NNP in_IN certain_JJ countries_NNS ,_, all_DT of_IN which_WDT are_VBP used_VBN in_IN certain_JJ www_NN ._.
com_NN countries_NNS under_IN license_NN by_IN the_DT Group_NNP ._.
Tel_NNP :_: 1_CD 877 353 1154_CD toll_NN free_JJ Tel_NNP :_: 1_CD 212 815 3700_CD outside_IN the_DT USA_NNP INVESTOR_NNP RELATIONS_NNP Customer_NN Response_NNP Center_NNP Investor_NNP Relations_NNPS may_MD be_VB contacted_VBN as_IN follows_VBZ :_: Tel_NNP :_: 1_CD 888 825 5249_CD toll_NN free_JJ UK_NNP The_DT administrators_NNS also_RB provide_VBP Global_JJ BuyDIRECT_NNP ,_, a_DT direct_JJ 980_CD Great_NNP West_NNP Road_NNP ,_, Brentford_NNP ,_, Middlesex_NNP TW8_NNP 9GS_NNP ADS_NNPS purchase_NN sale_NN and_CC dividend_NN reinvestment_NN plan_NN for_IN Tel_NNP :_: 44_CD 0_CD 20 8047 5557 5558_CD ADR_NNP holders_NNS ._.
Fax_NN :_: 44_CD 0_CD 20 8047 7807_CD USA_NNP One_CD Franklin_NNP Plaza_NNP ,_, PO_NNP Box_NNP 7929_CD ,_, Philadelphia_NNP PA_NNP 19101_CD Tel_NNP :_: 1_CD 888 825 5249_CD toll_NN free_JJ Tel_NNP :_: 1_CD 215 751 4638_CD outside_IN the_DT USA_NNP Fax_NNP :_: 1_CD 919 315 3344_CD GSK_NNP Annual_JJ Review_NNP 2005_CD 28_CD Chairman_NNP and_CC CEOs_NNS closing_VBG letter_NN Dear_RB shareholder_NN We_PRP value_VBP our_PRP$ investors_NNS and_CC hope_VB this_DT Annual_JJ Review_NNP has_VBZ highlighted_VBN what_WP your_PRP$ company_NN achieved_VBN during_IN the_DT year_NN and_CC what_WP we_PRP are_VBP aiming_VBG to_TO do_VB in_IN the_DT future_NN ._.
We_PRP remain_VBP focused_VBN on_IN delivering_VBG performance_NN and_CC making_VBG your_PRP$ company_NN one_CD you_PRP can_MD be_VB proud_JJ of_IN ._.
We_PRP continue_VBP to_TO meet_VB the_DT challenges_NNS of_IN improving_VBG productivity_NN in_IN R&D_NNP and_CC ensuring_VBG patients_NNS have_VBP access_NN to_TO medicines_NNS ,_, even_RB in_IN the_DT poorest_JJS parts_NNS of_IN the_DT world_NN ._.
This_DT review_NN highlights_VBZ some_DT of_IN the_DT work_NN we_PRP have_VBP done_VBN to_TO implement_VB our_PRP$ strategies_NNS to_TO meet_VB these_DT challenges_NNS ._.
Behind_IN each_DT one_CD is_VBZ a_DT human_JJ story_NN ._.
We_PRP thank_VBP all_DT our_PRP$ employees_NNS for_IN their_PRP$ efforts_NNS in_IN 2005_CD ._.
Their_PRP$ commitment_NN and_CC passion_NN ,_, both_DT individually_RB and_CC through_IN their_PRP$ teamwork_NN ,_, have_VBP helped_VBN us_PRP make_VB GSK_NNP the_DT success_NN it_PRP is_VBZ today_NN ._.
We_PRP also_RB appreciate_VBP the_DT great_JJ support_NN our_PRP$ employees_NNS receive_VBP from_IN their_PRP$ families_NNS for_IN the_DT work_NN they_PRP are_VBP doing_VBG at_IN GSK_NNP ._.
We_PRP are_VBP grateful_JJ for_IN the_DT significant_JJ contribution_NN of_IN Tachi_NNP Yamada_NNP ,_, Chairman_NNP of_IN R&D_NNP and_CC Executive_NNP Director_NNP ,_, who_WP is_VBZ to_TO retire_VB in_IN June_NNP 2006_CD ,_, and_CC we_PRP welcome_VBP Moncef_NNP Slaoui_NNP ,_, who_WP will_MD succeed_VB Tachi_NNP with_IN effect_NN from_IN 1st_CD June_NNP 2006_CD ._.
We_PRP would_MD also_RB like_VB to_TO thank_VB Jack_NNP Ziegler_NNP ,_, President_NNP of_IN GSK_NNP Consumer_NNP Healthcare_NNP ,_, who_WP retired_VBD from_IN the_DT company_NN in_IN January_NNP 2006_CD ,_, and_CC welcome_VB his_PRP$ successor_NN ,_, John_NNP Clarke_NNP ._.
We_PRP also_RB thank_VBP Dr_NNP Lucy_NNP Shapiro_NNP ,_, who_WP is_VBZ to_TO retire_VB as_IN a_DT Non-Executive_JJ Director_NNP at_IN the_DT companys_NNS Annual_JJ General_NNP Meeting_VBG in_IN May_NNP 2006_CD ,_, and_CC we_PRP welcome_VBP Tom_NNP fide_NNP Swaan_NNP ,_, who_WP joined_VBD the_DT Board_NNP in_IN January_NNP 2006_CD as_IN a_DT new_JJ Non-Executive_NNP Director_NNP ._.
As_IN a_DT shareholder_NN ,_, your_PRP$ views_NNS are_VBP important_JJ to_TO us_PRP ._.
We_PRP would_MD be_VB grateful_JJ if_IN you_PRP would_MD complete_VB an_DT online_JJ survey_NN to_TO let_VB us_PRP know_VB what_WP you_PRP think_VBP of_IN this_DT Annual_JJ Review_NNP ._.
You_PRP can_MD nd_VB the_DT survey_NN at_IN www_NN ._.
If_IN you_PRP would_MD like_VB to_TO know_VB more_JJR about_IN GSK_NNP ,_, please_VB contact_NN us_PRP or_CC go_VB to_TO the_DT information_NN sources_NNS listed_VBN on_IN the_DT back_JJ cover_NN ._.
Sir_NNP Christopher_NNP Gent_NNP ,_, Chairman_NNP ,_, and_CC JP_NNP Garnier_NNP ,_, Chief_NNP Executive_NNP officer_NN GlaxoSmithKline_NNP is_VBZ addressing_VBG the_DT key_JJ challenges_NNS that_WDT face_VBP both_DT the_DT pharmaceutical_JJ industry_NN and_CC society_NN as_IN a_DT whole_NN :_: Improving_NN productivity_NN in_IN research_NN and_CC development_NN Ensuring_NN patients_NNS have_VBP access_NN to_TO medicines_NNS ._.
Our_PRP$ strategies_NNS to_TO meet_VB these_DT challenges_NNS focus_VB on_IN several_JJ business_NN drivers_NNS :_: Build_VB the_DT best_JJS product_NN pipeline_NN in_IN the_DT industry_NN to_TO the_DT benefit_NN of_IN patients_NNS ,_, consumers_NNS and_CC society_NN Continuously_RB improve_VB performance_NN through_IN commercial_JJ and_CC operational_JJ excellence_NN Improve_NNP access_NN to_TO medicines_NNS through_IN a_DT range_NN of_IN extensive_JJ programs_NNS ,_, both_DT in_IN the_DT developed_VBN and_CC the_DT developing_VBG world_NN Be_VB the_DT best_JJS place_NN for_IN the_DT best_JJS people_NNS to_TO do_VB their_PRP$ best_JJS work_NN ._.
GSK_NNP Annual_JJ Review_NNP 2005_CD 29_CD Corporate_JJ Website_JJ brochure_NN About_IN us_PRP Meeting_VBG global_JJ challenges_NNS Our_PRP$ products_NNS Commitment_NNP to_TO innovation_NN Your_PRP$ health_NN Access_NN to_TO medicines_NNS Responsibility_NNP Therapy_NNP areas_NNS In_IN the_DT community_NN Our_PRP$ mission_NN Research_NNP &_CC Development_NNP A_NNP better_RBR future_JJ What_WP would_MD Investors_NNPS Media_NNP center_NN you_PRP like_VBP to_TO know_VB Careers_NNS about_IN GSK_NNP ?_.
com_NN Corporate_JJ Annual_JJ responsibility_NN review_NN report_NN Access_NNP to_TO medicines_NNS An_DT interview_NN with_IN the_DT Chairman_NNP and_CC CEO_NNP Research_NNP and_CC innovation_NN Focus_NN on_IN the_DT patient_JJ Ethical_JJ conduct_NN The_DT year_NN of_IN the_DT vaccine_NN Employees_NNS Annual_JJ Growing_VBG brands_NNS Human_JJ rights_NNS Powering_VBG performance_NN report_NN Environment_NNP Performance_NNP highlights_VBZ Community_NNP investment_NN Business_NN operating_VBG review_NN Summary_NNP remuneration_NN report_NN An_DT interview_NN with_IN Corporate_JJ governance_NN the_DT Chairman_NNP and_CC CEO_NNP Summary_NNP financial_JJ statements_NNS Financial_JJ summary_NN Shareholder_NN information_NN Description_NN of_IN business_NN Chairman_NNP and_CC CEOs_NNS Corporate_JJ governance_NN closing_VBG letter_NN Remuneration_NNP report_NN Operating_NN and_CC financial_JJ review_NN and_CC prospects_NNS Financial_JJ statements_NNS Notes_NNS to_TO the_DT financial_JJ statements_NNS Investor_NNP information_NN Do_VBP more_RBR ,_, feel_VB better_RB ,_, live_VBP longer_RBR Head_NNP Ofce_NNP and_CC Registered_NNP Ofce_NNP Produced_NNP by_IN Corporate_NNP Communications_NNPS ,_, GSK_NNP ._.
GlaxoSmithKline_NNP plc_NN 980_CD Great_NNP West_NNP Road_NNP Designed_VBN by_IN CGI_NNP London_NNP ._.
Brentford_NNP ,_, Middlesex_NNP TW8_NNP 9GS_NNP Printed_NNP in_IN the_DT UK_NNP by_IN St._NNP Ives_NNP Direct_NNP Edenbridge_NNP Ltd._NNP ._.
The_DT paper_NN United_NNP Kingdom_NNP used_VBD in_IN the_DT production_NN of_IN this_DT document_NN is_VBZ made_VBN from_IN pulps_NNS Tel_NNP :_: 44_CD 0_CD 20 8047 5000_CD harvested_VBN from_IN sustainable_JJ forests_NNS ,_, also_RB using_VBG sawmill_NN residues_NNS www_NN ._.
